News regarding Oslo Cancer Cluster

Innspill til Perspektivmeldingen

Oslo Cancer Cluster har uttalt seg om Perspektivmeldingen 2021. Vårt hovedpoeng er at helsenæring må være en større del av regjeringens strategi for norsk økonomi.

Hvert fjerde år legger Finansdepartementet fram en Stortingsmelding om utfordringer i norsk økonomi de neste førti årene, og regjeringens strategier for dem. Denne kalles Perspektivmeldingen.

Oslo Cancer Cluster deltok i høringen av denne meldingen i Stortingets Finanskomité 22. mars 2021. Flere andre aktører innen kreft og helse deltok også i høringen, blant annet Kreftforeningen, Norway Health Tech, Legeforeningen og Pårørendealliansen.

Helsenæringens potensial for norsk økonomi var et gjennomgangstema.

Helsenæringens aspekter

Perspektivmeldingen poengterer hvor viktig det blir med offentlig-privat samarbeid og investeringer i helsenæring fremover. Videre nevner meldingen at ny teknologi i helse bidrar til økt ressursbruk og økt levealder med flere funksjonsdyktige leveår. Dermed fører ny teknologi også til et økt skattegrunnlag for finansiering av offentlige velferdsordninger.

– Det er gode elementer som er med. Samtidig er det flere aspekter ved helsenæring som Oslo Cancer Cluster savner, og som vi ønsker å trekke frem, sa Ketil Widerberg, daglig leder i Oslo Cancer Cluster, under høringen.

Se Ketil Widerbergs innspill på video:

 

Det første aspektet som Oslo Cancer Cluster savner i Perspektivmeldingen, er at både uventede og forventede hendelser i helse gir store kostnader.

Uventede hendelser, som Covid19, har store budsjettkonsekvenser. I tillegg til kostnadene med nedstengte samfunn, er det store kostnader forbundet med innkjøp av teknologi til sporing, testing, behandling og vaksinering.

Forventede hendelser er for eksempel antallet nordmenn som får kreft og antallet som overlever kreftsykdom. Før fylte 75 år har nå én av tre nordmenn fått minst en kreftdiagnose, og dette tallet øker, ifølge Kreftregisteret. Det er også flere og flere som overlever og må leve med følgene av kreftsykdom. En slik prognose vil påvirke Norges finanser, og ved å utvikle norsk helsenæring blir ikke Norge stående kun på kjøpersiden, men vil også få inntekter fra et av verdens største og økende markeder.

Det andre aspektet er de økonomiske mulighetene. Slik ressursbruken i helse kan bidra til et økt skattegrunnlag, vil også store kostnader i helse representere store økonomiske muligheter for norsk helsenæring.

Norge har så langt bidratt til milliardeventyr i helse med blant annet Ugelstadkuler fra Dynal, som er sentrale i Covid19-testing, og med kreftmedisin fra Algeta og Vaccibody. Sistnevnte utvider nå sin vaksineplattform fra kreft til neste generasjons Covid 19-vaksiner.

– Dersom vi i Norge tilrettelegger godt for innovasjon innen helse og konkret følger opp Stortingsmeldingen om Helsenæringen, vil den voksende utgiftssiden også bli en voksende inntektsstrøm. Det er gode perspektiver, sa Ketil Widerberg under høringen.

Det tredje aspektet er økt samarbeid mellom det offentlige og privat næringsliv gjennom modne helseklynger.

– De norske klyngene er en etablert arena for samhandling mellom offentlig og privat sektor. Vi er også pådrivere for internasjonalt samarbeid og kunnskapssamarbeid. I tillegg legger vi til rette for kommersialisering av samfunnsnyttige, forskningsbaserte innovasjoner, og vi jobber med å koble bedrifter som søker finansiering med investorer og prosjekter. Dermed er vi med på å sikre nye selskaper viktig tilgang til kapital. Dette gir bedre kanalisering av tilgjengelig kapital, og er nettopp det Kapitaltilgangsutvalget ønsker mer av, sa Widerberg.

Spørsmål fra politikere

Oslo Cancer Cluster fikk spørsmål fra stortingsrepresentantene Sigbjørn Gjelsvik (Senterpartiet) og Ola Elvestuen (Venstre) under høringen. Spørsmålene var:

  • Hvilken rolle mener dere at det offentlige skal ha i et offentlig-privat samarbeid i helse?
  • Kan dere si noe mer om samarbeidet med helseforetakene om næringsutvikling og teknologiutvikling?

I denne videoen svarer Ketil Widerberg på spørsmålene:

 

Flere vil sikre helseklyngene

Kreftforeningen talte for at alle nå må gjøre alvor av satsingen på helsenæringen, blant annet gjennom å sikre finansiering av helseklyngene.

– Det er på tide å gjøre alvor av satsingen på helsenæringen. Vi må lykkes med å styrke samarbeidet mellom det offentlige, det private, akademia og ideell sektor. Et viktig ledd i denne satsingen må være å sikre finansieringen av klyngene på helseområdet, sa Thomas Axelsen, leder for samfunnspolitisk seksjon i Kreftforeningen, og viste til klyngene som deltok i høringen.

Axelsen understreket også behovet for umiddelbar handling:

– Vi må investere i teknologi og innovasjon i dag mens vi har et handlingsrom for å gjøre det, og sørge for at vi får på plass gode avtaler mellom det offentlige, det private og ideell sektor, slik at vi står klare neste gang vi trenger det.

Se videoen av Kreftforeningens innspill her.

Les mer: 

 

Norwegian life science @ SXSW2021

We put global health security on the agenda at the influential technology conference SXSW.

Oslo Cancer Cluster and the other Norwegian health clusters Norway Health Tech and The Life Science Cluster participated in the conference South by South West (SXSW) for the first time ever last week.

The conference usually takes place in Austin (Texas), but due to current corona restrictions it was made available through an online platform.

The full-day event Global Security Demo Day, arranged by The Texas Global Health Security Innovation Consortium (TEXGHS), attracted many big names in health and life science from across the globe on Wednesday 17 March.

“It is clear that there is a silver lining of accelerated development, new innovations and increased public-private partnership in health emerging from the current Covid-crisis,” said Ketil Widerberg, general manager of Oslo Cancer Cluster.

The Norwegian life science environment was also represented at this event, by keynote speaker Bent Høie, Minister of Health and Care Services, several representatives from private companies and the heads of the Norwegian health clusters Oslo Cancer Cluster, Norway Health Tech and The Life Science Cluster.

“It is great that Bent Høie, the Norwegian Minister of Health, supports innovative health companies at one of the world’s largest technology conferences in Texas,” said Ketil Widerberg.

View the panel sessions

Watch the video above for the panel session The race to a vaccine with Ketil Widerberg, general manager of Oslo Cancer Cluster and Trent Munro, Professor at Australian Institute for Bio-Engineering and Nanotechnology, moderated by Janet Walkow Executive Director and CTO, Drug Dynamics Institute, UT Austin.

The event was organised by TEXGHS, Austin Technology Incubator at the University of Texas at Austin, Australian Trade and Investment Commission (Austrade), Consulate General of Denmark in Houston, The Royal Norwegian Consulate General in Houston and European Network of Research and Innovation Centres and Hubs, USA (ENRICH).

Talking about cancer research and equality

International Women’s Day: three Norwegian researchers share their personal stories of being women in the cancer field.

Every year, International Women’s Day is marked on the 8th of March to put gender equality on the agenda. We wish to use this opportunity to celebrate women dedicated to developing new cancer treatments. It is important for us to highlight researchers that perform important research, who can also be role models.

We have reached out to cancer researchers across Norway, both in the public and the private sector. As a result, three accomplished Norwegian researchers share their personal perspectives. They are at different stages in their careers and focusing on different areas of research.

 


Åslaug Helland. Photo: Oslo University Hospital

Åslaug Helland. Photo: Oslo University Hospital

Combining family life and research

Åslaug Helland is a Group leader at the Institute for Cancer Research at the Norwegian Radium Hospital in Oslo and Senior Oncologist at the Department of Oncology at Oslo University Hospital. Helland’s research group focuses on translational studies on solid tumours, with a special interest in pancreatic cancers, lung cancers, ovary cancers and colorectal cancers.

“First of all, being involved in cancer research has been extremely rewarding. I started when still at med-school, in 1991, and since then we have learned a lot. Today we see that the insights gained some years ago benefit patients!

“When I started working in cancer research, there was a male dominance, which is not as obvious today. I started in Anne-Lise Børresen-Dale’s group at the Norwegian Radium Hospital. She was a world leading researcher in cancer molecular genetics and working with her was very inspiring.

“The regulations in Norway have made it possible for both men and women to combine family life and research.

“My family and I have lived abroad twice for research stays, first at Stanford University and thereafter at Peter MacCallum Cancer Centre in Melbourne, Australia, and my experience is that Norway is one of the most advanced countries in gender balance and equal opportunities.”

 


 

Sigrid Skånland. Photo: Private.

Sigrid Skånland. Photo: Private.

Let me hold the door for you

Sigrid S. Skånland is a PhD, Project group leader, lab leader and researcher at the Institute for Cancer Research at Oslo University Hospital. Skånland has established her own research group, focusing on functional precision medicine in haematological cancers, in particular the B-cell malignancy chronic lymphocytic leukemia.

“When I talk about gender equality, I do it for my daughters. Their future. When they show bold confidence, I think ‘You go, girl!’

I want them to feel that they can claim their space, even as girls. I want them to see that it is possible to be smart, strong and successful, even as a single mom. I want them to be valued equally to men, also when they become women.

“As a biologist, most of my fellow students were female, and most of my colleagues during my graduate and post-graduate studies were women. As I have become more senior, my perspective has changed. Most students and trainees are still women. But. When I go to conferences, I see that most of the speakers are men. When I apply for research funding, I see that most of the grants are awarded to men. And when I establish new collaborations, I see that most of the higher positions are filled by men. I want everyone to see this.

“My daughter sat with me through a virtual conference. She pointed to the screen and said: ‘Are there only men?’ At the age of five, she already sees it.

“As a woman, I need women in leading positions to look up to. And I greatly appreciate the men who also see the value of acknowledging and promoting excellent female scientists. After 40 years, the first female members were elected to the international workshop on chronic lymphocytic leukaemia in 2019. This could not have happened without the support from the men on the board. Together, we can raise awareness on gender equality and make the gender gap smaller.

“I hope that I can inspire other women. Kamala Harris said it nicely: ‘It’s on those of us leading the way to leave the door more open than it was when we walked in.’”

 


 

Simone Mester. Photo: University of Oslo

Simone Mester. Photo: University of Oslo

Follow your dreams!

Simone Mester is a PhD student at The Laboratory of Adaptive Immunity and Homeostasis, which is part of both the Medical Faculty at the University of Oslo and Department for Immunology and Transfusion Medicine at Oslo University Hospital. Her research focus is on development of new biomedical technologies that may make cancer treatments more precise and effective. Her ambition is to start a biotechnology company in Norway.

Mester attended Ullern Upper Secondary School, which has an active collaboration with Oslo Cancer Cluster to inspire students to pursue careers in science and entrepreneurship. She was also the youngest researcher to be selected to SPARK, the University of Oslo’s two-year innovation programme. When she won the SPARK “pitch challenge”, she was awarded a six-month stay in ShareLab, where she now is exploring the commercial potential of her research results together with her colleague Torleif Tollefsrud Gjølberg, also a PhD student in the same laboratory.

“Early in my career, I have experienced great opportunities and lot of support. I strongly feel that the life science ecosystem is supporting me and would like to see me succeed. This is very motivating!

“For me, it is important to be part of a dynamic research environment that allows me to explore and develop as a researcher.

“I would like to encourage students and young researchers to be brave, ambitious and to follow their dreams!”

 


Else Marit Inderberg. Photo: Oslo University Hospital

Else Marit Inderberg. Photo: Oslo University Hospital

Calling for clear career paths

Else-Marit Inderberg is a Senior Researcher and Group leader at the Department of Cellular Therapy at Oslo University Hospital-The Norwegian Radium Hospital. The focus of her research is immunomonitoring in clinical studies and the development of cell therapies in cancer treatments. Inderberg’s research group uses the offices and facilities in Oslo Cancer Cluster Incubator.

“My experience as a woman in cancer research in Norway is very good and my supervisors and mentors were always very supportive.

“I was always given opportunities to take on responsibility and to be independent and it was up to me to decide if I wanted or could grab them or not.

One of the key things to change to keep future generations motivated to do cancer research is to have clear career paths for researchers, both female and male.

 


 

Fundraising on the school curriculum

This article was first published in Norwegian on our School Collaboration website.

To set up a company, you need financing. In February, fundraising was a topic on the schedule for the students of entrepreneurship at Ullern Upper Secondary School. The lecturer was Øyvind Kongstun Arnesen who – as former CEO for Ultimovacs – has been through several fundraising rounds.

“Today, I will share my experiences with you and you can interrupt or ask questions as much as you like,” Øyvind Kongstun Arnesen began his lecture.

Kongstun Arnesen has 10 years of experience as CEO for Ultimovacs, a company that develops a universal cancer vaccine and has been through many rounds of raising funds.

Kongstun Arnesen shared his experiences with the students about what things companies need to organise before actively seeking financing.

“It is very important to have solid patents, which is the basis for any pharmaceutical or biotech company,” said Kongstun Arnesen.

He also stressed the importance of creating good investor presentations based on what kind of information the potential investors need.

Then, the former CEO explained the different stages of fundraising that the company had been through.

Kongstun Arnesen talks to the students of entrepreneurship at Ullern Upper Secondary School.

Kongstun Arnesen talks to the students of entrepreneurship at Ullern Upper Secondary School. Photo: Elisabeth Kirkeng Andersen

From flying start to stock market

“In the beginning, we were lucky, because one of Norway’s wealthiest men, Bjørn Rune Gjelsten, invested in the company and was also involved in the management. The reason for this was that his father was diagnosed with prostate cancer and he wished to contribute to something more than a donation to the Radium Hospital,” said Kongstun Arnesen.

Kongstun Arnesen continued to explain that having Gjelsten on the team was important for the next time the company needed to raise funds.

“Gjelsten contacted his network and we got large owners onboard, such as Canica led by Stein-Erik Hagen and others. It went surprisingly well,” said Kongstun Arnesen.

Then the company needed to go on the financial market to raise funds. The financial market consists of companies that are set up to earn money from investments. The only thing they have in common is that the companies are different and invest in differing ways.

“It is about collecting so called venture capital and going to ‘family offices’. In other words, family-owned businesses that invest funds in order to manage families’ fortunes in the best way,” said Kongstun Arnesen.

During the next round, Ultimovacs was set to raise NOK 130 million.

“That is when you need to reach the big and heavy players, for example different types of retirement funds, banks and other types of investment funds,” said Kongstun Arnesen.

Finally, was the biggest ask. The company wanted to raise NOK 450 million.

“To raise such a big sum, you need to be listed on the stock market. Everyone can invest on the stock market and it demands a lot of a company to get listed and raise money. We still managed it. At that milestone, we had the funds we needed to show that the vaccine worked. That is when it was time for me to step down as CEO,” said Kongstun Arnesen.

 

LEGEN OG PASIENTEN: Fra venstre møteleder Siri Lill Mannes, kreftpasient Kjetil og lege Andreas Stensvold.

Evaluerer Nye metoder: – Tar arbeidet på største alvor

– Evalueringen av Nye metoder er viktig for så mange, og det handler om liv og helse. Så vi går til dette arbeidet med stort alvor, sier Jens Plathe, prosjektleder i Proba samfunnsanalyse.

Jens Plahte, Proba Samfunnsanalyse

Jens Plahte, Proba Samfunnsanalyse

– Vi må velge ut noen enkeltsaker som dels kan belyse når systemet fungerer etter hensikten, og saker som kan belyse hvordan systemet fungerer når det settes under stress. Vi har fått mange innspill fra referansegruppen, og fortsetter å samle inn data frem til sommeren. Innen utgangen av oktober skal vi levere sluttrapporten, sa Plathe.

Han var invitert til å fortelle om prosjektet på årets første møte i møteserien Fremtidens kreftbehandling, der temaet var nettopp evalueringen av Nye metoder. Møteserien er i flere år blitt arrangert av Kreftforeningen, Oslo Cancer Cluster og LMI, i samarbeid med Janssen, MSD og AstraZeneca.

Her kan du se hele møtet

Kreftpasient Kjetil betalte gentesten selv

Evalueringen av systemet, som så mange er enige om at må forbedres, har vakt stor interesse, og det digitale møtet samlet rundt 370 deltakere rundt i hele landet. Vi fikk også høre historien til Kjetil, som har prostatakreft, og hvordan han sammen med legen sin, Andreas Stensvold, har funnet stadig nye måter å teste ut nye medisiner på – også delvis på tross av systemet – slik at han fortsatt er i live i dag. Historien hans sier noe om hvordan systemet, slik det er rigget i dag, har fått konsekvenser for pasientene og deres – til tider – kronglete vei til riktig behandling.

– Jeg har kjent Kjetil i mange år, og han har gjennomgått alt av standardbehandling, både cellegift og godkjente medisiner. Men disse virket veldig dårlig.  Det var tydelig at Kjetil ikke var en standardpasient, så vi måtte tenke på en annen måte, og gjøre flere undersøkelser – blant annet genanalyser. Men han disse måtte han betale for selv, forteller Stensvold.

Blant annet ville de finne ut om Kjetil hadde en genprofil som tilsa at han trengte en medisin som var beregnet på brystkreft, ikke prostatakreft. For Kjetil var det ikke vanskelig å ta valget om å betale for gentesten selv.

– Det var ikke noe annet alternativ enn å finne de pengene. Det begynte å se mørkt ut, så det var min eneste mulighet, sier han.

Da resultatene fra gentesten kom fra USA, satte Kjetil seg i bilen og kjørte hjem til legen sin for å levere resultatene.

– Vi endte med en off label-behandling, det vil si at Kjetil fikk en medisin som er godkjent i Norge, men til en annen kreftform. Og dette var ikke en avgjørelse jeg tok alene, den ble tatt etter en grundig juridisk og etisk vurdering. Det var også et kostnadsaspekt her, for hvis vi hadde sagt nei til off label-behandlingen måtte Kjetil ha betalt medisinen av egen lomme, sier Stensvold.

Behandlingen, som er en kombinasjonsbehandling med to immunterapier, startet de med i oktover 2020, og i løpet av få uker merket Kjetil at klumpene ved kragebeinet var borte. I desember var PSA-verdiene så lave at de ikke var målbare. Kreftlege Stensvold er rørt.

– Jeg har utsatt Kjetil for bivirkninger og nerveskader med de tidligere behandlingene. Men ingenting er likevel hyggeligere enn å se at nå har kreftsvulstene forsvunnet. Det er første gang siden 2014 at vi ikke ser noen metastaser hos ham, nesten alle kreftsvulster har forsvunnet. Det er veldig gøy, og man blir litt rørt selv, sier legen.

Men han etterlyser et bedre system, med mulighet for genanalyser og persontilpasset behandling. Noe er allerede på vei, men det er på overtid.

– Vi tilbyr behandlinger som ikke har effekt, fordi ny behandling er for dyr eller av andre grunner får nei i Nye metoder. Jeg syns danskene har et godt system der fagpersoner er dypt involvert, og der er det åpenhet og transparens om beslutningene, sier Stensvold.

Evalueringen skal besvare to hovedspørsmål

Prioriteringssystemet Nye metoder ble etablert i 2013, og har hatt noen «startproblemer» som etter 7 år ikke lenger kan kalles startproblemer. Myndighetene har derfor bestemt at systemet skal evalueres, og Helse og omsorgsdepartementet ga Proba evalueringsoppdraget. Proba har knyttet til seg Institutet för Hälso- och Sjukvårdsekonomi (IHE) i Lund i Sverige, samt flere uavhengige forskere: professor Kristin Bakke Lysdahl ved Universitetet i Sørøst-Norge, professor emeritus Ivar Sønbø Kristiansen og professor emeritus Aslak Syse. Professor Olav Helge ved Universitetet i Tromsø og førsteamanuensis Anne Kjersti Befring fra Universitetet i Oslo er eksterne kvalitetssikrere. I tillegg har Proba opprettet en rådgivende referansegruppe med 14 medlemmer som representerer pasientene, industrien, sykehusene, myndighetene og andre aktører.

Sluttrapporten Proba skal levere, skal besvare to hovedspørsmål.

Er dagens organisering og saksbehandlings¬proses¬ser i sys¬temet hensiktsmessig utformet og egnet til å oppnå de fastsatte målene?

Og er sys¬temet rustet til å møte fremtidens medisinsk-teknologiske utvikling, herunder utvikling av persontilpas¬set medisin?

Stor enighet om utfordringene

Hva er utfordringene med Nye metoder? Det er stor enighet om at tiden det tar, mangelen på åpenhet og hvordan usikre data i studier med presisjonsmedisin skal håndteres, er blant de viktigste. Også behovet for alternative prisløsninger går igjen i ønskene. Nederst i saken kan du se videoer der alle møtearrangørene fremhever de tre viktigste sakene de mener evalueringen av Nye metoder bør ta for seg.

Revolusjonen de siste årene, med immunterapier, målrettede behandlinger og genterapier, gjør at behandlingsmulighetene overstiger tilgjengelige ressurser, og særlig innen kreftbehandling. Flere av de nye kreftbehandlingene er så lovende at enkelte kreftformer går fra å være dødelige til å kunne leves godt med, og kanskje til og med bli kurert. Men hvordan skal helsetjenesten, som betalere, og legemiddelindustrien, som leverandører, bli enige om verdien av disse behandlingene når usikkerheten om effektene er så store? Hvordan kan de ulike aktørene bidra til at systemet blir mer rigget for fremtidens kreftbehandling?

Tid og nye dokumentasjonspakker

For Legemiddelverket, som gjør metodevurderingene som ligger til grunn for beslutningene i Nye metoder, gjør de nye avanserte terapiene hverdagen mer utfordrende. Enhetsleder Einar Andreassen sier at deres oppgave er å følge det som står i Prioriteringsmeldingen.

– Vi må vurdere hvilken nytte behandlingen har for pasienten, hvor alvorlig sykdommen er og hvor mye behandlingen koster eller hvor mye vi sparer. Dette vurdere vi hver for seg, og Beslutningsforum veier disse opp mot hverandre. Mest krevende nå er at vi får en dokumentasjonspakke fra firmaene, som viser effektdokumentasjonen, og den opplever vi blir mer sparsom med de nye teknologiene. Det kan det være fornuftige grunner til, andre ganger er det vanskelig å si hvorfor disse er vanskelige å vurdere for oss, sier han.

Færre pasienter i studiene kan være én grunn, men også etiske årsaker, sier han.

– Det vi også opplever er at disse studiene får midlertidig godkjenning i EMA. De godkjenner medisinene på bakgrunn av studier som er gjort på tidligere fase enn før, de fungerer godt i forhold til bivirkningene. Da vil den dokumentasjonen sendes videre til oss, som skal gjøre metodevurdering, og det er da utfordringene kommer. Ikke fordi kvaliteten er dårlig, men fordi den ikke sier like mye som vi er vant til fra før, sier Andreassen.

Han bekrefter at tid er en utfordring.

– Vi bruker de 180 dagene vi har på oss, og vel så det, og det jobber vi for å få ned. Men det handler om vår ressurskapasitet. Det handler også om tiden det tar for industrien å sende inn sin dokumentasjon.

Han sier at Legemiddelverket bør bli bedre til å velge ut hvilke saker de skal bruke tid på, slik at de kan behandle disse enklere og raskere. Her kan europeisk samarbeid, og nordisk samarbeid, gjøre at man kan dele på arbeidsbyrden og ikke gjøre unødvendig dobbeltarbeid.

Styrke testkapasiteten og finne nye betalingsløsninger

Jan Frich, viseadministrerende direktør i Helse Sør-Øst, mener en styrking av kapasiteten innen diagnostikk blir viktig fremover, med tanke på persontilpasset medisin. Han påpekte at det jobbes med å ruste opp dette i sykehusene nå. Han sier at det i mangelen på dokumentasjon i ny behandling blir en glidende grense mellom etablert behandling og utprøvende behandling, og viste i likhet med Karita Bekkemellem (i videoen) til IMPRESS-studien.

– Jeg hørte legemiddelindustrien nevne IMPRESS, som er en stor plattform for å prøve ut utprøvende behandling og samle dokumentasjon. Det er positivt å høre at industrien er med på dette, og vil bidra. Det har vi ønsket oss, at vi kan stå sammen for å bli bedre, sa Frich.

Også Frich mener industrien må levere dokumentasjon raskere.

– Jeg er enig i at vi skal prøve alt vi kan for å få saksbehandlingstiden ned, men noen ganger er det vårt system som er årsaken, men en god del ganger er det også industrien som ikke sender dokumentasjon. Så vi venter og venter på dokumentasjon, som kanskje ikke finnes. I noen av disse studiene er det kanskje 10-15 pasienter, sier Frich.

På spørsmål fra ordstyrer Siri Lill Mannes svarte han også på behovet for nye pris- og betalingsløsninger.

– Ja vi må lage forutsigbare finansieringsløsninger, slik at industrien blir mer på en løsning. Der må vi lage en ny modell for finansiering. Det blir en viktig nyskaping.

Politisk enighet

Tuva Moflag fra Arbeiderpartiet og Marianne Synnes fra Høyre var enige om det meste da de diskuterte temaene i en paneldebatt mot slutten av møtet. Blant annet er de helt enige om at de må se på det jurist Marianne Hammer tok opp, nemlig at pasienter i praksis har fått redusert sin rett til individuell vurdering fordi lovverket er så vanskelig å forstå.

– Vi må vurdere å endre lovteksten på det som går på pasientrettigheter. Dette er interessant for oss å se videre på, vi som tross alt er lovgivere, sa Moflag.

Hun mener evalueringen av Nye metoder og Beslutningsforum kommer sent, men godt.

– I fjor ble Beslutningsforum lovfesta. Vi ønsket at Beslutningsforum skulle evalueres før det ble lovfestet. De legger blant annet i for stor grad vekt på gruppetenkning. Hvis en kvinne på 30 år får en kreftform som vanligvis rammer menn over 75, blir den i systemet ikke funnet kostnadseffektiv. Og vi får stadig flere tilbakemeldinger om det med pris, at den delen vektes for tungt. Det gjelder ikke bare kreftpasienter. Innen MS er standardbehandlingen en gammel kreftmedisin. Det er helt fint hvis det fungerer, men problemet er at vi ikke vil betale for ny medisin til de som ikke har nytte av den gamle medisinen. Da har det gått for langt. Det handler om samspillet mellom pris og individuell vurdering, og det handler om at vi gjør prioriteringer ut fra hvordan dette påvirker sykehusbudsjettene. Hun som ikke får MS-behandlingen må nå få hjemmetjeneste og kan ikke lenger jobbe, sier Moflag, som mener dette bør tas med i det store regnestykket.

Marianne Synnes i Høyre er enig.

– Med evalueringen av Nye metoder kan vi se på nye ting som gjør at vi får til et bedre system likevel. Off label-behandling, at ikke alle vurderinger gjøres på gruppenivå,  og at vi skal implementere persontilpassa medisin. Det kommer til å bli krevende, men det må vi politikere også ta innover oss. Og så syns jeg det var et godt forslag fra Tuva om å se hele samfunnsregnskapet når man tar disse avgjørelsene.

Hege Edvardsen, seniorrådgiver i LMI, er fornøyd med møtet og alle innspillene som kom.

– Både vi i industrien og det offentlige må ta ansvar for å samarbeide bedre, og komme opp med gode løsninger som gjør at pasientene får raskere og bedre tilgang til de innovative medisinene som utvikles av industrien. En innovasjon som ikke tas i bruk er av liten verdi både for pasientene, samfunnet og for industrien, vi må derfor sammen finne løsninger som ivaretar både et bærekraftig helsevesen og næringsinteressene til en av de næringene Norge skal bygge sin fremtid på. Tilgang handler om mer enn bare pris, og industrien ønsker å være en samarbeidspartner både innen kliniske studier, pasienters tilgang til compassionate use og ved innføring av legemidler i standard pasientbehandling, sier Edvardsen.

 

 

Ketil Widerberg, general manager of Oslo Cancer Cluster

Mer presis behandling kan redde liv

Originally published in Dagbladet on 4 February 2021.

Verdens kreftdag markeres 4. februar hvert år for å styrke den globale innsatsen mot kreft. Vi har kommet langt – både i forebygging, tidlig behandling og bedre livskvalitet for mange pasienter. Vi er imidlertid langt ifra ferdige …

Vi har sett store fremskritt de siste 20 årene. Forskning innen immunologi har ledet til utviklingen av nye terapier som gjør at vi kan behandle pasienter mer effektivt, gir færre bivirkninger så de kan leve bedre og lengre liv. I dag kan behandlingen og kombinasjoner av behandlinger i økende grad målrettes til den enkelte pasienten og den spesifikke krefttypen, noe som kalles persontilpasset medisin eller presisjonsmedisin.

Norge har verdensledende miljøer som har bidratt i utviklingen av disse behandlingene som forlenger og redder liv. Dette har skapt fremgangsrike bedrifter, gitt oss arbeidsplasser og tiltrukket internasjonale investeringer til en helsenæring i vekst.

Legemiddelindustrien spiller en viktig rolle for å utvikle nye medisiner. Kliniker jobber hardt for å tilby beste behandling til sine pasienter. Ledere i helseforetakene kjemper med å prioritere kost og nytte for å godkjenne nye medikamenter fortest mulig.

I dag står vi overfor en stor utfordring.

Vi lever lengre. Vi har en voksende eldre befolkning. De nye kreftbehandlingene er dyrere og setter økt press på velferdsstaten Norge. For å lykkes i å gi god behandling til alle kreftpasienter må alle samarbeide. Politikerne må gi klar beskjed om hvordan pengesekken skal brukes. Helseforetak må snakke sammen med industrien for å finne nye måter å dokumentere og godkjenne medisiner raskere. Kliniker og pasienter må bli hørt gjennom hele prosessen.

CONNECT er et nytt offentlig-privat samarbeid som samler alle universitetssykehusene i Norge, ledende legemiddelselskaper, Kreftforeningen og offentlige instanser rundt et bord. Til sammen skal de diskutere problemstillinger og hindringer, samt pilotere nye løsninger for å ta i bruk presisjonsmedisin raskere. Oslo Cancer Cluster har en koordinerende rolle for å sikre en bred, balansert og informert tilnærming og debatt. Målet er at vi gjennom initiativet får fart på innføring av presisjonsmedisin.

Koronakrisen har vist oss att om vi jobber sammen er det mulig å utvikle vaksiner på mindre enn et år. Nå må vi gjøre det samme med kreft.

Vårt mål er at nye kreftbehandlinger i samarbeid skal utvikles på 5 istedenfor 10 år.

 

Ketil Widerberg

Daglig leder, Oslo Cancer Cluster

First pharma company joins IMPRESS-Norway

Roche is the first pharmaceutical company included in the national clinical study in cancer precision medicine called IMPRESS-Norway.

IMPRESS-Norway is a national clinical trial in precision oncology. Approved drugs will be used to treat new cancer indications (“off label”) based on the molecular profile of the patient’s tumour. The success of IMPRESS-Norway is dependent on molecularly targeted drugs contributed by pharmaceutical companies. Roche is the first company to officially join IMPRESS-Norway. The company will contribute eight different medicines and provide a diagnostic gene test through its subsidiary Foundation Medicine.

“Positive and important news that Roche wishes to contribute their resources. Now, this will be a joint investment in both diagnostics and treatment, so that precision medicine for advanced cancer disease can be offered at all hospitals in Norway. We are very happy that Roche wishes to participate in this initiative,” commented Egil Støre Blix, oncologist at the Cancer Department at the University Hospital of North Norway and member of the Trial Management Committee at IMPRESS-Norway.

IMPRESS-Norway is in dialogue with several other pharmaceutical companies about contributing cancer medicines. These companies have also joined CONNECT, the newly established public-private partnership initiated to accelerate the implementation of precision medicine for cancer patients in Norway (see the fact box below for a complete list of CONNECT Founding Partners).

“The CONNECT partnership and IMPRESS-Norway are important milestones in the implementation of personalised medicine and will drive the development of a more personalised health service,” commented Ingvild Hagen, Area Owner for Personalized Healthcare in Roche. “We hope that in signing the IMPRESS agreement, we are motivating other companies to do the same. To realise the potential of this project, we are dependent on as many partners as possible. We are definitely stronger together!”

Oslo Cancer Cluster has played an active role in setting up the initiatives IMPRESS-Norway, CONNECT, InPreD and INSIGHT, to gather the Norwegian oncology community with the common goal of getting cancer precision medicine faster to Norwegian patients.

Ketil Widerberg, General Manager at Oslo Cancer Cluster. Photo: Stig Jarnes/Oslo Cancer Cluster

Ketil Widerberg, General Manager at Oslo Cancer Cluster. Photo: Stig Jarnes/Oslo Cancer Cluster

“Cancer is a genetic disease. However, we often treat according to where in the body the cancer is discovered and not based on the genetic profile. This changes now when technology and medicine are merging in precision medicine. Roche is one of the companies that has come furthest in this development. Their involvement in IMPRESS and CONNECT is highly appreciated. This is an important milestone, and we look forward to more companies following their example,” commented Ketil Widerberg, General Manager, Oslo Cancer Cluster.

Precision medicine is about providing the right treatment for the right patient at the right time. There are many cancer therapies today that can be targeted towards specific molecular changes in the cancer cells. Patient access to molecular diagnostics is one of the prerequisites for the successful implementation of precision medicine.

Randi Hovland, Head of Section for Clinical Genetics at Haukeland University Hospital and member of Trial Management Committee in IMPRESS-Norway. Photo: Mathilde Oseberg

Randi Hovland, Head of Section for Clinical Genetics at Haukeland University Hospital and member of Trial Management Committee in IMPRESS-Norway. Photo: Mathilde Oseberg

“The establishment of broad genetic testing is essential to offer patients our treatments in clinical studies and IMPRESS drives the implementation of this in Norway. For patients whose tumour tissue isn’t available, the contribution from Roche through Foundation Medicine is of great importance to examine whether blood can replace tissue when identifying relevant biomarkers,” commented Randi Hovland, Head of Section for Clinical Genetics at Haukeland University Hospital and member of Trial Management Committee in IMPRESS-Norway.

IMPRESS is based on the DRUP (Drug Rediscovery Protocol) trial in the Netherlands, a precision medicine trial evaluating the effects of a broad portfolio of precision treatments based on the molecular profile of the patient’s tumour. The benefits of this study were highlighted by Emile Voest, Medical Director of The Netherlands Cancer Institute, at the recent Cancer Crosslinks. The  learnings from IMPRESS and related trials will be discussed in CONNECT and are important to develop novel implementation models for cancer precision medicine.

Read more about CONNECT, InPred and INSIGHT here: Landmark public-private agreement for precision cancer medicine

 

CONNECT Founding Partners:

  • Akershus universitetssykehus HF
  • Helse Bergen HF
  • Helse Stavanger HF
  • Olavs hospital HF
  • Universitetssykehuset Nord-Norge HF
  • Oslo Universitetssykehus med Kreftregisteret og OUH Comprehensive Cancer Center
  • Folkehelseinstituttet
  • Oslo Cancer Cluster SA
  • Kreftforeningen
  • Legemiddelindustrien
  • Roche Norge AS
  • Bristol-Myers Squibb Norway Ltd NUF
  • Novartis Norge AS
  • Merck AB NUF
  • Takeda AS
  • Amgen AB Norge NUF
  • AstraZeneca AS
  • AbbVie AS
  • Bayer AS
  • PubGene AS
  • Pfizer Norge AS
  • NEC Corporation

 

Please get in touch with Jutta Heix, Head of International Affairs at Oslo Cancer Cluster, to learn more about our initiatives in precision medicine and how to join CONNECT.

Eivind Lysheim

From pupil to full-time employee

This article was first published in Norwegian on our school collaboration website. Read it here.

Through the collaboration between Oslo Cancer Cluster and Ullern Upper Secondary School, former Ullern-student Eivind Lysheim has found his way in life – both academically and professionally. “I am very thankful for this,” said Eivind.

“I want to thank you for helping me find a summer job with Kongsberg Beam Technology (KBT). I appreciate that you took the time to help, despite problems caused by the pandemic.

“I worked for KBT last summer and felt right at home. I have since then worked a few hours every week with the company, next to my studies. A couple of days ago, I signed a permanent contract with KBT and I will begin to work in the company’s prospective office at Oslo Cancer Cluster Incubator from the summer 2021.”

This is the e-mail that Eivind Lysheim sent to Bente Prestegård in Oslo Cancer Cluster at the end of November 2020.

A guiding placement

Eivind Lysheim has half a year left of his degree at the Norwegian University for Science and Technology (NTNU), where he is working intensely to finalise his master’s in Medical Physics.

Eivind chose this degree after participating in a one-week placement at the Department for Medical Physics at the Radium Hospital in March 2016. The placement is an annual option for students at Ullern Upper Secondary School, as a part of the opportunities the students receive through the collaboration between Oslo Cancer Cluster and Ullern Upper Secondary School.

Eivind attended Ullern between 2013 and 2016 and specialised in different science subjects.

“I did not know exactly what do to after graduation. I liked science but didn’t know what I could do with it. When I participated in the placement, everything fell into place and I changed my first choice from Economics to Medical Physics at NTNU,” said Eivind.

Eivind said that choosing his degree was a direct consequence of the placement.

The physicist Taran Hellebust Paulsen explains to Kristian Novsett Borgen, Aurora Opheim Sauar, Edvard Dybevold Hesle, Alexander Lu, Trym Overrein Lunde and Tuva Askman Nærby about the use of radiation in cancer therapy. Photo: Elisabeth Kirkeng Andersen

The physicist Taran Hellebust Paulsen explains to Kristian Novsett Borgen, Aurora Opheim Sauar, Edvard Dybevold Hesle, Alexander Lu, Trym Overrein Lunde and Tuva Askman Nærby about the use of radiation in cancer therapy. Photo: Elisabeth Kirkeng Andersen

“It was an incredibly exciting placement and I was very fascinated by the researchers and clinicians that use radiation to treat cancer, even though radiation is deadly. This duality awakened something in me,” said Eivind.

He also found the people responsible for the placement genuinely enthusiastic about teaching their subjects to him and his co-students. They took time out of their busy schedules and were excellent communicators.

Summer job in a relevant company

Half a year after the placement, Eivind was in Trondheim at NTNU studying Medical Physics. This was the same degree that Taran Paulsen Hellebust, associate professor at the Department for Medical Physics and responsible for the placement that Eivind participated in, had studied.

In January 2020, Eivind sent an e-mail to Bente Prestegård. Bente is project manager for the collaboration between Oslo Cancer Cluster and Ullern Upper Secondary School.

“Eivind sent me a very nice e-mail, in which he told me he was a former student at Ullern and that he had participated in the placement with Taran. He wondered if I knew of any relevant summer jobs,” said Bente.

Bente asked around in her network among start-up companies in Oslo Cancer Cluster Incubator: were there any companies that needed Eivind’s skill set?

“Bjørn Klem, the manager of the Incubator, suggested the company Kongsberg Beam Technology that he was actively advising. I connected Per Håvard Kleven, the general manager at the time, with Eivind and, as a result, he got a summer job there during 2020,” said Bente.

Eivind and his co-students from Ullern at a placement at the Department for Radiobiology at the Radium Hospital in 2016. Photo: Elisabeth Kirkeng Andersen

Eivind and his co-students from Ullern at a placement at the Department for Radiobiology at the Radium Hospital in 2016. Photo: Elisabeth Kirkeng Andersen

Only positive references

Kongsberg Beam Technology is a member of Oslo Cancer Cluster Incubator and develops technologies to improve the accuracy of proton therapy machines.

“The core of the project is to achieve industrial precision in cancer radiation therapy, to avoid damaging healthy tissue. By achieving higher precision, the cancer cells can be radiated with more powerful doses than today,” said Per Håvard Kleven, founder of Kongsberg Beam Technology.

Per Håvard Kleven, founder of Kongsberg Beam Technology

Per Håvard Kleven, serial entrepreneur and founder of Kongsberg Beam Technology. Photo: Oslo Cancer Cluster.

Per Håvard is a serial entrepreneur and started the project that Kongsberg Beam Technology has spun out from in 2016. The company was officially founded in 2018.

In the summer of 2020, Eivind worked with different types of research for the company and it went so well that he continued in a 20 per cent position next to his studies during the fall. In November, Eivind was offered a permanent job beginning in August 2021.

“I am thrilled about this job. The assignments are exciting, and the colleagues are nice, so I am very happy and thankful for the opportunity. It was a good match with Kongsberg Beam Technology, and I feel that I am also contributing to a relevant part of the project. It is fun,” said Eivind.

Per Håvard only has words of praise for the new employee.

“Eivind is endlessly interested in the project and what we do. He receives tasks from a project manager. Many of the assignments are about researching different things. I receive great feedback on his work and efforts,” said Per Håvard.

New offices in the incubator

Kongsberg Beam Technology is in a research and development phase, the goal is to develop finished control systems for proton machines during the next years, in order to transition to a commercial phase by 2025. That is when Kongsberg Beam Technology will sell the systems globally.

“If we succeed with this, it will mean a revolution in radiation treatment of cancer patients.”

“We are in the lucky position that no one else globally is doing exactly what we are doing. If everything goes according to plan, we will be in a unique position on the market in only a few years,” said Per Håvard.

Per Håvard has recently hired Kerstin Jakobsson as new CEO of the company. She has long experience from radiobiology in Sweden, where this is an established commercial field, which it hasn’t become in Norway – yet.

“From the fall of 2021, Kerstin and Eivind will be in Oslo Cancer Cluster Incubator, while I will be leading the Kongsberg-side of things in the Incubator Kongsberg Innovation,” said Per Håvard.

He is very impressed by the collaboration between Oslo Cancer Cluster and Ullern Upper Secondary School and says this is important to secure the recruitment of highly competent employees to a knowledge-intensive industry in Norway.

“It is very smart and positive that they have managed to build a collaboration between the school, the hospital, Oslo Cancer Cluster and the Incubator, where there is such a clear common goal on many levels,” said Per Håvard.

A unique network

Eivind says that the degree he chose was because of the placement. Now, the permanent position he has secured before finishing his master is very important to him.

“I realised in Trondheim that I had a network through Oslo Cancer Cluster that opened doors for me.”

“This made it easier for me, compared to my fellow students, to find a relevant summer job. I knew who to turn to,” said Eivind.

Bente is extremely happy to hear that Eivind, starting this fall, will be one of the many employees that share a workplace with her in Oslo Cancer Cluster Incubator.

Bente Prestegård, Project Manager, Oslo Cancer Cluster

Bente is project manager in Oslo Cancer Cluster and responsible for the collaboration with the school on behalf of the cluster. Photo: Gunnar Kopperud

“This is a really nice story that fully shows what we wish to achieve with the school collaboration. It should inspire further education and we wish to recruit for our members, both the companies and academic institutions,” said Bente.

“This fall, corona is hopefully under control so that I can meet Eivind in the incubator. It is really a cross-disciplinary environment, which is truly inspiring to work in. It will be fun to have him here,” said Bente.

  • Eivind was interviewed by Oslo Cancer Cluster in August 2020 about his summer job with Kongsberg Beam Technology – read the interview here.

 

About Kongsberg Beam Technology

  • Founded and led by serial entrepreneur Per Håvard Kleven, who has had a long career in the Kongsberg industry
  • Owned by Oslo Cancer Cluster Incubator, Kongsberg Innovation, VIS Innovation and 18 private owners. Partner with Semcon Norway on development.
  • Kongsberg Beam Technology will, by using precision technology from industrial control systems, make proton therapy to treat cancer tumours more precise and with fewer side effects.
  • Have developed a system for this called MAMA-K, which is short for Multi-Array Multi-Axis Cancer Combat Machine.
  • In 2020, the company received NOK 22,7 million in support from the Norwegian Research Council to develop the system.
  • The plan is to work with the development of the technology until 2025 and then transition to patient treatment.
  • The company has received support from Oslo Cancer Cluster Incubator for business development and obtaining capital.

 

Read articles about the company

 

Sign up for our monthly newsletter to see the latest news and events

illustrasjon av handlingsplan for kliniske studier

New political paper: Action Plan for Clinical Studies

The Norwegian government wants to double the number of clinical studies by 2025, but is this goal ambitious enough?

The highly anticipated political paper “Action Plan for Clinical Studies (2021-2025)” was released in Norway by the Ministry of Health and Care Services this week. The government’s vision is to make clinical studies an integrated part of patient care.

A clinical study is a type of research study that tests how well new medical approaches, such as screening, prevention, diagnosis, or treatments, work in people.

The action plan is the first of its kind and has been requested by researchers, clinicians, the health industry and patient organisations for several years.

The number of clinical studies in Norway is on a negative, spiralling trend. This is especially alarming for cancer patients, who are eager to receive novel treatments.

The Norwegian Health Minister Bent Høie now sets the goal to double the number of clinical studies in Norway and include 5% of all patients in the specialist health services before 2025.

“The action plan includes many important points, we believe the bar should be raised higher,” commented Ketil Widerberg, general manager of Oslo Cancer Cluster.

“Our goal should be to make clinical studies available for all cancer patients in Norway – not just a small fraction.”

The government also announced in the State Budget proposal in October 2020 that NOK 30 million will be allocated through the NorTrials scheme. The funds will be used to employ study nurses and improve competency in clinical research.

The Norwegian Health Minister also calls for a change in work culture, in order to make clinical trials an integrated part of patient treatment.

Another major obstacle is the difficulty to recruit patients quickly. The regional health authorities are now tasked with developing a best practice for patient recruitment.

Oslo Cancer Cluster contributed input to the development of this political paper in September 2019. Our major suggestions included:

  • the need for financial incentives to improve patient recruitment,
  • establishing Norway and the Nordic countries as an international testbed for innovative medicine,
  • authorities to collaborate with industry on guidelines on how to approve precision medicine treatments and the documentation requirements.

Read our entire input here (in Norwegian): Innspill Kliniske Studier til Helse- og omsorgsdepartementet (September 2019) fra Oslo Cancer Cluster

 

Sign up for our monthly newsletter to see the latest news and events

Landmark public-private agreement for precision cancer medicine

Scroll down to read the press release in Norwegian.

While more than 30 000 Norwegians are diagnosed with cancer every year and the incidence is still increasing, more precise treatments can save lives. CONNECT is a new initiative aiming to ensure that precision medicine reaches the patients.

“A serious cancer disease is an existential challenge for the individual. Cancer research gives hope. The pharmaceutical industry and the public health sector, clinicians and executive authorities, have to collaborate to offer new treatments, balancing the latest research with hospital operations,” says Åsmund Flobak, Oncologist at St Olav’s Hospital, Trondheim University Hospital.

The new initiative, called CONNECT (Norwegian Precision Cancer Medicine Implementation Consortium), is a direct response to Health Minister Bent Høie’s political guidance to accelerate the implementation of precision medicine for Norwegian patients. It also responds to the Health Minister’s ambition to increase research and collaboration between public and private actors, including hospitals, other public stakeholders, the Norwegian Cancer Society, and the pharmaceutical industry.

CONNECT is one of four interconnected initiatives that will ensure infrastructure and collaboration on diagnostics, clinical trials, implementation of advanced precision medicine and use of health data e.g. for health economics analysis. This could eventually affect how Nye Metoder (The National System for Managed Introduction of New Health Technologies within the Specialist Health Service in Norway) is adapted for personalized medicine and treatments for small patient groups in cancer.

See the fact boxes about the different initiatives at the bottom of this page.

Precision medicine for the future

Precision medicine, or personalised medicine, is a type of treatment tailored to the individual patient based on individual diagnostic and clinical information. In simple words, it is about giving the right treatment to the right patient at the right time.

“The research front is continuously moving forward. With modern technology, today’s clinicians can analyse specific changes in the cancer of each patient. There are individual changes in a patient’s tumour that can be treated with targeted therapies tailored to every individual patient,” says Bjørn Tore Gjertsen, Director of Research at Haukeland University Hospital, Helse Bergen Health Trust.

“Precision medicine changes healthcare. The implementation of precision medicine requires new types of interactions and partnerships among patients, clinicians, companies, regulators, and payors. CONNECT is a new public-private partnership allowing all stakeholders to jointly address key obstacles and piloting novel solutions,“ says Jutta Heix, Project Manager for CONNECT and Head of International Affairs at Oslo Cancer Cluster.

A nationwide effort towards a common goal

CONNECT is a unique national partnership where the central players join forces to accelerate the implementation of precision medicine.

All six university hospitals in Norway are partners in CONNECT. More than ten leading pharmaceutical companies have joined the initiative so far. As representative for patients, the Norwegian Cancer Society will play a central role.

“We are also having a good dialogue with the Norwegian Directorate of Health, the Norwegian Institute of Public Health and the Norwegian Medicines Agency about participating in CONNECT and contributing with their competency. The Institute of Public Health joins as an observer from the start and the Directorate of Health has expressed an intention to join as an observer as well,” says Kjetil Tasken, Head and Director of the Institute for Cancer Research at Oslo University Hospital.

Karen Marie Ulshagen, Area Director at the Norwegian Medicines Agency, says in a comment that the Medicines Agency supports the project and intends to engage.

“A culture for public-private collaboration is not created through strategic plans, political ambitions or celebratory speeches, but through actions and behaviours that set a new standard. CONNECT is not about money or donating pharmaceuticals. It is the combined expertise of the different players and agencies that will increase the competency essential to ensure the implementation of precision medicine. Novartis is happy to participate, and I think that is true for the other industry players too,” says Lars Petter Strand, Head of Medical, Novartis Oncology Norway. He has worked closely together with representatives from Roche, BMS and Merck in the working group for CONNECT.

CONNECT and the associated public initiatives work towards common goals: giving patients access to medicines they otherwise wouldn’t receive, increasing the precision medicine experience of clinicians and researchers nationwide, generating data and insights important for analysing the outcomes and adopting health technology assessments for these new treatment concepts. Via CONNECT a structured dialogue, information sharing and planning for national precision medicine and diagnostics will be established, with Oslo Cancer Cluster having the coordinating role.

Unique public-private partnership

CONNECT will be an arena for all partners and stakeholders to address important issues and will ensure a balanced, broad, and informed approach and debate.

“This is a concrete and important milestone for public-private collaborations in the health sector and builds on the ambitions from, among other things, HelseOmsorg21. This is a completely new way to work in Norway and I hope it paves the way for more collaborative projects and pilots between private and public players in healthcare,” says Karita Bekkemellem, CEO of Legemiddelindustrien (LMI).

 

Press release in Norwegian:

Inngåelse av historisk offentlig-privat kreftsamarbeid

Mer enn 30 000 nordmenn diagnostiseres med kreft hvert år og antall krefttilfeller øker, mer presis behandling vil kunne redde liv. CONNECT er et nytt initiativ med mål å sørge for at presisjonsmedisin når pasientene.

– Alvorlig kreftsykdom er en eksistensiell utfordring for den enkelte. Kreftforskning er håp. Privat legemiddelindustri og offentlig helsevesen, både behandlere og overordnet byråkrati, må samarbeide for å kunne tilby ny behandling i grenseflaten mellom forskningsfront og sykehusdrift, sier Åsmund Flobak, lege ved Kreftklinikken St Olavs hospital.

Det nye initiativet, som kalles CONNECT, er en direkte respons til helseminister Bent Høies ønske om å akselerere implementering av presisjonsmedisin for norske pasienter. Det svarer også helseministerens ønske om mer forskning, og aktivt samarbeid mellom offentlige og private aktører som blant annet sykehus, andre offentlige interessehavere, Kreftforeningen og legemiddelindustrien.

Avtalen er en del av flere initiativ som vil sikre en infrastruktur og samarbeid for diagnostikk, kliniske studier, implementering av avansert presisjonsmedisin og bruk av helsedata til blant annet helseøkonomiske analyser. Dette vil etter hvert kunne påvirke hvordan systemet for Nye Metoder tilpasses persontilpasset medisin og behandlinger til små pasientgrupper innen kreftområdet.

Se faktaboks om de ulike initiativene nederst i saken.

Presisjonsmedisin for fremtiden

Presisjonsmedisin, eller persontilpasset behandling, er en form for kreftbehandling som er tilpasset spesielt den enkelte pasient. Kort fortalt handler dette om å gi riktig medisin til riktig pasient og til riktig tid.

– Forskningsfronten flytter seg stadig fremover, og med moderne teknologi kan leger i dag undersøke detaljerte forandringer i kreftsvulster hos hver enkelt pasient. Det finnes individuelle forandringer i arvestoffet som kan behandles med målrettede behandlinger som er tilpasset hvert enkelt individs behov sier Bjørn Tore Gjertsen, forskningssjef, Helse Bergen

– Presisjonsmedisin forandrer hele helsetjenesten og krever nye typer samarbeid og partnerskap mellom pasienter, klinikere, selskaper, regulatoriske myndigheter og betalere. CONNECT er et helt nytt offentlig-privat samarbeid som vil gi alle parter felles muligheter for å adressere utfordringer og prøve nye løsninger, sier Jutta Heix, prosjektleder for CONNECT og leder for internasjonal kontakt i Oslo Cancer Cluster.

Samler hele Norge for felles mål

CONNECT er et unikt partnerskap der alle de sentrale aktørene er samlet for å akselerere innføringen av presisjonsmedisin.

Alle seks universitetssykehus i Norge er med som partnere. Over ti ledende legemiddelselskaper har også gått med i initiativet. Som representant for pasientperspektivet er Kreftforeningen sentral.

– Vi har også hatt en god dialog med Helsedirektoratet, Folkehelseinstituttet og Legemiddelverket om å delta i CONNECT og bidra med sin kompetanse. Folkehelseinstituttet kommer inn som observatør fra starten, Helsedirektoratet har uttrykt en intensjon om å være med som observatør i CONNECT, sier Kjetil Tasken, leder for Institutt for Kreftforskning ved Oslo Universitetssykehus.

Karen Marie Ulshagen, Områdedirektør, SLV sier i en kommentar at Legemiddelverket støtter prosjektet og har en intensjon om en nærmere tilknytning dersom det er mulig.

– Kultur for offentlig-privat samhandling skapes ikke ved strategiske planer, politiske ambisjoner eller festtaler, kun gjennom handling og adferd som setter en ny standard. CONNECT handler ikke om penger eller donasjon av legemidler, det er den faglige ekspertisen fra de ulike aktører og instanser som utgjør kompetanseløftet som er essensielt for å sikre innføring av presisjonsmedisin. Novartis er glad for å kunne ta del i dette, og det tror jeg gjelder de andre industriaktørene også, sier Lars Petter Strand, Medisinsk Direktør i Novartis. Han har arbeidet tett sammen med representantene fra firmaene Roche, BMS, Merck i arbeidsgruppen for CONNECT.

Målet er at CONNECT og de underliggende initiativene sammen kan bidra til å gi pasienter tilgang til medisiner som de ikke ellers ville fått, helsepersonell og forskere får unik erfaring med denne type medisiner og diagnostikk, og helsevesenet vil få data og erfaring fra hvordan presisjonsmedisin fungerer og påvirker måten vi i dag regner helseøkonomi. Gjennom CONNECT skal det etableres strukturert dialog, kunnskapsutveksling og planlegging for persontilpasset medisin og diagnostikk hvor Oslo Cancer Cluster vil ha den koordinerende rollen.

Unikt offentlig-privat samarbeid

Alle medlemmer og interessenter vil kunne ta opp saker som er viktige for dem, da målet er at CONNECT blir en arena som sikrer en bred, balansert og informert debatt.

Dette er et konkret og viktig løft for offentlig-privat samarbeid på helsefeltet og bygger videre på ambisjonene fra blant annet HelseOmsorg21-rådet. Det er en helt ny måte å jobbe på i Norge og jeg håper det baner vei for flere samarbeidsprosjekter og piloter mellom private og offentlige helseaktører, sier Karita Bekkemellem, Administrerende direktør i Legemiddelindustrien (LMI).

 

Fact boxes:

InPreD (Infrastructure for Precision Diagnostics) is a national infrastructure for advanced molecular diagnostics that will secure a robust, interactive structure facilitating clinical cancer trials on a national level by providing equal access for patients to advanced diagnostics, state-of-the art competence and technology.
IMPRESS-Norway (Improving public cancer care by implementing Precision medicine in Norway) is a prospective, non-randomized clinical trial evaluating efficacy of commercially available, anti-cancer drugs prescribed for patients with advanced cancer diagnosed with potentially actionable alterations as revealed by standardized molecular diagnostics. IMPRESS-Norway is a nation-wide study and all hospitals with an oncology and / or hematology department will be invited to participate in the study. As of December 2020, 17 Norwegian Hospitals have agreed to join IMPRESs. The study will use a combined umbrella and basket design and a Simon two-stage model of expanding cohorts to follow up potentially effective combinations of biomarker and drug on specific indications. Sampling of biological material will be performed at presentation, during treatment and upon progression. Additional biomarker and translational analyses including whole genome sequencing (WGS) on tumour material and liquid biopsies, identifying mechanisms underlying drug sensitivity versus resistance will be performed.
INSIGHT (Regulatory framework for implementing precision medicine into the Norwegian health care system) will develop an analytic framework for using synthetic control data for evaluating effects of small-scale one-armed clinical trials, as in IMPRESS-Norway. INSIGHT will use the developed control arms and data from IMPRESS-Norway and InPreD to evaluate cost-effectiveness of the PCM-model and suggest new reimbursement scheme that reflects the uncertainty in PCM. Concrete ethical and legal challenges when integrating clinical research as part of standard-of-care e.g. the need for informed consent, access and data sharing, storage of molecular data as part of diagnostic pipeline will also be addressed. Taken together, the project will deliver fundamental knowledge and suggest regulatory changes/models necessary for implementation of PCM.

 

CONNECT Founding Partners:

  • Akershus universitetssykehus HF
  • Helse Bergen HF
  • Helse Stavanger HF
  • Olavs hospital HF
  • Universitetssykehuset Nord-Norge HF
  • Oslo Universitetssykehus med Kreftregisteret og OUH Comprehensive Cancer Center
  • Folkehelseinstituttet
  • Oslo Cancer Cluster SA
  • Kreftforeningen
  • Legemiddelindustrien
  • Roche Norge AS
  • Bristol-Myers Squibb Norway Ltd NUF
  • Novartis Norge AS
  • Merck AB NUF
  • Takeda AS
  • Amgen AB Norge NUF
  • AstraZeneca AS
  • AbbVie AS
  • Bayer AS
  • PubGene AS
  • Pfizer Norge AS
  • NEC Corporation

 

 

Oslo Cancer Cluster’s highlights 2020

Networking events, political meetings, ambitious students, funding for SMEs and expansion of the laboratory… Here is a “pick and mix” of our many news from the past year.

Another year has passed and as we look back on a year filled with both challenges and successes, we are inspired with renewed energy to continue our work in 2021. It is never easy to summarise an entire year in only a few paragraphs, but here is an attempt to present a variety of the many positive experiences, fruitful meetings and engaging activities that Oslo Cancer Cluster has enjoyed.

 

Cancer Crosslinks 2020

The speakers, chairpersons, introducers and organizers of Cancer Crosslinks 2020

The speakers, chairpersons, introducers and organizers of Cancer Crosslinks 2020. Photo: Oslo Cancer Cluster

The year began with the 12th Annual Cancer Crosslinks on 16 January. This year’s topic “Progress in Cancer Care – A tsunami of promises or Game Changing Strategies?” included engaging presentations by leading international and Norwegian experts on the latest advances in immune-oncology. These sparked stimulating discussions between colleagues in the networking breaks. Cancer Crosslinks 2020 was one of the few physical meetings this year and gathered more than 350 delegates from all of Norway and abroad at the Oslo Cancer Cluster Innovation Park.

Please visit the official Cancer Crosslinks website at https://www.cancercrosslinks.com to register for Cancer Crosslinks 2021, which will be presented digitally on 21 January.

 

Oslo Cancer Cluster Incubator developed cell therapy lab

Björn Klem and Janne Nestvold celebrate that the Oslo Cancer Cluster Incubator has been nominated among Europe's 20 best incubators.

Bjørn Klem, general manager, and Janne Nestvold, laboratory manager, at Oslo Cancer Cluster Incubator. Photo: Oslo Cancer Cluster.

Oslo Cancer Cluster (OCC) Incubator invested in the laboratory’s cell therapy infrastructure, thanks to a grant from the Oslo City’s Regional Innovation Programme. Moreover, Radiumhospitalets Legater have kindly donated a valuable instrument, called a Seahorse, which was set up in the OCC Incubator in November, to boost research into cancer cells further. Cell therapies have the potential to cure cancer and turn it into a chronic disease. More research is however needed to document the full potential of cell therapies and the OCC Incubator is happy to facilitate this.

Please visit Oslo Cancer Cluster Incubator’s website to learn more about their facilities and services

 

First-year researchers held poster session

Linnéa M. Skille, May Dagny Kollandsrud Hutchings, Tonje Marie Bjørklund Hopen and Elakhiya Dushyanthan presented their research project at the school's poster session. Photo: Elisabeth Kirkeng Andersem

Linnéa M. Skille, May Dagny Kollandsrud Hutchings, Tonje Marie Bjørklund Hopen and Elakhiya Dushyanthan presented their research project at the school’s poster session. Photo: Elisabeth Kirkeng Andersem

Oslo Cancer Cluster has collaborated with Ullern Upper Secondary School for several years to inspire students to pursue careers in science, research and entrepreneurship. In 2019, we launched the research programme in partnership with the school and this year marked the end of its first year. The grand finale was a real poster session, similar to those at large science conferences, where the students presented their research projects to their mentors. We are proud of these talented, ambitious students and delighted to follow their journey onwards.

Please visit our School Collaboration website for more information

 

Oslo Cancer Cluster joined Oslo Science City

Christine Sørbye Wergeland, CEO of Oslo Science City, was delighted to welcome Oslo Cancer Cluster as a new member in June. Photo: Oslo Science City

Christine Sørbye Wergeland, CEO of Oslo Science City, was delighted to welcome Oslo Cancer Cluster as a new member in June. Photo: Oslo Science City

Oslo Cancer Cluster joined Oslo Science City, the first innovation district in Norway, in June 2020. The district already includes more than 30 000 students, 7 500 researchers, the country’s foremost universities, hospitals and world-class research institutions, as well as more than 300 companies. Now, the aim is to become a world leading innovation district that contributes to research excellence, jobs creation, the green shift and sustainable economic development. Oslo Cancer Cluster is eager to contribute to Oslo Science City to solve the hard problems of the future, such as cancer.

Please visit Oslo Science City’s official website to learn more

 

Ministers met at Oslo Cancer Cluster

Danish Foreign Minister meets with Norwegian Trade Minister at Oslo Cancer Cluster

Ministers Jeppe Kofod and Iselin Nybø met at Oslo Cancer Cluster Innovation Park in August 2020. Photo: The Embassy of Denmark in Norway

Oslo Cancer Cluster was honoured by a visit from the Foreign Minister of Denmark Jeppe Kofod and the Minister for Trade, Industry and Fisheries Iselin Nybø in August 2020. The ministers discussed current topics, such as export, international trade and foreign investments. The ministers also listened to presentations from key representatives from the health industry on the potential of Nordic collaboration on life science and cancer. A central issue was how to reduce the development time of cancer treatments from 10 to 5 years, and to make the Nordics a destination for health innovation.

 

Oslo Cancer Cluster Innovation Park 5-Year Milestone

Five years ago, Prime Minister Erna Solberg was welcomed by Jónas Einarsson, founder of Oslo Cancer Cluster, at the opening of the Oslo Cancer Cluster Innovation Park. Photo: Gunnar Kopperud

Five years ago, Prime Minister Erna Solberg was welcomed by Jónas Einarsson, founder of Oslo Cancer Cluster, at the opening of the Oslo Cancer Cluster Innovation Park. Photo: Gunnar Kopperud

This year marked five years of innovation in Oslo Cancer Cluster Innovation Park. The milestone was commemorated with a virtual event that will be live until 31 December 2020. The virtual event includes greetings from Prime Minister Erna Solberg, perspectives from members of Oslo Cancer Cluster, reflections from stakeholders in the Oslo Cancer Cluster Innovation Park and comments from Innovation Norway, SIVA and the Research Council of Norway.

 

Leading the way for precision medicine

Dr. Kjetil Taskén, Dr. Åslaug Helland and Dr. Hege Russnes are part of the enthusiastic team at Oslo University who are behind the national study IMPRESS. Photo: Oslo University Hospital

Dr. Kjetil Taskén, Dr. Åslaug Helland and Dr. Hege Russnes are part of the enthusiastic team at Oslo University behind the national study IMPRESS. Photo: Oslo University Hospital

IMPRESS-Norway, a national clinical study starting in 2021 working towards implementing cancer precision medicine in Norway, was officially announced in October. IMPRESS involves the active support of leading global pharmaceutical companies that will provide the study drugs and contribute with per patient fees. Public funding will help to ensure this innovative study paves the way for more cancer clinical trials in Norway. A new public-private partnership called CONNECT is also being established with Oslo Cancer Cluster as project coordinator. CONNECT will provide an arena for all stakeholders to jointly address key obstacles and to pilot novel solutions to advance the implementation of precision cancer medicine.

 

DIGI-B-CUBE funding for SMEs

DIGI-B-CUBE Open Call Deadline no 1 Results in Numbers

The first round of voucher applications by SMEs in the DIGI-B-CUBE project was a success. On 29 August 2020, the successful applicants were announced, with funding support of more than 1,4 million euros to SMEs for fostering cross-sectoral Innovation. Of the 217 applications, 22 SMEs were granted financial support to implement their customized solution innovation ideas with an overall budget of more than 1 million euros, ranging from topics like a sleep apnea test device, to Covid-19 monitoring, to in-vitro cellular immunoassays. In addition, 21 SMEs with an overall budget of more than 400 000 euros will be financially supported by the DIGI-B-CUBE project to implement their prototypes.

Please visit DIGI-B-CUBEs official website to learn more

 

Oslo Cancer Cluster events went digital

The Organising Partners from Europe and North America opened the first virtual version of the International Cancer Cluster Showcase this year.

The Organising Partners from Europe and North America opened the first virtual version of the International Cancer Cluster Showcase this year.

This year we had to think of new, creative ways to meet and deliver key events in a new format. Here is a selection of this year’s virtual events:

In May, we live-streamed a political meeting on integrating clinical studies in standard patient care in Norway from Oslo, in collaboration with Kreftforeningen, LMI, MSD, AstraZeneca and Janssen.

On 8 June 2020, the 9th International Cancer Cluster Showcase was launched as a virtual event presenting 20 early-stage oncology companies and sparking record-high participation with about 400 registrations.

During Oslo Innovation Week in September 2020, we arranged the virtual event “What does it take to impact innovation?”, with talks from stakeholders who inspire innovation, protect innovation and provide the necessary tools for innovation.

As a long-standing conference supporter of EHiN “E-health in Norway”, we participated in the first-ever fully digital EHiN in several sessions, covering current topics such as gene technology, artificial intelligence and health data.

Please visit the Oslo Cancer Cluster Event Calendar for an overview of all upcoming events.

 

New members announcement

The Oslo Cancer Cluster member wheel gives a glimpse of the membership base, which has grown this year.

The Oslo Cancer Cluster member wheel gives a glimpse of the membership base, which has grown this year.

During 2020, Oslo Cancer Cluster has welcomed several new members to our organization. We are happy to announce that the following companies have joined us and been introduced to the rest of the cluster: Glaxo-Smith Kline, Hubro Therapeutics, Kaiku Health, Ledidi, Hemispherian, PharmaRelations, Vesteraalens, Adjutec Pharma, K og K and Worldwide Clinical Trials.

Please visit the Oslo Cancer Cluster Member Overview to see all our members and to visit their websites.

 

 

Sign up for our monthly newsletter to see the latest news and events

Mentor meeting: many roads to reach your goal

The second-year class of the Researcher Programme at Ullern Upper Secondary School has been assigned new mentors for the school year 2020/2021. The first meeting with the mentors was about how the road to becoming a researcher or doctor or other occupation can be diverse and take many different routes.

This article was originally published in Norwegian on our School Collaboration website.

The students in the second year of the Researcher Programme at Ullern Upper Secondary School are used to having mentors guiding them during the school year, and inspiring and challenging them. This year, all the mentors, except for Øyvind Kongstun Arnesen, are new to the students. These are the mentors:

  • Henrik Sveinsson, a physics researcher at the University of Oslo,
  • Steven Ray Wilson, a chemist and professor at the University of Oslo,
  • Janne Nestvold, laboratory manager at Oslo Cancer Cluster Incubator,
  • Severin Langberg, a PhD student in machine learning and cancer at the Norwegian Cancer Registry (absent from this meeting).

The meeting included introductions of all the mentors and a Q&A session.

Henrik Sveinsson

“I was fascinated by the financial crisis in 2008 and how they used math to cover up the fraud in big banks like Lehman Brothers. I applied to Norway’s Business School in Bergen to study economy, but I learnt quickly that I should have gone to the University of Oslo to study social economics, so I did that instead. Coincidentally, I took up a physics course and became very interested in that, and ended up as a physicist.”

Henrik Sveinsson became interested in the financial crisis of 2008, and how math was used to cover up the economic situation in the big banks that led to the crisis. Photo: Elisabeth Kirkeng Andersen.

Henrik Sveinsson became interested in the financial crisis of 2008 and how math was used to cover up what the big banks were doing. Photo: Elisabeth Kirkeng Andersen.

 

Steven Ray Wilson

Steven studied psychology first, but then switched to chemistry, and is today professor at the Institute for Chemistry at the University of Oslo. He and his students work with pharmaceuticals, drugs and doping, and use chemistry to measure concentration levels in the body.

“Chemistry was the core of everything I thought was cool,” he said to the students of the Researcher Programme about why he chose to study chemistry.

Steven is also a musician, has worked professionally as a musician for periods and even won the Norwegian music award “Spellemanspris”. He encourages the students to have a passion besides their jobs. In one of the research projects he leads, they are cultivating mini-organs to faster test the efficacy and side-effects of drugs, as an alternative to animal testing.

Steven Ray Wilson to the left in the image, tells the students about his experiences from a combined life as a researcher and musician. Photo: Elisabeth Kirkeng Andersen

Steven Ray Wilson (to the left) tells the students about his experiences from combining careers in research and music. Photo: Elisabeth Kirkeng Andersen

 

Øyvind Kongstun Arnesen

Øyvind is a doctor by education, has worked as a surgeon and led the cancer vaccine company Ultimovacs. He tells the students that the road to get there was not always straightforward:

“I dropped out of upper secondary school and went for a long time on unemployment activities as a youth. One of the jobs was to clean test tubes in the laboratory at the Dentist School. After a while, I got more fun assignments and even participated in research into fluor in drinking water, among other things. Then, I finished upper secondary school by picking up some courses and worked at Dikemark as an unskilled worker. That was when I decided to study medicine and retook some subjects to be accepted to the medical programme.

“After that, I worked a lot with developing a vaccine against a contagious form of meningitis at the Norwegian Institute for Public Health. I am very proud to have been a part of that because this vaccine now saves hundreds of thousands of people’s lives.”

Janne Nestvold

Janne manages the research laboratory at Oslo Cancer Cluster Incubator and helps biotech start-ups. She has a PhD in immunology and a background as a cancer researcher at the Institute for Cancer Research, and several other places. Before her career in research, she studied social anthropology and worked with drug addicts in Oslo. That was when she became interested in the combination of drugs and psychology and began to study biology.

Image caption: Janne Nestvold today manages the laboratory in Oslo Cancer Cluster Incubator and has a background in both social anthropology and cancer research. Photo: Elisabeth Kirkeng Andersen.

Janne Nestvold today manages the laboratory in Oslo Cancer Cluster Incubator and has a background in both social anthropology and cancer research. Photo: Elisabeth Kirkeng Andersen.

 


Questions & Answers


Steven, what kind of music do you like – besides your own band?

“To play in a band and be creative is in many ways like being a researcher. Miles Davies is my biggest musical hero. He was extremely innovative and a tough guy unafraid to make any mistakes. When the band played something wrong, the point was to use the mistake to make something completely new in the music.

“Making mistakes is more about how you handle them than anything else. It is about being able to use the imperfect creatively, which I always remember in life, both generally and in research.”

 

Øyvind, how was everyday life when you worked as a surgeon?

“When I worked shifts as a surgeon, they would go on for about 27 hours. We would start at 7:00 am in the morning with a meeting, where we would learn something new. Then, we reviewed all the patients scheduled for surgery that day and assigned the tasks and surgeries among ourselves. The shift team got the easiest surgeries, so we could help the surgeons in the emergency room at Oslo University Hospital when seriously injured patients were admitted. If you were lucky, you got to sleep a little during the night.

“Then, it was the next morning. We had another meeting to report what had happened during the shift, and then we were supposed to visit the patients. I refused to do that, because it is not acceptable for the patients that an exhausted, tired doctor comes in to talk with them.”

The students listened intently to all the advice from their new mentors: Steven, Henrik, Øyvind and Janne. Photo: Elisabeth Kirkeng Andersen.

The students listened intently to all the advice from their new mentors: Steven, Henrik, Øyvind and Janne. Photo: Elisabeth Kirkeng Andersen.

 

Janne, how do you get a reliable result when you perform research?

“Preparations make up half the work. I worked a lot with animal testing, which means you must think through everything before the experiment. For example, the accurate dosage for sick animals and healthy animals. It is very expensive to do these experiments, so it is important that everything is set up correctly. Afterwards, you analyse the results in a research group, and then you publish the results. If others cite your research, it spreads in the environment, and has an impact on other research in the same field.”

 

Question for everyone: why do you want to be our mentors?

Janne: “I want you to know that a career in science is an exciting path to take. Every day you are in the middle of everything here at Oslo Cancer Cluster Innovation Park. There are a lot of opportunities here with the Incubator and the Institute for Cancer Research. I want to show you what some of those opportunities are.”

Steven: “It is fun to follow your journeys. As I told you earlier, I have been a mentor for over 40 students so far, and it is like being in a time machine. In a couple of years, you will do academic and professional things that are amazing, so it is fun to participate and observe and help a little in your lives.”

Henrik: “I am not completely sure, but I accepted the offer immediately. It feels important, when I think it through now, to give you an insight into physics and to contribute to the choices you will make.”

Øyvind: “Some of the most fun things I do are to teach, and I can’t decline when I am the Chairman of Oslo Cancer Cluster (jokingly). Honestly, it is fun for me to contribute as your mentor, so that is the reason.”

 

The mentors gathered with one metre distance apart. From left to right: Steven Ray Wilson, Henrik Sveinsson (behind), Øyvind Kongstun Arnesen (in front) and Janne Nestvold. Photo: Elisabeth Kirkeng Andersen.

The mentors gathered with one-metre distance apart. From left to right: Steven Ray Wilson, Henrik Sveinsson (behind), Øyvind Kongstun Arnesen (in front) and Janne Nestvold. Photo: Elisabeth Kirkeng Andersen.

 

Sign up for our monthly newsletter to see the latest news and events

 

Ketil Widerberg, general manager, Oslo Cancer Cluster.

More precise cancer treatments with digital solutions

Ketil Widerberg, general manager of Oslo Cancer Cluster, gives his perspectives on why EHiN and digital health are important for faster development of new cancer treatments in Norway.

 

This interview was first published on EHiN’s website in Norwegian.

 

What do you think are the biggest challenges in the health sector today?

One challenge in cancer treatments is to give the right medicine to the right patient at the right time. This is called precision medicine and means that cancer treatments can to a greater extent be tailored to the individual patient. The government recently proposed more money for this in the State Budget for 2021. There are already digital tools that can identify more targeted treatments ready to be put to use. One example is our member NEC OncoImmunity, who are using artificial intelligence to develop new personalised immunotherapies against cancer.

Another big challenge is to shorten the development time for new cancer medicines. The corona pandemic has shown us that it is possible to quickly develop new treatments, initiate clinical studies and gather data. The analysis of health data will be essential for the development and approval of new treatments. It is important that national infrastructure, such as the Health Analysis Platform, is put in place. One inspiring company is our member Ledidi; their software solution was recently approved for all Covid-19-studies at Oslo University Hospital. This tool can also be used in cancer research to make quick statistical analysis and to cooperate across research groups, hospitals and countries.

A third challenge is how we involve the cancer patient in their own treatment. New technology, for example the data platform from our member Kaiku Health, enables the patients to self-report symptoms in real-time. If we can gather data on pain and side effects every day, instead of every third month, our understanding of cancer improves and the doctor can do a better job.

 

How can you contribute digitally to the health sector?

Oslo Cancer Cluster contributes to the digitalisation of the health sector by connecting pharmaceutical companies and biotech start-ups in cancer with tech companies.

Among other things, we are coordinating the Horizon 2020 EU-project “DIGI-B-CUBE”, which provides funds to collaboration projects between small to medium-sized companies in IT and health. They try to find digital solutions to challenges in the health sector.

Our cluster is also a part of the consortium «NORA EDIH – Norwegian Artificial Intelligence Research Consortium» that was recently selected as one of eight Digital Innovation Hubs that Innovation Norway will recommend to Digital Europe Programme. These innovation centres will be essential to stimulate increased use of digital solutions.

 

How has Covid-19 affected you?

Oslo Cancer Cluster Incubator has put several measures in place to keep laboratories and offices open to ensure that important cancer research and patient treatment can continue as normal during the pandemic. Start-ups, researchers and the incubator have received more support from the financial apparatus for business development, in order to strengthen the health industry in this period of uncertainty. In addition, the Incubator has updated its IT infrastructure to facilitate the increased use of digital solutions from home offices and streaming of meetings and events.

Covid-19 has proven that the health industry is important for society – to fight pandemics, to contribute to better health and to create value. Norwegian companies in health experience great interest from investors now. One example is our member Vaccibody, who signed the largest biotechnology agreement in Norway ever this month and later was listed on Merkur Market (Oslo Stock Exchange), valued at NOK 17 billion.

Covid-19 has also created challenges for cancer patients that missed treatments because of the risk of getting infected and for those who have avoided important health checks because they don’t want to put any extra stress on the health services. Pharma companies experienced a challenge to keep clinical trials running in the beginning of the pandemic, but most hospitals have facilitated this now.

One positive side-effect of the pandemic is that social distancing has led to a rapid digitalisation of the health sector and put digital health at the top of the agenda.

 

What do you expect from EHiN?

EHiN is an arena that connects cross-sectional initiatives in digitalisation and biology across public institutions and private companies. It is a meeting place to find good digital solutions that can be implemented in the health sector and can position Norway internationally in long-term trends, which also creates great value for society.

At EHiN, you will meet different decision makers and participate in setting the political agenda for e-health. We need to continue to stress the importance of good public-private collaboration to develop, test and approve treatments for cancer patients.

 

What else would you like to communicate?

EHiN is important because collaboration is the key to create changes in health. We are working now with an application to become a health catapult centre, in collaboration with several innovation environments in health. If we succeed, we can strengthen the health industry by offering important services to small and medium-sized enterprises in digital health.

We also think it is very positive that the Norwegian Cancer Society have a good collaboration with EHiN. It shows how important e-health in Norway is for the entire cancer community.

 

Meet Ketil Widerberg as he moderates the session “Fremtidsmennesket” on 10 November 2020 at 11:00-12:00 during EHiN 2020. 

Register to EHiN here

 

Sign up for our monthly newsletter to see the latest news and events

First-year students met their mentors

This fall, 32 students have begun their first year of the Researcher Programme at Ullern Upper Secondary School. Earlier in October, they met their four mentors, who will support them throughout the school year – and the mentors include some big names in the field.

Thirty-two nervous first-year students are sitting in Jónas Einarsson Auditorium. They are all attending the Researcher Programme. This is a unique opportunity for young people in Oslo who wish to immerse themselves in science, especially in biomedicine, and gain a more practical introduction to subjects like maths, physics, chemistry, biology, and IT and programming.

First of three meetings

Ragni Fet, former cancer researcher and currently biology teacher at Ullern school, is responsible for the first-year students at the Researcher Programme.

“It is nice to see all of you here and it is my pleasure to introduce the four mentors to you,” Fet says.

The mentors are:

  • Vegard Vinje, researcher at Simula and former Ullern student
  • Jónas Einarsson, CEO of Radforsk and initiator of Oslo Cancer Cluster and Oslo Cancer Cluster Innovation Park
  • Simone Mester, PhD student and former Ullern student
  • Bjørn Klem, general manager of Oslo Cancer Cluster Incubator and former Head of Research at Photocure.
The mentors. From left to right: Vegard, Jónas, Simone and Bjørn. Photo: Elisabeth Kirkeng Andersen.

The mentors. From left to right: Vegard, Jónas, Simone and Bjørn. Photo: Elisabeth Kirkeng Andersen.

Fet tells the students that they will meet the four mentors today and twice more during the school year. The next time the visit will take place at one of the mentor’s workplaces. Read more about what the students of the Researcher Programme (2019/2020) experienced when they visited Simone Mester at her workplace in December 2019.

The following time, the students will present their own research to the mentors and receive an evaluation from them. Read more about the type of research the students of the Researcher Programme (2019/2020) presented to their mentors.

“Today you can ask the mentors as many questions you like about their choices concerning education, focus, career, what they have learnt and experienced, and what they are doing today. Please feel free to ask your questions,” Fet says.

Question time

The students are eager to ask their questions to Vegard, Jónas, Simone and Bjørn during the next hour. It is obvious that the students have done some in-depth research on their four mentors.

When the question time was over, Jónas said:

“This was fun! You asked us good and interesting questions. This was both educational and entertaining for me too.”

You can read some of the questions and answers that occurred during the course of the hour they spent together below.

Q&As

Question: What is the most exciting thing you have experienced during your careers?

Vegard:

I was interviewed by NRK radio and they produced an article about our research. The research is about how breathing affects flows in the brain, something that can help to clear the brain from toxins.

An accumulation of toxins in the brain can be associated with an increased risk to develop Alzheimer’s disease, so NRK’s angle was: “Norwegian study: Your breathing can play a part in Alzheimers” even though our research does not say anything about causation. In the comments under the piece, the conclusion was practically “Yoga is good for the brain”, since breathing is an essential part of yoga.

It was interesting to see how our research was communicated so differently from what our work actually was.

The first-year students of the Researcher Programme listened intently to the mentors' stories. Photo: Elisabeth Kirkeng Andersen.

The first-year students of the Researcher Programme listened intently to the mentors’ stories. Photo: Elisabeth Kirkeng Andersen.

Jonas:

My biggest moment was two years ago when I was sitting at a science conference on immunotherapy against cancer in New York. The same day, it was announced that the two researchers Tasuku Honjo and James Allison had been awarded the Nobel Prize in Medicine for their discovery of how checkpoint inhibitors, a form of immunotherapy, can make the body’s own immune system fight cancer.

When the conference opened, Jim – which is James Allison’s nickname – came into the auditorium to give a presentation. This had already been decided long ago and had nothing to do with the Nobel Prize. The whole room stood up and clapped. That was huge. Jim was also here last year and visited the students who are now in the second year of the Researcher Programme.

Simone:

When I was finished with my master I was accepted into SPARK, which is the University of Oslo’s innovation programme. Because of that, I was also invited to Arendalsuka to present my project to many important people, and it was a big thing for me to be able to contribute.

In addition, it is always big when I experience an Eureka! moment in the laboratory: it is fun when you get a result that proves that your theory actually works.

Bjørn:

To find solutions to different things is what I like the most. If I had to choose one individual event, it would have to be this: I had worked for a long time in Photocure as Head of Research, and developed a medical device called Cevira, which is made to treat cervical cancer. We tested it in humans and it had good results, but then it was put on hold for many different reasons.

Then, about one year ago, the news came that a Chinese company had licensed this product for billions of NOK. They are already underway with the last part of the testing of Cevira, so maybe it will enter the market and be used by women all over the world in only a few years. I knew this product would work, so it is fun it is no longer forgotten about.

Question: Where do you think your research careers will take you, Simone and Vegard?

Vegard:

I dream about finding out more about the different flows in the brain that I am doing research on, but I am not sure I will find the answers. It is a simple transition between research and private industry, so maybe I will start my own company in time.

Simone:

I really want to start my own company and it is scary to even say it, but I am already underway. To start a company and develop a pharmaceutical that can make a difference for patients would be fun. I think it is a very exciting and challenging journey, and I am lucky to have guides that help me to do this.

Question: Why are you working with what you are doing now?

Vegard:

When I think back, it seems completely random. I did not have a plan about what I wanted to become when I attended upper secondary school. I liked maths and physics, and got an education in that, which was really fun. When I completed my bachelor degree, I got a summer job at Simula. This was in 2013 and after that, they have continued to offer me work and research projects.

Jónas:

I am a doctor by education and worked for many years as a general practitioner in Western Norway. When I moved from Western Norway to Oslo because of family, I did not have any job to go to and I did not know what I wanted to do either. A friend of mine worked at the Radium Hospital’s Research Foundation and offered me a project-based position for six months so that I could have time to think about the future, and since then I have remained.

Bjørn:

I do not think it is completely random, even if Vegard and Jónas say so, but it seems like that for me too. I studied pharmacy and later I was hired into Photocure and afterwards, I ended up here in the Incubator. But it isn’t completely random. We are affected by our surroundings: just think about what you do here at Ullern and what you are exposed to in the Oslo Cancer Cluster Innovation Park. Even if things seem random sometimes, they are not.

Bjørn Klem tells about his background as a pharmacist. Photo: Elisabeth Kirkeng Andersen.

Bjørn Klem tells the students about his background as a pharmacist. Photo: Elisabeth Kirkeng Andersen.

Jónas:

What you are talking about, Bjørn, is called Serendipity and is a type of unplanned discovery or a positive surprise when looking for something else.

For example, I was a rascal during upper secondary school and I wanted to study medicine, but my grades were not nearly good enough for that. So one day, my brother who was the president of ANSA, the association for Norwegian students who study abroad, called me. He told me that all Icelandic people are accepted to the first year of medical school in Iceland, and since I am an Icelandic citizen, that became my way in. That is typical serendipity.

Simone:

I studied science at Ullern Upper Secondary School and thought medicine would be a safe choice. But I wasn’t really interested of patient care, which made me very unsure. I talked a lot with Ragni, who was my biology teacher, and she encouraged me to study molecular biology at the university.

I was lost and confused the first year, because I wanted to study and work with something that has a value and is of use to others: to make a difference. Luckily, I found the research group led by Jan Terje Andersen and Inger Sandlie, where I have received a lot of support to go my own way and be innovative.

By the way, Inger Sandlie is my role model as a researcher and innovator. She has the most innovations registered with Inven2, the tech transfer office of the University of Oslo and Oslo University Hospital, and is behind Vaccibody, that recently entered Norway’s largest agreement in biotechnology.

Simone and Ragni. Ragni Fet, a former cancer researcher and now biology teacher at Ullern was crucial in Simone’s study choice. Photo: Elisabeth Kirkeng Andersen.

Simone and Ragni. Ragni Fet, a former cancer researcher and now biology teacher at Ullern was crucial in Simone’s decision to study molecular biology. Photo: Elisabeth Kirkeng Andersen.

Articles about previous mentor meetings

 

Sign up for our monthly newsletter to see the latest news and events

IMPRESS leads the way for cancer precision medicine

IMPRESS Norway is a national clinical study starting in 2021 working towards implementing cancer precision medicine in Norway.

As one of the initiators behind IMPRESS-Norway, Oslo Cancer Cluster is thrilled to see this national clinical study in cancer precision medicine become a reality.

Precision medicine is an approach to patient care that allows doctors to select treatments that are most likely to help patients based on a genetic understanding of their disease, according to the National Cancer Institute.

During 2019, Oslo Cancer Cluster hosted a series of workshops with public and private stakeholders in cancer. The joint goal was to accelerate the implementation of cancer precision medicine in Norway. The initial idea for IMPRESS emerged in one of these workshops. A dedicated team, including Kjetil Taskén, Sigbjørn Smeland, Åslaug Helland and Hege Russnes, at Oslo University Hospital quickly turned it into a national effort together with colleagues at university hospitals across Norway.

IMPRESS involves the active support of leading global pharmaceutical companies that will provide the study drugs and contribute with per patient fees. Public funding will help to ensure this innovative study paves the way for more cancer clinical trials in Norway.

National infrastructure for precision diagnostics is needed and is currently being set up at all Norwegian cancer hospitals. Cancer patients who are eligible for clinical trials can soon be tested and selected based on their specific genetic profile.

A new public-private partnership called CONNECT is also being established with Oslo Cancer Cluster as project coordinator. CONNECT will provide an arena for all stakeholders to jointly address key obstacles and to pilot novel solutions to advance the implementation of precision cancer medicine.

In the newly released Norwegian state budget, an additional NOK 30 million is allocated for personalized medicine. NOK 25 million is earmarked for the implementation of genetic precision diagnostics at the Norwegian hospitals. This demonstrates a commitment from the Norwegian government to advance the implementation of precision medicine for Norwegian cancer patients.

Learn more: Read the article (in Norwegian) at Oslo University Hospital’s website or the English translation below.

 

IMPRESS NORWAY: Large national precision medicine study in cancer

IMPRESS-Norway, a large national study on precision medicine against cancer, starts in the beginning of 2021. The study will, based on individual and expanded gene analysis give its participants the opportunity to receive so-called off-label medicines, that is medicines approved for the treatment of other diseases, to fight their specific unique cancer disease.

IMPRESS-Norway is a national clinical cancer study in precision medicine. The goal with the study is to test approved pharmaceuticals on new patient groups based on their cancer type and genetic mutations (molecular profile). The study is open for all hospitals in Norway that treat cancer patients and so far, thirteen hospitals have decided to participate in the study.

In the study, we will, in addition to data on clinical efficacy, collect comprehensive information about the molecular changes in the cancer tumour, by performing a complete DNA analysis, whole genome sequencing. This will provide us with a unique and comprehensive dataset that can be used by researchers across Norway to answer key questions in cancer treatment, such as improving the selection of patients for treatment and understanding resistance mechanisms.

For patients with advanced cancer who have received standard treatment

Patients with advanced cancer who have already received standard treatment are eligible to participate in IMPRESS-Norway, and we expect between 250 and 500 patients to be recruited every year. The patients will be included in patient groups (cohorts) based on molecular profiles, cancer diagnosis and medicine. Each cohort will first include eight patients. If one or more patients respond to the treatment, then another sixteen patients will be included. A cohort is considered positive if five or more patients of the total twenty-four patients, respond to the treatment.

The protocol for the study has been sent to The Norwegian Medicines Agency and it is expected to start in the beginning of 2021. The patients need to be referred to the study by their general practitioner or hospital clinician.

The study requires a national infrastructure

IMPRESS-Norway requires that cancer patients are offered an in-depth analysis of the cancer tumour’s genetic mutations. Therefore, the academic environments have worked, with dedicated funds from the regional health authorities, to establish a national infrastructure for precision diagnostics for cancer patients (National infrastructure for precision diagnostics called InPred).

Mapping 500 genes

The establishment of these new diagnostic services is already well underway at several hospitals. The goal is to offer expanded molecular diagnostics with mapping of 500 genes to all cancer patients who are eligible for clinical trial inclusion. The molecular results will be discussed in a national molecular tumour board, consisting of clinicians, pathologists and informaticians, and if the analysis shows that the patient has genetic mutations that can be treated with targeted therapy, the patient can be referred to the appropriate clinical trial or to IMPRESS-Norway.

Collaboration with pharmaceutical companies

IMPRESS-Norway is in dialogue with 17 pharmaceutical companies about contributing approved drugs that can be tested outside their approved indication (off-label). One goal with the study is to try out a concrete model for the implementation of personalized medicine. The clinical study will give health personnel and researchers unique experience with precision medicine and the use of molecular diagnostics in treatment, and will offer new treatments to a group of patients who have used up all other options. In addition, the collaboration partners of IMPRESS-Norway are planning to build a public – private collaboration (called CONNECT) where the experiences from IMPRESS-Norway will provide knowledge of how precision medicine affects, among other things, health economy, the health industry and the health services.

Learning from the Netherlands

IMPRESS-Norway is modelled on a precision medicine study called DRUP, which is currently ongoing in the Netherlands. Similar studies are being planned in several European countries and IMPRESS-Norway plans to collaborate on data sharing with the other Nordic countries. This is especially important since we know from experiences with the DRUP study that individual molecular profiles are so rare that it is difficult to fill the cohorts in a single country and therefore it becomes important to compile data from similar cohorts across studies.

statsbudsjett 2021

State budget: 61,3 million to personalized medicine

Funds for personalized medicine, clinical trials, mature clusters, and digitalisation – these are some of the main points for cancer innovation in the newly released state budget.

In this week’s state budget, the Norwegian government increases the funding for personalized medicine with NOK 30 million to a total of NOK 61,3 million.

NOK 25 million will be used to establish precision diagnostics with advanced molecular profiling in the hospitals, which will give cancer patients a more precise diagnosis. This is also an important requirement for cancer patients to participate in clinical trials.

“The infrastructure for precision diagnostics will improve Norway’s ability to attract clinical studies internationally, it will give more cancer patients the opportunity to participate in clinical trials and it will provide valuable data for further research,” said Ketil Widerberg, general manager of Oslo Cancer Cluster.

The remaining funds for personalized medicine will be used to build competences and begin to establish a national genome centre.

More funding for clinical trials

The Norwegian government announces NOK 75 million to health innovation and clinical studies. The establishment of NorTrials, which will be a partnership between industry and hospitals on clinical studies, will receive NOK 30 million. NorTrials will offer a one-stop-shop for small- and medium-sized enterprises in the health industry and for public institutions that want to conduct clinical trials in Norway.

“Oslo Cancer Cluster has long worked for the establishment of a partnership model for clinical studies between industry and public actors. It is great to see this important aspect addressed in the state budget,” said Widerberg.

More information about NorTrials and the infrastructure for precision diagnostics will be announced in the Action Plan for Clinical Studies, to be presented in December 2020.

As a follow-up to The White Paper on the Health Industry, the Norwegian government also proposes to establish a scheme to improve collaboration between industry and public institutions on health innovation, called Pilot Helse (Pilot Health). This scheme will receive NOK 20 million in funding.

100 million for Norwegian export

A total of NOK 100 million will be used for strategic investments in export opportunities. Most of these funds, NOK 75 million, will go directly to the new unit Business Norway. Another NOK 20 million will strengthen the Norwegian mature clusters through Innovation Norway’s cluster programme. The remaining NOK 5 million will support Norwegian cultural export.

“The mature clusters can assume a central role in creating export opportunities for Norwegian industry abroad. The aim for Oslo Cancer Cluster is to put Norwegian health industry on the agenda internationally, and develop a leading European cancer innovation centre,” said Widerberg.

Greenlight for Horizon Europe

In 2021, an impressive NOK 40,9 billion will be used for research and development, which is 1,1 per cent of Norway’s total BNP.

The government also announced that Norway will participate in the EU programme Horizon Europe. The programme will replace Horizon 2020 and covers the period 2021-2027. It has a total budget of 75,9 billion euro over the entire period.

“It is important for Norwegian industry to participate in Horizon Europe, it brings access to novel knowledge and capital, and encourages cross-disciplinary collaboration, which is essential for cancer innovation,” Widerberg commented.

A new data factory

The budget for digitalisation will be doubled next year: NOK 1,5 billion is set aside. NOK 56,2 million will be used for Norwegian participation in the Digital Europe Programme, which will give Norwegian businesses access to skills and resources in the areas of artificial intelligence, supercomputers, IT security and advanced digital competency.

Another NOK 16 million goes to the creation of a “Data Factory”, which will be set up by The Agency for Digitalisation in cooperation with Digital Norway. The Data Factory will provide services that will help small companies to develop business ideas and create value from data.

At the same time, the newly established Health Analysis Platform, which will make it easier for scientists to conduct research on health data, gains another NOK 35 million.

“There is a massive unleashed potential in Norwegian health data, to create value for both industry and patients. Important hurdles and opportunities are addressed; however, we see the need for even more efforts to understand and treat illnesses like cancer better in the future. With the help of digital tools, we can develop new cancer medicines in 5 instead of 10 years,” Widerberg commented.

Sign up for our monthly newsletter to see the latest news and events

Ketil Widerberg and Bjørn Klem

The new frontier in cancer innovation

This column was originally published in the Nordic Life Science magazine (September 2020 Issue).

Oslo Cancer Cluster (OCC) Innovation Park and Incubator plans to expand by 5o ooo m² in the coming years. The goal is to create an international innovation hub in cancer. Why? Because personalized medicine is changing cancer innovation.

The Norwegian Prime Minister Erna Solberg had great expectations when she opened OCC Innovation Park in July 2015, including a 5 000 m² Incubator, situated next to the Oslo University Hospital. The goal was to accelerate the development of new cancer treatments.

With world-class researchers in-house, Jónas Einarsson, CEO of Radforsk, investing in cancer biotechs, and one thousand noisy high school students in the same building, what could go wrong? Possibly everything.

At the time of opening, lab inventory and equipment were missing and only a few lease agreements were signed. More importantly, would scientists, investors and students be viewed as weird outcasts or would an attrac­tive innovation platform be created?

The idea is simple; the OCC Incubator helps entrepreneurs to quality check research ideas, to recruit competent people to board and management roles, and to fund projects. One example is Ultimovacs that started working back-to-back with academics in the OCC Incubator lab to develop cancer vaccines. The company is today listed on the Oslo Stock Exchange with an estimated value of NOK 1.3 billion.

Siva, the governmental infrastruc­ture for innovation, has been essential in making this a success. Their long­term commitment as owner and their support for start-up services has helped start-ups reach the next phase. Kongs­berg Beam Technology, for example, recently attracted NOK 27 million from the Norwegian Research Council and private investors to develop real-time cancer radiation steering systems.

The OCC Incubator was awarded the Siva Innovation Prize in 2017 and is frequently listed among the top 20 innovation hubs in Europe. The start-ups in the OCC Incubator have raised more than NOK 5 bil­lion in equity and treated hundreds of patients since its opening.

The Norwegian Prime Minister’s expectations on both job creation and cancer care are certainly being fulfilled.

So why strive for more? Because precision medicine is changing the world and digital oncology is the new frontier.

From personalized vaccines to cell therapy, medicines are increasingly developed for smaller patient groups. However, government systems for approvals and sharing of data go painfully slow, while global technology companies’ efforts in health fail repeatedly. The recent corona pan­demic has proven the importance of both international collaboration and regional sustainability, from develop­ment of tests to treatments.

It is time to join forces in the Nordics!

Real-world data and artificial intelligence will shorten develop­ment times and reduce costs for new cancer treatments. The OCC Incubator will provide labs and infrastructure next to patients, clinicians and researchers to help achieve this.

Our goal is to reduce the develop­ment of new cancer treatments from 10 to 5 years.

 

Written by: Ketil Widerberg, general manager of Oslo Cancer Cluster, and Bjørn Klem, general manager of Oslo Cancer Cluster Incubator

 

Sign up for our monthly newsletter to see the latest news and events

Welcome first-year students

This article was first published in Norwegian on our School Collaboration website.

The school collaboration days were a little bit different this year, but we are still incredibly happy to see all the Ullern students back at school.

The corona pandemic dampened the spirit of the school collaboration days this year. This is usually when the first-year students at Ullern Upper Secondary School get to visit the different institutions and companies that are located in Oslo Cancer Cluster Innovation Park together with the school. However, the traditional lecture with Jónas Einarsson, one of the founding fathers of the Innovation Park, was still held.

Jónas Einarsson is the CEO of Radforsk, an early stage evergreen fund that invests in and develops cancer companies. The fund is also behind Oslo Cancer Cluster Innovation Park, which houses Ullern Upper Secondary School.

“I will tell you a little about the history behind the Norwegian Radium Hospital, cancer and cancer treatments, but first I have to talk a little about Covid-19 and the pandemic that we are all in the middle of,” Einarsson began his speech for the first-year students.

He continued by explaining that a corona vaccine may be available in 2021, but that it will take time before everyone receives the vaccine and for the whole population to gain immunity so that everything can go back to normal again.

“This has a big effect on young people in particular, but you are very smart. Just make sure to stay away from rave parties in caves,” Einarsson said and the students smiled.

Then, Einarsson told the story of how modern cancer treatment came into being when Marie Curie discovered the potential of radium to destroy cancer tumours, and how the Norwegian doctors Heyerdahl and Huitfeldt worked tirelessly for almost 20 years to establish the Norwegian Radium Hospital, which opened in 1932. Right next to it, Ullern Upper Secondary had recently opened its doors, so the school and the hospital have a long history as neighbours.

“In 2015, we opened Oslo Cancer Cluster Innovation Park and the neighbourhood became even closer. The school collaboration project between the school and the members of Oslo Cancer Cluster was established already in 2009, when we knew that we would move in together,” Einarsson said.

The rest, as they say, is history, but the corona pandemic has put a damper on the collaboration. Due to the current disease prevention in place, the usual placements have been cancelled and the close collaboration between students and researchers needs to be adapted. Exactly how this will take shape during the autumn of 2020, no one knows yet, but lectures and video conferences will serve as replacements.

Read more about what the school’s first-years usually do during the Collaboration Days.

Sign up for our monthly newsletter to see the latest news and events

 

Danish Foreign Minister meets with Norwegian Trade Minister at Oslo Cancer Cluster

Ministers meet at Oslo Cancer Cluster

The corona pandemic and international trade were on the top of the agenda when the Foreign Minister of Denmark Jeppe Kofod met with the Minister for Trade, Industry and Fisheries of Norway Iselin Nybø at Oslo Cancer Cluster Innovation Park.

Norway and Denmark are close friends and allies, and the current corona situation has made conversations between Nordic colleagues more valuable than ever.

Export, international trade and investments will be crucial to overcoming the challenges the corona pandemic has brought to Nordic economies.

These pressing issues were discussed when the two ministers from Denmark and Norway met at Oslo Cancer Cluster Innovation Park on 13 August 2020.

Ministers Nybø and Kofod

Ministers Nybø and Kofod discussed how to increase export from and attract international investments to the Nordic countries. Photo: The Embassy of Denmark in Norway

The starting point of the meeting was how many companies in the health industry need access to international markets and value chains to grow.

The Norwegian government are preparing an Export Action Plan. It will include several measures to help Norwegian industry come through the corona crisis.

“In the development of the Export Action Plan, the government is collaborating with both industry and financial organisations. We want to gain as much knowledge as possible about where the challenges lie and evaluate which measures are most effective,” Nybø said in a press release from the Department of Trade, Industry and Fisheries.

The Embassy of Denmark in Norway released the following statement after the meeting:

“It is important to attract foreign investments and there is a big potential in Nordic collaboration within the life science sector, since Denmark and Norway have complementary competencies in this field.”

Ketil Widerberg, general manager at Oslo Cancer Cluster, was happy to facilitate the visit and to give input to the ministers on how international collaboration helps the development of cancer treatments:

“Denmark and Norway collaborate on important research areas, including cancer. Our countries have national health data that attract international recognition. Our countries also collaborate on purchasing of developed drugs.

“The opportunity now is the collaboration on how to use our health data and collaborative efforts to better and faster approve new innovative treatments.

“This could reduce development time from 10 to 5 years, and make the Nordics a destination for health innovation.”

Sign up for our monthly newsletter to see the latest news and events

Digital bootcamp for better cancer care

A digital bootcamp for better cancer care

Molecular diagnostics, clinical studies and exercise plans for cancer patients were three key topics raised in last week’s event.

We teamed up with Aktiv mot Kreft, Merck Norway and GSK Norway to put a spotlight on innovative cancer treatments in Norway.

Due to corona restrictions, we transformed this event (originally planned for Arendalsuka) into a digital bootcamp with short training intervals between each panel. This was livestreamed from Pusterommet at Akershus University Hospital on Wednesday 12 August 2020 at 5:00 pm.

The meeting consisted of three parts with different perspectives: diagnostics, treatments and exercise plans.

View the entire meeting via Facebook here or watch it via our YouTube channel below:

 

Warming-up to genetic testing

The warm-up session involved a discussion on how improved diagnostics can help doctors determine the best treatment for each individual patient.

Dr. Andreas Stensvold, Head of the Cancer Department at Sykehuset Østfold, talked about how he has used off-label treatments to help some of his patients.

One example is Kjetil Nerland who had already received the traditional treatment methods: surgery, radiotherapy and chemotherapy, but found they did not work for him over longer periods of time.

After going through genetic testing and detailed analysis of the tumour cells, Stensvold could offer Nerland an off-label treatment. The medicines had already been approved for a different cancer type.

“It’s not fun to have cancer, but it is fun to live longer and to not have to go through chemotherapy again,” Nerland said.

Jan Frich, vice administrative director for the South-Eastern Regional Health Authority, explained they are setting up the infrastructure for advanced molecular diagnostics.

“We need to build up the diagnostics – that is the basis for personalized medicine,” Frich said.

Professor Jan Helge Solbakk from The Centre for Medical Ethics at the University of Oslo was however critical of how little is being done to approve new cancer treatments and implement personalized medicine in Norway.

“Norwegian authorities are a little bit too scared of personalized medicine. When there is a big breakthrough or when we see great effect in one patient, they worry about the cost,” Solbakk said.

 

High-intensive discussions on clinical studies

The next panel discussed: How can Norway keep up with other countries on implementing precision medicine?

Professor Kjetil Taskén, Director of the Institute for Cancer Research at Oslo University Hospital, highlighted three things: building infrastructure for molecular cancer diagnostics, attracting more clinical studies that utilise molecular diagnostics and implementing this in regular clinical practice.

The initiative IMPRESS Norway works towards a public-private collaboration, with public financing to do a large clinical study in collaboration with several private companies. They will follow a set of guidelines to find out which cancer treatment is best for which patient.

“I think the dialogue between governmental institutions and private companies has been good so far. We are aiming to get a shift towards more public-private collaborations,” Taskén said.

The clinical study IMPRESS Norway is modelled on studies done in the USA and Netherlands. Results from the ongoing Dutch study show that if enough patients and companies are involved, it is possible to find one extra treatment option for 50% of the patients by using molecular diagnostics.

The pharmaceutical industry agrees that this is an important step towards precision medicine.

“It should be a political goal that clinical studies become part of ordinary cancer patient treatment, so that all patients who have been through treatment are offered a place in a clinical study,” Steinar Thoresen, Head of Oncology and Strategy, Merck Nordics and Netherlands, said.

Frøydis Høyem, State Secretary at the Ministry for Health and Care Services, was positive about more public-private collaboration on cancer care.

“The Norwegian government genuinely cares about cancer patients and wants to land a public-private collaboration. We need to come together, discuss this more and agree on how to take it further,” Høyem said.

 

Relaxing perspectives on exercise

How do we prepare the patient to be in the best possible shape to handle a cancer treatment? This was the key question in the last panel of the meeting.

A new initiative at Akershus University Hospital has put educating patients about coping with cancer, along with exercise and diet plans, at the forefront for all their treatments.

The results?

“We have higher patient satisfaction. They experience a higher degree of involvement, shorter waiting times and less complications,” Dr. Geir Arne Larsen, Head of Department for General and Digestive Surgery at Akershus University Hospital, said.

“It is neither high tech medicine nor resource demanding. In total, we use less resources on these patients, so the hospital’s capacity for intensive care, surgery and hospital beds can be used for other patients,” Larsen continued.

Hanne Garde is one of the patients who has been involved. She is happy she could take part in an individualised plan for diet, exercise and managing the disease, which made all the difference for her during treatment and recovery.

“It was perfect for me personally to be able to take an active role in my own treatment,” Garde said.

Yngvar Andersen, Ambassador for Aktiv mot kreft and training enthusiast, led all the exercise intervals and finished the meeting with some exercises for all the participants.

“I have seen how meaningful exercise is for many cancer patients. Life might not become longer, but it becomes a little bit better,” Andersen said.

 

Meeting participants:

  • Siri Lill Mannes, host
  • Frøydis Høyem, State Secretary in the Ministry of Health and Care Services
  • Jan Frich, vice administrative director at the Norwegian South-Eastern Regional Health Authority
  • Andreas Stensvold, oncologist and Head of the Cancer Department at Sykehuset Østfold
  • Jan Helge Solbakk, professor at the Centre for Medical Ethics at the University of Oslo
  • Kjetil Taskén, Director of the Insitute for Cancer Research at Oslo University Hospital
  • Steinar Thoresen, Head of Oncology and Strategy, Merck Nordics and Netherlands
  • Geir Arne Larsen, Head of Department for General and Digestive Surgery at Akershus University Hospital
  • Yngvar Andersen, Ambassador for Aktiv mot kreft and training enthusiast

 

Thank you to all participants and organising partners for making this meeting possible!

 

 

Sign up for our monthly newsletter to see the latest news and events

 

 

Eivind Lysheim

Studying medtech with cancer patients at heart

Former Ullern student Eivind Lysheim has been inspired to make a difference for cancer patients

Eivind Lysheim had decided to study economics at university, until a work placement at the Norwegian Radium Hospital caught his interest in 2016, during his last year at Ullern Upper Secondary School.

The placement was arranged by Oslo Cancer Cluster and took place in the Department of Medical Physics. For an entire week Eivind was mentored by Professor Taran Paulsen Hellebust and her co-workers on medical imaging and how radiotherapy is used to treat cancer patients. The Ullern student learnt how to use the machines and how to create a theoretical treatment plan for a former patient.

“I have always been interested in the natural sciences. I felt that the combination of technology and medicine was extremely interesting. It is fascinating how you can use something that is perceived as deadly – such as gamma radiation, x-rays or high energy particles – and cure someone. When I saw the high-tech machines at the hospital, I got a little bit carried away,” Eivind said with a smile.

Eivind immediately changed his application from economics to the mathematics and physics programme with specialisation in biophysics and medical technology at NTNU in Trondheim.

Four years later, Eivind has one year left of his master’s degree and is still intent on working on technology that can improve the lives of cancer patients.

“Cancer can happen to anyone and almost everyone in Norway knows someone who has been affected by it. It is important that we develop the very best treatments for the people who get ill,” Eivind said.

Eivind got in touch with Bente Prestegård, project manager at Oslo Cancer Cluster, who helped him find a summer internship with our member Kongsberg Beam Technology. The company recently acquired funding to develop control systems for proton therapy machines.

“Among medtech students in Norway, proton therapy is probably the most popular area to work in. Everyone dreams about getting a job in this field. This internship has really been like hitting the jackpot for me,” Eivind said.

Kongsberg Beam Technology is developing a system called MAMA-K, which is short for Multi‑Array Multi-Axis Cancer Combat Machine. The machine treats the tumour with a number of simultaneous proton beams and is especially adapted for more mobile tumours, and it can be added to both existing and new proton machines.

Eivind has spent the summer doing research in the offices belonging to Semcon, who is one of Kongsberg Beam Technology’s partners.

Norway is in the process of building its first two proton centres, at Oslo University Hospital and at Haukeland University Hospital. Many medtech students are eager to work at these centres to develop cancer treatments. Moreover, the technology used in proton machines is an intriguing area of research constantly in development, which makes it highly attractive for new students.

“If I can work with proton therapy, I can look forward to a very exciting and varied career, because the field is always changing and you have to continually learn new things,” Eivind said.

The IT-revolution in oncology

This article was first published in Teknisk Ukeblad in Norwegian on 23 June 2020. Scroll down for a version in Norwegian.

EHiN, E-Health in Norway, is Norway’s largest conference on the digitalization of the health sector. Save the date 10-11 November 2020!

“At EHiN you will meet the key players of the health sector, politicians and decision-makers,” said Ketil Widerberg, general manager of Oslo Cancer Cluster.

EHiN has proven to be an important arena to gather the industry, the public sector and the research environment around the digitalization of the health sector.

“During two days, we will learn from one another and share knowledge about technological solutions to benefit the health service and individual patients. This creates a basis for further collaboration,” Widerberg said.

Oslo Cancer Cluster is a non-profit member organization that connects public and private key players in cancer research and a Norwegian Centre of Expertise since 2009. Oslo Cancer Cluster is a collaboration partner in EHiN.

Artificial intelligence changes cancer treatments

Digitalisation is a central area in cancer research and the advent of precision medicine demands that different academic disciplines work closely together. Using artificial intelligence will be important to develop new treatments.

“Artificial intelligence will change how we treat cancer. It is about understanding cancer. The same way that a microscope can show us what cells look like, AI can help us to discover patterns we never would have seen otherwise.

“This makes it possible to give patients personalized treatments because we can identify how the patient will react to the treatment. Eventually, modern machine learning systems will make the treatments even better.

“The goal is to give the right treatment to the right patient at the right time,” Widerberg explained.

The IT-revolution in the oncology field is also of great interest to the tech industry. It is about handling enormous amounts of health data through storage, analysis, machine learning, pattern detection and secure connections between different data sources.

“Personalized medicine, genetics and the use of health data is quickly developing into one of the most important areas in digital health.”
Ketil Widerberg, general manager of Oslo Cancer Cluster.

“EHiN wishes in collaboration with Oslo Cancer Cluster to build Norway as an important international hub in the area of e-health,” Widerberg said.

The programme for EHiN 2020 is currently under development. Information about the venue and ticket sales will be announced at a later date. Please visit the official EHiN website for updates on how corona affects EHiN 2020.

 


IT-REVOLUSJON PÅ ONKOLOGIFELTET

EHiN, EHelse i Norge, er Norges største konferanse om digitalisering i helsesektoren. – Merk deg datoene 10. og 11. november allerede nå.

På EHiN møter du de fremste aktørene i helsesektoren, politikere og beslutningstakere, sier Ketil Widerberg, daglig leder i Oslo Cancer Cluster.
EHiN har vist seg å være en viktig arena for å samle næringsliv, offentlig sektor og forskning rundt digitalisering av helsesektoren.

– I to dager i  skal vi lære av hverandre og dele kunnskap om teknologiløsninger til det beste for helsevesen og enkeltpasienter. Det skaper grobunn for videre samarbeid, poengterer Widerberg.

Han forteller at Oslo Cancer Cluster (OCC) er en non-profit medlemsorganisasjon som samler offentlige og private aktører innen kreftforskning, og et Norwegian Centre of Expertise. OCC er samarbeidspartner i EHiN.

Presisjonsmedisin

Presisjonsmedisin krever ifølge Widerberg at forskjellige fag-grener jobber tett sammen, og digitalisering er et sentralt område innenfor kreft. Han trekker frem betydningen av kunstig intelligens (AI).

– AI vil endre kreftbehandlingen. Det handler om å forstå kreften. På samme måte som mikroskopet tar oss helt ned på cellenivå, vil AI hjelpe oss til å se et mønster vi aldri ellers ville oppdaget. Dette gjør det mulig å gi pasienter individbasert behandling – nettopp fordi vi kan se et mønster på hvordan pasienten reagerer på behandlingen. Etter hvert vil moderne selvlærende datasystemer gjøre behandlingsmetodene bedre.
Målet er å gi den rette behandlingen til den rette pasienten til rett tid, forklarer Widerberg.

IT-revolusjonen på onkologifeltet har også stor interesse for IT-bransjen. Det handler blant annet om å håndtere enorme mengder helsedata gjennom lagring, analyse, maskinlæring, mønstergjenkjenning og sikker kobling av forskjellige datakilder.

– Persontilpasset medisin, genetikk og bruk av helsedata utvikler seg snart til et av de viktigste områdene innen digital helse, sier Ketil Widerberg, daglig leder i Oslo Cancer Cluster.

– EHiN ønsker i samarbeid med OCC å bygge Norge som en viktig internasjonal hub på området e-helse, avslutter Widerberg.

Følg med på ehin.no hvordan koronaviruset påvirker EHiN 2020.

Oslo Cancer Cluster becomes a member of Oslo Science City

How can we solve societal challenges, such as cancer, by creating a power centre for innovation in Oslo? This is the key question Oslo Science City – the first innovation district in Norway – hopes to answer.

The ambition of Oslo Science City is to become a world leading innovation district that contributes to research excellence, jobs creation, the green shift and sustainable economic development.

“We intend to develop a vibrant city area where people meet to innovate and explore what we still don’t understand,” said Christine Wergeland Sørbye, CEO of Oslo Science City.

In order to achieve this, Oslo Science City’s strategy is to facilitate cooperation between leading research groups, students, businesses and the public sector. Key actors in the district, including the City of Oslo, Oslo University Hospital and the University of Oslo, are now working together to facilitate the development of the area.

“We will develop a powerhouse for innovation, research and business, and a good place to live,” said Wergeland Sørbye.

Oslo Cancer Cluster joined Oslo Science City in June 2020 to contribute to boosting innovation in this knowledge-intensive area.

”Innovation thrives where there are hard problems that need to be solved,” said Ketil Widerberg, general manager of Oslo Cancer Cluster.

“Cancer is one of the major societal challenges we face today. For over a decade, Oslo Cancer Cluster has worked tirelessly to enable researchers and investors, private companies and public hospitals to work closer together to solve this challenge. We have succeeded in some first steps, now is the time to get to the next level. Utilizing the potential in immunology and digitalisation with Oslo Science City will be key to achieve this.”

Ketil Widerberg, daglig leder, OCC

Ketil Widerberg, general manager of Oslo Cancer Cluster, sees the potential of connecting immunology and digitalisation in the future innovation district. Photo: Oslo Cancer Cluster / Stig Jarnes

Wergeland Sørbye is happy to welcome Oslo Cancer Cluster as an active partner in developing Oslo Science City:

“Oslo Cancer Cluster has unique competencies and a long track record, and we are looking forward to learn from you! Together with the University of Oslo, SINTEF, Oslo University Hospital, the City of Oslo and our other members, Oslo Cancer Cluster will play an important role in realizing the potential for innovation, new jobs and value creation. It is important, and it will be fun!”

Oslo Cancer Cluster Innovation Park, the Oslo University Hospital research building and Norwegian Radium Hospital are located in the new innovation district Oslo Science City.

Oslo Cancer Cluster Innovation Park, the Oslo University Hospital research building and Norwegian Radium Hospital are located in the new innovation district Oslo Science City. Photo: Oslo Cancer Cluster / Christian Tandberg

A vibrant area to live, work, play

There are many innovation districts around the world, yet there is no fixed recipe for how successful innovation districts are developed.

“Developing such an area could be described more as an art than science.” Wergeland Sørbye said.

“However, research highlights the need for certain key functions. For example, you need strong anchor institutions that attract other actors, such as a university or university hospital, and you need to facilitate the cooperation based on trust between the different organizations and stakeholders in the area. Many do this by establishing a joint membership organization, which is what we did with Oslo Science City.”

Furthermore, it is essential to develop a multifunctional area with a critical mass of knowledge-intensive businesses. The ideal innovation district is a vibrant place where people can “live, work and play”, with services and cultural functions. It must also be easy to move around in the area, on foot, bike or public transportation.

“A key lesson from other innovation districts is the importance of adapting to the local context,” Wergeland Sørbye said.

However, no one has previously developed innovation districts in Norway. This makes it valuable to learn from international examples. Some innovation districts that have provided inspiration in the endeavour to develop Oslo Science City are Stockholm Science City, Copenhagen Science City, White City in London and Kendal Square in Boston.

Please follow the Oslo Science City official website for further updates on the development of the innovation district.

Ullern students presented their own research

This article was originally published in Norwegian on the School Collaboration website.

Arranging a poster session may seem like an unusual way to end the school year, but for Ullern’s researcher students it is the perfect way to finish.

The first year of the Researcher Programme at Ullern Upper Secondary School was brought to an end by the students presenting their research projects to the four mentors, the principal, their teachers and co-students. A sunny, warm morning in June the Ullern schoolyard was transformed into a poster session, an activity that normally only takes place at science conferences.

The presentation of their research projects is the “grand final” of the school year for the students on the Researcher Programme, says Monica Flydal Jenstad and Ragni Fet, who are the two teachers in charge of the programme.

“The students have worked on their own experiments related to radiation and made real research posters. This has been a bit challenging, because of the corona pandemic and studying from home during a long period. They were supposed to present their research projects to the four mentors already in April, but this was of course not possible. It is really fun that we managed to do this at all,” says Ragni.

The teachers Ragni Fet and Monica Flydal Jenstad are responsible for the Researcher Programme. They were really impressed by the research projects the students presented during their first poster session. Photo: Elisabeth Kirkeng Andersen

The teachers Ragni Fet and Monica Flydal Jenstad are responsible for the Researcher Programme. They were really impressed by the research projects the students presented during their first poster session. Photo: Elisabeth Kirkeng Andersen

The four mentors that Ragni is referring to is Jónas Einarsson, CEO of Radforsk and founder of Oslo Cancer Cluster and Oslo Cancer Cluster Innovation Park, Øyvind Kongstun Arnesen, consultant in Radforsk and former CEO of Ultimovacs, Simone Mester, cancer researcher at Oslo University Hospital and former student at Ullern Upper Secondary School, and Bjørn Klem, general manager of Oslo Cancer Cluster Incubator and former head of research in Photocure.

Bjørn Klem, general manager of Oslo Cancer Cluster Incubator and former head of research in Photocure, is studying the research posters in depth.

Bjørn Klem, general manager of Oslo Cancer Cluster Incubator and former head of research in Photocure, is studying the research posters in depth.

The mentors’ task is to advise the students during their studies and contribute with guidance, inspiration and experience. The mentors were more than pleased with what was presented to them:

“I tutored the students in February when they were designing the experiments and brainstorming. It was really fun to see the finished results in the poster format. I think everyone reflected well on their own results and it was fun to discuss with them. I am very impressed by the results!” said Simone Mester.

Jónas Einarsson agreed:

“I am impressed by the students’ work in spite of all the complications with the closed school. They explored interesting issues and executed the projects very well.”

Øyvind Kongstun Arnesen believes the students had a great advantage in their experienced teachers, who both have backgrounds in cancer research, when performing their own research projects:

“I think the students were especially good at formulating clear hypotheses. It is obvious they have understood the main reason for this type of research. They have great teachers and clear heads.”

A great success

A total of ten research projects were presented in poster format in the schoolyard. The principal, the science teachers, the mentors and the students walked among the posters, just like at a real science conference, read about the research and asked questions to the research talents.

The teacher Ragni Fet opens the poster session. To her left: the mentors Øyvind Kongstun Arnesen, Jónas Einarsson and Bjørn Klem. In front of her: the nervous students prepared to present. Photo: Elisabeth Kirkeng Andersen.

The teacher Ragni Fet opens the poster session. To her left: the mentors Øyvind Kongstun Arnesen, Jónas Einarsson and Bjørn Klem. In front of her: the nervous students prepared to present. Photo: Elisabeth Kirkeng Andersen.

“The poster session was a success! The students were brilliant. Both the mentors and teachers were impressed. The students’ task was to design and complete an experiment of their choosing related to the topic of radiation and to present the results of the experiment on a poster,” said Ragni Fet.

Two projects were awarded special prizes out of the ten research projects that were presented. The first prize was awarded by a jury consisting of the four mentors and the teachers. The second prize was awarded by the students themselves.

The winners

"Research into plants and microwaves" by Christofer Woxholt, David Venker and Jonathan Løvdal won the Jury’s Choice.

“Research into plants and microwaves” by Christofer Woxholt, David Venker and Jonathan Løvdal won the Jury’s Choice.

"Research into radiation of yeast" by Alexander Hustad, Alexander Marks and Martin Thormodsrud won Student’s Choice. Photo: Elisabeth Kirkeng Andersen.

“Research into radiation of yeast” by Alexander Hustad, Alexander Marks and Martin Thormodsrud won Student’s Choice. Photo: Elisabeth Kirkeng Andersen. 

The runner-ups

"How does light with different wavelength affect the growth of plants?" by Linnéa M. Skille, May Dagny Kollandsrud Hutchings, Tonje Marie Bjørklund Hopen and Elakhiya Dushyanthan won second place in both the Student’s Choice and the Jury’s Choice. Photo: Elisabeth Kirkeng Andersen

“How does light with different wavelength affect the growth of plants?” by Linnéa M. Skille, May Dagny Kollandsrud Hutchings, Tonje Marie Bjørklund Hopen and Elakhiya Dushyanthan won second place in both the Student’s Choice and the Jury’s Choice. Photo: Elisabeth Kirkeng Andersen

"Can you fry an egg with ultrasound?" by Sebastian Heuser and Victor Garman won a shared second place in the Student’s Choice category. Sebastian was unfortunately not present for the poster session. Photo: Elisabeth Kirkeng Andersen

“Can you fry an egg with ultrasound?” by Sebastian Heuser and Victor Garman won a shared second place in the Student’s Choice category. Sebastian was unfortunately not present for the poster session. Photo: Elisabeth Kirkeng Andersen 

All research posters

"Water’s ability to slow gamma radiation" by Nikita Upadhyaya, Henrikke Thrane Steen Røkke and Lara Barazangy. Lara was not present when the picture was taken. Photo: Elisabeth Kirkeng Andersen

“Water’s ability to slow gamma radiation” by Nikita Upadhyaya, Henrikke Thrane Steen Røkke and Lara Barazangy. Lara was not present when the picture was taken. Photo: Elisabeth Kirkeng Andersen

"The effect of different amounts of radiation on yeast cells" by Jakub Michalowski, August André Lukkassen and Emil Gråbøl-Undersrud. Photo: Elisabeth Kirkeng Andersen

“The effect of different amounts of radiation on yeast cells” by Jakub Michalowski, August André Lukkassen and Emil Gråbøl-Undersrud. Photo: Elisabeth Kirkeng Andersen

"Radiation of e-coli" by Peder Hellesylt, Carl Thagaard, Fredrik Røren and Felix Gundersen. Photo: Elisabeth Kirkeng Andersen

“Radiation of e-coli” by Peder Hellesylt, Carl Thagaard, Fredrik Røren and Felix Gundersen. Photo: Elisabeth Kirkeng Andersen

"The effect of different types of radioactive radiation on bacteria" by Isha Mohal and Nada Darwiche. Photo: Elisabeth Kirkeng Andersen

“The effect of different types of radioactive radiation on bacteria” by Isha Mohal and Nada Darwiche. Photo: Elisabeth Kirkeng Andersen

"Does microwave radiation affect the growth of seeds?" by Anine Sundnes, Julia Beatrice Braaten and Tia Sauthon. Tia was not present when the photo was taken. Photo: Elisabeth Kirkeng Andersen

“Does microwave radiation affect the growth of seeds?” by Anine Sundnes, Julia Beatrice Braaten and Tia Sauthon. Tia was not present when the photo was taken. Photo: Elisabeth Kirkeng Andersen

"Radiation of plants" by Iselin Langås Sunde, Andrea Øfstaas, Henrik E. Corneliussen and Fredrik Hansteen. Photo: Elisabeth Kirkeng Andersen

“Radiation of plants” by Iselin Langås Sunde, Andrea Øfstaas, Henrik E. Corneliussen and Fredrik Hansteen. Photo: Elisabeth Kirkeng Andersen

The mentors together with the winning group. Photo: Elisabeth Kirkeng Andersen

The mentors together with the winning group. Photo: Elisabeth Kirkeng Andersen

The mentors together with the group that got second place in Jury’s Choice and Student’s Choice. Photo: Elisabeth Kirkeng Andersen.

The mentors together with the group that got second place in Jury’s Choice and Student’s Choice. Photo: Elisabeth Kirkeng Andersen.

 

More about the Researcher Programme

The Researcher Programme (Forskerlinja) is a unique opportunity for motivated and talented aspiring researchers. The students receive a tailored three-year educational programme with a specialisation in the natural sciences. The academic year 2019/2020 is the first year that Ullern Upper Secondary School has run this programme, which offers a first insight into biomedical research, technology and innovation. Teachers and researchers give the students a taste of how world-class research is done. The students learn in completely new ways in the Oslo Cancer Cluster Innovation Park, which Ullern Upper Secondary School is a part of.

The students have through the years participated in the unique collaboration with Oslo Cancer Cluster, which offers them exciting work placements with researchers, companies and laboratories associated with the cluster and the Oslo Cancer Cluster Innovation Park. Because of the corona pandemic, the students have unfortunately missed out on many of the planned activities.

The students still have two years left of the programme and they will present two more research projects, but first, they will enjoy a well-deserved summer holiday.

Hva er viktigst, hytta eller helsen?

This opinion piece was originally published in Aftenposten on 25 June 2020. Scroll down for a version in English.

Deaktiver Smittestopp-appen med en gang – med god samvittighet, skriver Joacim Lund. Han bør heller ha dårlig samvittighet.

Smittestopp-appen samler inn bevegelsesmønstre for å spore spredningen av covid-19. Personvern står høyt, og derfor bør vi ta det alvorlig når Datatilsynet protesterer mot appens datalagring og datahåndtering. Ved stans av datainnsamling brukte kun 11 prosent av Norges befolkning den. Det er langt under de nødvendige 50 prosent for å få en reell sykdomsoversikt.

Dette står i kontrast til det at store deler av oss bruker Google Maps, som også samler inn lokasjonsdata, så vi finner køfri vei til hytta.

Hva er viktigst, hytta eller helsen? Kan vi kombinere godt personvern og tillit til myndighetene for å se effekten av og begrense tiltakene mot covid-19? Folkehelseinstituttet og Simula gjorde en fantastisk jobb med Smittestopp. Appen bør utvikles med bedre sikkerhet og anonymisering, men det å ønske Smittestopp død er feil. Å samle inn og dele data for vår felles helse er viktig, i umiddelbare kriser som covid-19 og mot samfunnsutfordringer som kreft.

Smittestopp er død. Lenge leve Smittestopp.


What is more important: your holiday cabin or your health?

Deactivate the app Smittestopp at once – with good conscience, Joacim Lund writes in Aftenposten. This should rather give him a bad conscience.

The app Smittestopp collects people’s movement patterns to track the spread of covid-19. Privacy is important, and that is why we should take it seriously when The Norwegian Data Protection Authority (DPA) protests against the app’s storage and handling of data. Only 11 percent of Norway’s population used the app, when the data collection was stopped. That is far from the necessary 50 percent to get a real overview of the spread of the disease.

This is in contrast to the fact that many of us use Google Maps, which is also collecting location data, so that we can find the quickest way to our holiday cabins.

What is more important, the holiday cabin or our health? Can we combine good privacy and trust in government to see the effect of and limit the measures against covid-19? The Norwegian Institute of Public Health and Simula did a fantastic job with Smittestopp. The app should be developed with better security and anonymization, but to wish Smittestopp dead is wrong. To gather and share data for our common health is important, in immediate crises like covid-19 and against societal challenges like cancer.

Smittestopp is dead. Long live Smittestopp.

GLIMT UB, Arif and Unge Ferrari at Rikshospitalet, Oslo.

Helping teens in the hospital

This article was originally written in Norwegian and published on our School Collaboration website.

Ullern students helped teenagers in the hospital while learning how to become entrepreneurs.

GLIMT UB, a youth company at Ullern Upper Secondary School, wants to give chronically ill teenagers the activities they need while they are in hospital. The pizza night with the famous Norwegian rappers Arif and Unge Ferrari was a big success, but then the corona pandemic put a temporary stop to the newly started company.

“GLIMT offers teens in hospital different activities, which are planned and carried out by other teens. We offer an arrangement for the hospitals, which is better adapted and more resource-efficient.”

Teenagers who stay in the hospital for long periods of time are often isolated and have few other fulfilling activities in their everyday lives. GLIMT UB decided to do something about this and thought of the idea to arrange pizza nights at the hospital, inviting famous people as guests for the young patients.

The concept was a success and the pizza night with Arif and Unge Ferrari at Rikshospitalet in January 2020 attracted five times as many young patients as other activities. Arif and Unge Ferrari hung out with the teens who are staying in the hospital because of different illnesses. The night was spent eating pizza, playing cards and beading.

“The mother of one of the patients said that we need to come back and arrange this more times. She insisted that this was an important optional activity because it was planned by teens for teens,” said Tyra Kristoffersen.

Tyra has worked in GLIMT UB, together with the other Ullern students Andreas Bjurstrøm, Carl Ruge, Miriam Idsøe and Alexander Floskjer, during the last school year.

Young patients are isolated

“During the age when you have the greatest need to be social and gain new experiences, one group is getting left out of the traditional social framework. Across Norway, there are children and young adults staying in hospitals and, in spite of both internal and external measures, many end up being isolated from the rest of society. The age group 13 to 19 is a very challenging group to reach and they lack adequate activities. To improve the health service in Norway, we need better adapted activities for this age group.”

This quote is from GLIMT UB’s business plan, which awarded the company first place in the category Best Business Plan in the Oslo Championship for Young Entrepreneurs.

The team behind the youth company GLIMT UB gathered at Ullern Upper Secondary School. Photo: GLIMT UB’s Facebook page

The team behind the youth company GLIMT UB gathered at Ullern Upper Secondary School. Photo: GLIMT UB’s Facebook page

The concept of GLIMT is based on young, famous people’s motivation to help young people in a challenging situation, without getting paid for their time.

“If we had paid the celebrities to come, this wouldn’t have worked because the hospitals have such a limited budget. The famous people still benefit from positive mentions in social media and can use the activity to promote themselves if they wish,” Tyra said.

Before the corona pandemic, GLIMT UB had planned several pizza nights at Rikshospitalet, since the first one was such a success.

“We have been in touch with several celebrities, such as Herman Flesvig, Ulrikke Falck and Tix, who were all very positive to participate. Unfortunately, the corona pandemic forced visitation restrictions in place at hospitals in Norway, so we couldn’t arrange more pizza nights than the one with Arif and Unge Ferrari,” Tyra said.

The students behind GLIMT UB still think they have learned a lot.

A valuable mentor

Entrepreneurship is one of many subjects that the students at Ullern Upper Secondary School can choose in their second or third year. The students learn how to start a company and the theory behind what makes some businesses succeed and why other businesses fail.

The students also need to establish and run their own youth company during the course.

The team behind GLIMT UB considered an idea about redesign, but scrapped it when they realised that this was a concept that many youth companies were interested in.

“We started thinking about what is close to our school and of course the hospital is right next door. We discussed with our entrepreneurship teacher Karin if we could think of something in relation to that. We quickly found out that teens in the hospital don’t have many activities. The younger kids get visits from hospital clowns and their own playroom,” Tyra said.

At the Norwegian Radium Hospital, there are however not many young adults admitted. Most teenage patients are at Rikshospitalet and Ullevål.

“Through our mentor Bente, we got in touch with the activity leader for teenagers at Rikshospitalet and Ullevål. He liked our idea a lot, and other people were also positive, so we just had to keep working,” Tyra said.

Mentor Bente Prestegård and the students Andreas Bjurstrøm, Carl Ruge, Tyra Kristoffersen and Miriam Idsøe, standing outside Ullern Upper Secondary School. Alexander Flåskjer is also a part of the GLIMT team, but was unfortunately not present on the day the image was taken. Photo: Elisabeth Kirkeng Andersen

Mentor Bente Prestegård and the students Andreas Bjurstrøm, Carl Ruge, Tyra Kristoffersen and Miriam Idsøe, standing outside Ullern Upper Secondary School. Alexander Flåskjer is also a part of the GLIMT team, but was unfortunately not present on the day the image was taken. Photo: Elisabeth Kirkeng Andersen

Bente, that Tyra mentioned, is Bente Prestegård. She is a project manager in Oslo Cancer Cluster and one of her many projects is the school collaboration between Ullern Upper Secondary School and Oslo Cancer Cluster.

“I have had a few meetings with the students behind GLIMT. I have specially advised them about how to relate to patients and staff in the hospital, and I helped them with pitch training in advance of the Oslo Championship in Young Entrepreneurship,” said Prestegård.

Prestegård thinks that it is a lot of fun to be a mentor for GLIMT and she is impressed about how driven the students have been and how much they have accomplished, even though the corona pandemic but a sudden stop to the company’s activities in March.

The students also learned a lot from Bente’s advice and are grateful for all the coaching they have received while running the company.

“Bente introduced us to several key people at Oslo University Hospital, which was very valuable for us. She is also very knowledgeable about the economy and has given us a lot of good input on that aspect too,” Tyra said.

Learning in practice

It is June now and homeschooling is fortunately over, but there are still strict visitation rules at Norwegian hospitals because of the pandemic. GLIMT UB is dissolved since the school year is over and the students have gained a sense of what it is like to be a founder.

“It has been fun and educational. We would, of course, had wanted to do more for these teens, but hopefully, the hospitals across the country can be inspired by our idea,” said Carl, the company’s interim manager.

One thing that has been challenging for GLIMT is to find a way to make money out of the idea since the hospitals have limited resources.

“We still had NOK 7 000 left in our budget this year, which we have donated to Oslo University Hospital,” said Tyra.

Sign up to our monthly newsletter

 

International Cancer Cluster Showcase 2020

The 9th International Cancer Cluster Showcase has been launched on June 8th as a virtual event presenting 20 early-stage oncology companies.

For the first time, the annual International Cancer Cluster Showcase (ICCS) is presented in a digital format. Although we are missing the lively networking elements this year, there is a clear advantage: participants from around the globe can view the full program or selected presentations whenever suitable until July 8th – independent of time-zones and location. The record-high participation with about 400 registrations confirms that this flexible format offers an interesting opportunity to meet new companies in times when travelling is limited.

The organising partners from North America and Europe have jointly selected 20 emerging oncology companies from 8 countries advancing novel therapeutic, diagnostic and digital solutions. The CEOs of this outstanding group of early-stage companies present their latest innovations and partnering opportunities in four thematic sessions.

“We hope that this 9th International Cancer Cluster Showcase again creates novel collaboration opportunities and contacts for presenters and participants and stimulates relevant discussions.”

Jutta Heix, Head of International Affairs, Oslo Cancer Cluster.

A joint welcome from the organising partners opens the first session with the theme Targeting novel mechanisms. Our member EXACT Therapeutics is one of the companies selected for this session. CEO Rafiq Hasan introduces the company’s unique Acoustic Cluster Therapy for ultrasound-mediated, targeted therapeutic enhancement.

“It was important for EXACT Therapeutics to participate at ICCS as this is one of the leading opportunities for us to communicate progress with our innovative Acoustic Cluster Therapy (ACT) platform in oncology to key stakeholders and potential partners.

“We are impressed by the virtual format and the agility with which the in-person meeting was transformed to a digital platform. This ensures that the objectives of the meetings are achieved despite the challenges of the current situation.”

Rafiq Hasan, CEO, EXACT Therapeutics

CEO Rafiq Hasan, EXACT Therapeutics

Rafiq Hasan, CEO of EXACT therapeutics, is one of the presenters at ICCS 2020.

The theme of the second session is Immuno-Oncology and Cell therapy. Here the Oslo Cancer Cluster member Nextera introduces their NextCore technology and relevant applications in oncology.

“It was important for Nextera to present our unique drug and target discovery platform at the stage we are now, since we believe we can enable immuno-oncology therapies to new levels both from efficacy and safety points of view.

“The digital format fosters a great flexibility as well as the message reaches a larger audience.”

Ole Henrik Brekke, Chief Business Officer, Nextera

Geir Åge Løset, CEO of Nextera, presented at ICCS 2020.

Geir Åge Løset, CEO of Nextera, is one of the presenters at ICCS 2020.

The third session has the theme Immuno-Oncology, oncolytic viruses and vaccines, featuring companies from the US, UK and France showcasing their technologies and lead candidates.

As final Nordic company, our member Kaiku Health presents their platform for personalized digital health interventions in the fourth session titled Diagnostics and digital health interventions.

“ICCS is a good platform to reach like-minded innovators in oncology interested in making cancer care more personalised. We were happy to have the opportunity to go virtual during these exceptional times.”

Lauri Sippola, CEO and Co-Founder, Kaiku Health

Lauri Sippola, CEO of Kaiku Health, is one of the presenters at ICCS 2020.

Lauri Sippola, CEO of Kaiku Health, is one of the presenters at ICCS 2020.

The Virtual International Cancer Cluster Showcase is available online, via the official ICCS website, until 8 July 2020.

Details of all the presenters can be found in the ICCS 2020 event guide.

We kindly thank the sponsors and partners BIO, DNB, Precision for Medicine and Takeda for their ongoing support and program contribution.

 

Organising partners:

Sponsors:

Fremtidens Kreftbehandling: Kreft og kliniske studier. Et veikart for bedre kreftbehandling.

Integrating clinical trials in cancer treatment

How can we make clinical trials an integrated part of cancer treatment in Norway so that more patients can gain access to new and better treatments?

We arranged a webinar with key experts and politicians to answer this question. Watch the entire webinar on Youtube:

“The number of patients that get considered to participate in clinical studies in Norway is too low and it is difficult to arrange clinical studies across borders in the Nordics. This is unacceptable, but how can we change it?” This is how the moderator Ketil Widerberg, general manager of Oslo Cancer Cluster, set the scene for our first webinar, which was live-streamed from Kreftforeningens Vitensenter in Oslo.

A visionary plan

The Norwegian Ministry of Health and Care Services has said that clinical studies should be an integrated part of patient treatment in Norway. This is especially relevant when it comes to the advent of new cancer treatments and the fact that the number of clinical trials is decreasing in Norway. The Ministry is now working on a Clinical Studies Action Plan to be completed in 2020.

Maiken Engelstad, Deputy Director General of The Department of Specialist Health Care Services, gave a presentation on its contents so far. An overarching goal is to get more, useful clinical studies to Norway, so that more patients can receive better treatments, and ultimately achieve a more efficient health service.

Engelstad mentioned many important aspects to achieve this. For example, to create more collaborations between the industry and public sector, with NorCRIN as a “one-stop-shop” for clinical studies. Engelstad stressed that Norway needs to build capacity, so that feasibility, recruitment and approval is accelerated. Engelstad also talked about building competency, by including clinical research, gene therapy and artificial intelligence in education. Moreover, Engelstad wants to increase the multitude of different studies, catering to both big and small patient groups, vulnerable patients, assessing both new and established treatments, and conducting the trials both locally, nationally and internationally. 

“We need to look to Norway’s advantages, such as real world data, which can be used from designing the drugs to implementing new therapies in the clinic.” Maiken Engelstad

Engelstad said that there needs to be a national and regional framework in place to achieve this, with regulations, financing, infrastructure and competency. Engelstad finally highlighted that one of the biggest challenges is to achieve a cultural change towards conducting clinical trials in Norway.

The tangle of rules

The legal framework that regulates clinical studies in the Nordics is very difficult to navigate for patients who wish to participate in and for companies that wish to arrange clinical trials. Wenche Reed, Head of Research in The Section for Research, Innovation and Education at Oslo University Hospital, talked about how complicated it is to interpret the regulations. 

“There are many laws to consider when conducting clinical studies. It is not easy to navigate the legal landscape – not even for lawyers!” Wenche Reed

Reed explained that the advent of personalized medicine in cancer is challenging the division between patient treatment and clinical research. Moreover, the ethical and legal framework for handling big data is being challenged, because of new developments using artificial intelligence in diagnostics.

Tearing down the barriers

The introductory presentations were followed by a lively panel discussion, divided into three sections. The first section included a video message from Tone Skår, project manager in VIS Innovation and founder of the MED.hjelper project and #SpørOmKliniskeStudier social media movement. Skår emphasised the importance of informing patients of the possibility of participating in trials and creating incentives for doctors and hospitals to run the trials.

Sigrid Bratlie, Special Adviser in The Norwegian Cancer Society, commented that a cultural change is needed. Bratlie said we need to look at concrete cases to learn how to conduct successful clinical studies in cancer personalised medicine.

Bratlie highlighted that Norway has world-class cancer research milieus, especially in cell therapy, but the total number of clinical trials is dwindling. Europe risks falling far behind the US and China, because of the complicated legal framework.

“The Biotechnology Act is just one small piece of the puzzle. Soon there will be a hearing for the Genetechnology Act. We need to look at the bigger picture and how the different laws interact.” Sigrid Bratlie

The second part of the panel conversation turned to both clinicians and industry for their perspectives. Daniel Heinrich, Senior Consultant Oncologist at Akershus University Hospital and Head of The Norwegian Oncology Association, wants to offer his patients the opportunity to try new treatments, which potentially can be better than the standard treatment. Heinrich highlighted that it is difficult for patients that need to travel to different hospitals and private clinics for testing because the hospitals lack capacity. He said that the directives need to come from above, from hospital management, the Directorate of Health and the politicians.

“It is almost impossible to include patients in studies in other countries now. Often it is difficult to understand why!” Daniel Heinrich

Baldur Sveinbjørnsson, Chief Scientific Officer in Norwegian cancer start-up Lytix Biopharma, has tried to arrange a clinical trial in Norway, but found that it was better to conduct it from a hospital in Copenhagen. When patient recruitment was too slow and costs were mounting every day, Sveinbjørnsson travelled around the Nordics to attract patients. There was great interest, but the differing regulations and processes in the Nordic countries put a stop to recruitment.

“We have started looking towards the US and filed an application to the authorities to conduct our next clinical study there.” Baldur Sveinbjørnsson

Hege Edvardsen, senior adviser in Legemiddelindustrien (LMI), thinks Norwegian companies should be able to conduct their trials in Norway. Edvardsen said we need to establish a “one-stop-shop” for clinical studies in Norway. Edvardsen said that the pharmaceutical industry often turns to the most successful cancer centres and hospitals when placing their clinical trials.

“Dedicated enthusiasts are the ones running the clinical studies, but we need targeted financing, so the people doing the work are acknowledged.” Hege Edvardsen

The final part of the panel discussion included two politicians’ visionary perspectives for the future.

Marianne Synnes Emblemsvåg, politician for The Conservative Party of Norway – Høyre, said she was touched by the ambitious plans in the Action Plan. Emblemsvåg commented that she is an impatient person, but that the bureaucratic process takes time to change.

“We need to market Norway in a way that makes us attractive for clinical trials.” Marianne Synnes Emblemsvåg

Emblemsvåg commented that there are many exciting developments considering artificial intelligence and diagnosing cancer, but that they come with some very challenging ethical considerations.

Tuva Moflag, politician for The Labour Party of Norway – Arbeiderpartiet, agreed that things take time to change. Moflag emphasised that part of the political work is to “clean up” some of the bureaucratic mess and to remove the legal barriers.

“We should have high ambitions for clinical studies, considering that we are a rich country and should assume responsibility for our patients.” Tuva Moflag

Moflag also stressed that there needs to be infrastructure, personnel and financing to complete it. Creating a culture of innovation, so that medical personnel feel they are part of something bigger than themselves.

The webinar ended with some final comments from Engelstad, who had been listening and taking diligent notes to bring with her in her work with the Action Plan going forward.

We want to direct a special thank you to all the meeting participants, to the organising partners and to everyone who followed the live stream.

Our next meeting in this series will take place this fall. More details will be published on our website closer to the event.

 

Event organisers:

 

 

 

Sign up to our monthly newsletter

 

Pavlova, Photo by Alice Ponce from Pixabay.

May 17th Virtual Greeting

”Gratulerer med dagen” (Congratulations!) on Norway’s Constitution Day from the entire Oslo Cancer Cluster team.

As a prelude to the May 17th celebrations, Oslo Cancer Cluster hosts an annual networking breakfast for our cluster’s members, neighbours in Oslo Cancer Cluster Innovation Park and the wider oncology community.

The Norwegian Constitution Day Breakfast 2020 has been adapted in the form of this virtual greeting as we observe social distancing together.

The team at Oslo Cancer Cluster and Oslo Cancer Cluster Incubator would like to wish Norwegians everywhere “Gratulerer med dagen!” with best wishes on this special day for Norway.

Oslo Cancer Cluster members in Norway and around the world, thank you for your support toward collective efforts to positively impact oncology research.

 

Henrik and Tia receive homeschooling during the corona lockdown.

Homeschooling for researchers-to-be

This article was originally published in Norwegian on our School Collaboration website.

Even during the corona lockdown, the researcher students have received inspiring classes online, but they miss the practical work and are happy to soon return to school.

The researcher programme is an opportunity for upper secondary students who want to specialise in the natural sciences and the teaching is based on a combination of practical work and in-depth theory. So, how has home schooling been during corona lockdown? Digital classes in biology have replaced the usual work placements in professional research laboratories and performing experiments in school. We talked to the students Tia and Henrik, and their teacher Monica, to find out more.

CORONA UPDATE


This article was written before the Norwegian government released the positive news that students will return to school during week 20.


Since Ullern Upper Secondary School houses almost 1 000 students, they will return gradually to control the spread of COVID-19. The Researcher Programme starts on Wednesday 13 May and the class will be off to a flying start.


“The students will receive a lecture from an astrophysicist on their first day back. It was supposed to be delivered digitally, but now it might take place in the classroom, which will be extra special!” says Monica.


Both Monica and the students are looking forward to returning to the school. Henrik and Tia were hoping to begin school again during May and now they are getting their wish fulfilled.

“I think home schooling works. It is effective. The teachers have made great arrangements and we are learning new things,” says Henrik Corneliussen, who is in his first year of the Researcher Programme.

“I think it is going surprisingly well in many subjects, but it is difficult to stay motivated and focused on the teaching when we are doing so much on our own. Math is a bit more difficult now and biology is also challenging,” says Tia Morigaki Sauthon, who is in the same class as Henrik.

Monica Flydal Jenstad and Ragni Fet are Natural Science teachers and have both been cancer researchers. They are responsible for the new Researcher Programme at Ullern Upper Secondary School and teach biology and natural science to the class of 32 students for 10 hours every week.

Almost overnight, the teachers had to change their planned classes, because of the corona pandemic. They went from being physically present in the classroom – with all the available lab equipment and the possibility to perform experiments to exemplify different theories – to communicating with the whole class over the video-calling system Teams and teaching the students by using PowerPoint presentations and group tasks.

“Ullern Upper Secondary School is following the normal curriculum during homeschooling. When class begins, everyone checks into our Teams chatroom and says hi. Ragni or I deliver the teaching, usually through a lecture, and then the students complete tasks in a program called ‘OneNote’. We can see if the students are completing the tasks and help them if they are stuck or wondering about something,” Monica says.

Monica explains that life as a teacher has become more hectic and intense during corona lockdown, delivering classes in a digital format and being more available via messaging and calls over Teams.

Missing the practical aspects

Even though Henrik and Tia are generally happy with the digital classes, there are a few things they miss during homeschooling.

“I really miss the practical schoolwork, which we can barely do at all, because we lack access to equipment that we need to perform experiments at home. We have also missed out on many placements, which is a shame. I have luckily already participated in one placement, but it is sad for the students who haven’t had the opportunity,” Henrik says.

The Ullern students visited the Core Facility for Advanced Light Microscopy at Oslo University Hospital.

Image caption: Henrik, second person from the left, is one of the lucky students on the Researcher Programme, who has already participated in a placement. The other students in the picture are Peder, Isha and Christopher. The placement was with the research group for advanced cancer therapy in February. Photo: Elisabeth Kirkeng Andersen

“It is really sad that we have missed out on so much practical work, which was why I chose the Researcher Programme. Fortunately, we have done a few experiments at home. We have, among other things, made our own solar thermal collectors and learnt how to measure light strength in lux, which we have used to understand how to measure the distance from the Earth to the stars,” says Tia.

Monica shares the students’ feelings.

“The students were in the middle of their independent research projects when the school closed. Some had already performed experiments at home with plants that they could follow up, but other students were dependent on finishing their projects at school. The purpose was always for them to present the results of their research during a poster session, which is a presentation format that researchers use to show data and other findings from their research, but we have had to postpone this activity. Hopefully, we can complete it in June with the students’ mentors present,” Monica says.

The poster session is not the only thing the students have missed. Four placements with different research groups at Oslo University Hospital and the company Thermo Fisher Scientific, and three relevant lectures by researchers, were planned for the period they have been stuck at home.

“The students have missed out on many aspects of the Researcher Programme in this period, because it is difficult to perform the practical work, both in the regular teaching and in the form of placements. It is simply a more boring school day,” Monica says.

The corona pandemic itself can however be used in the teaching, both in mathematics to learn about exponential growth and in biology to learn about viruses.

Happy to return to school

Tia and Henrik really miss being in school together with the other students of the Researcher Programme and other friends, both at Ullern and outside of school.

“I look forward to meeting my friends again. I don’t see many of them now. I also look forward to getting started with the practical work at school, with experiments in the natural sciences and biology. It is really fun, and the teachers are good at organising interesting experiments and placements, in collaboration with Oslo Cancer Cluster,” says Henrik.

Tia also misses her friends a lot.

“Maybe what I look forward to the most is getting back to the normal everyday routine – going to school and being with friends. I talk to my friends over Teams and have one friend I meet a lot, but I miss being with many people at once,” says Tia.

She thinks the learning is more challenging from home.

“It is easier to ask for help in school. It is much more difficult to get a verbal explanation without being shown how everything is connected by the teacher, so I spend a lot of time trying to figure things out myself instead of asking for help,” says Tia.

The students are also sorely missed by their teachers.

“I miss them all and especially the contact with the students in a classroom setting, one-on-one. It is much more fun and better to follow the students directly, especially when they think the subject is a bit heavy,” says Monica.

Tia is still sure that even though the corona pandemic has had far-reaching consequences, not all of them are bad.

“I think it seems like everyone has made the best out of the situation. It could have gone much worse and been much worse. In many ways, I think this is a useful experience and, one way or another, something good will come of it,” says Tia.

Summary of postponed or cancelled plans for the students:

  • Poster session about their own research projects with the mentors
  • Lecture on screening of new-borns with Janne Strand, Child- and Youth Clinic, Oslo University Hospital
  • Lecture on structural biology and drug design with Bjørn Dalhus, Oslo University Hospital
  • Lecture on organising research with Barbra Noodt, Cancer Clinic, Oslo University Hospital
  • Placement with Thermo Fisher Scientific
  • Placement with Harald Stenmark at the Department of Molecular Cell Biology, Oslo University Hospital
  • Placement with Hans Christian Aas at Flow Cytometry Core Facilities at Oslo University Hospital
  • Placement with Bjørn Dalhus’ research group Structural Biology and DNA repair, Oslo University Hospital.

 

Sign up to our monthly newsletter

Research on gene-edited embryos allowed

Important cancer research into gene-edited human embryos will now be possible in Norway

Research on gene-edited human embryos will now be allowed in Norway, after a majority agreement has been reached among parties in the Norwegian Parliament. The news was given at a press conference on Thursday, when representatives from the three political parties Arbeiderpartiet, Fremskrittspartiet and Sosialistisk Venstre presented the amendments to the Biotechnology Act (“bioteknologiloven”). This is the act relating to the application of biotechnology in medicine.

The changes to the Biotechnology Act are good news for cancer patients and researchers, as they allow for research into gene-edited human embryos. This will give us important knowledge about how cancer arises and how to develop effective treatments against cancer.

Oslo Cancer Cluster gave input to these changes, during a hearing on 6 February 2020 at the Ministry for Health and Care Services. We emphasised that it is important that the regulations are in line with technological developments to promote research, so that we in the future have improved access to personalised cancer diagnostics and treatments.

“These are important changes to promote cancer innovation in Norway. It will help accelerate research into new cell therapies, which will benefit cancer patients both here in Norway and abroad,” said Ketil Widerberg, general manager of Oslo Cancer Cluster.

Gene technology is an important area in cancer research, with many recent break-through discoveries. By gene-editing human embryos, researchers can develop personalised cancer treatments and diagnostics.

Cell division in embryos and uncontrolled cell division in cancer cells is regulated by the same genes. That is why research on gene-edited human embryos will give us valuable knowledge about genetic diseases like cancer.

Gene technology can be used to create genetic changes and give us more knowledge about cell division. For example, researchers can insert genetic markers in DNA and follow the cell’s development from stem cell to cancer cell. They can also produce mutations in an embryo and study how cancer develops at an early stage.

You can read more about cancer research and gene-editing on the Cancer Research UK Science Blog.

It is important to note that the embryos used for research and gene-editing are not allowed to be implanted in a female uterus for pregnancy. This is in line with the current Swedish regulations on gene-edited human embryos.

The fact that gene-editing human embryos will be allowed in Norway means that we can attract world-class cancer clinical studies and deliver new personalised treatments to cancer patients.

The Norwegian Parliament (“Stortinget”) will officially vote on the amendments on 26 May 2020 and we will follow any further developments closely.

Sign up to our monthly newsletter

 

Helsenæringens Verdi 2020

Helsenæringens verdi 2020

Helsenæringen er en dobbel mulighet for Norge: næringen kan løse mange av våre helse- og omsorgsutfordringer de neste tiårene og samtidig bli en av våre største næringer, med eksport til et globalt marked.

Den norske helsenæringen hadde en samlet omsetningsvekst på 4,7 prosent i 2018. Rapporten dokumenterer at denne veksten særlig var drevet av store selskaper i den norske helseindustrien. Bedriftene i alle bransjene i helsenæringen rapporterer om ytterligere vekst 2019, noe som resulterer i et vekstestimat for næringen som helhet på 6,2 prosent for 2019 – dette er høyere enn næringens gjennomsnittlige årlige vekst for de siste ti årene.

Bedriftene rapporterer samtidig om svært sterke forventninger til treårsperioden fra 2020 til 2022. Bedriftenes egne vekstprognoser for disse årene er imidlertid hentet inn før Koronakrisen utviklet seg til en global krise. Det er av den grunn svært høy usikkerhet knyttet til disse prognosene.

Koronakrisen er en «helsekrise». Dette gjør at krisen påvirker helsenæringen med en langt større variasjon mellom bransjer og segmenter enn for andre næringer. I rapporten redegjøres det både for segmenter i helsenæringen som aldri har opplevd høyere etterspørsel og aktivitet enn nå under Koronakrisen samt for bransjer og segmenter som har tilnærmet stoppet helt opp.

Den norske helsenæringen fremstår som godt forspent for videre vekst også i etterkant av Koronakrisen. Krisen har bidratt til å rette fokus på beredskap og innenlandsk produksjonskapasitet. En trend mot dette er ventet å styrke selskaper og produksjonsland som kan levere kvalitet, profesjonalitet og trygghet for leveranser, også i krisesituasjoner. Dette er en trend som bør kunne gagne Norge og norske helsebedrifter, både produsenter av legemidler eller medisinsk teknologi så vel som leverandører av helsetjenester.

Helsenæringens verdi 2020 dokumenterer at det er særlig er to ting bedriftene etterspør for å sikre videre vekst,

  • Markedstilgang – bedriftene i helsenæringen, både industri- og behandlingsbedriftene, trekker frem tilgang til offentlige anbud og konkurranse på like vilkår som den største flaksehalsen for videre vekst. Det er særlig mindre bedrifter og selskaper med inntekter fra både inn- og utland som opplever tilgangen på offentlige anbud som dårlig.
  • Skaleringskapital – det trekkes frem av et flertall av bedrifter at de savner støtteordninger som er innrettet mot skalering og internasjonalisering

Se lanseringen av Menon-rapporten

Les rapporten Helsenæringens Verdi 2020

Aktørene som står bak Menon-rapporten:

arrangørers logo

Students learning Artificial Intelligence, Machine Learning and Neural Networks

Programming to understand artificial intelligence

This article was originally published in Norwegian on our School Collaboration website.

How can programming, artificial intelligence and machine learning help us understand the human brain?

Four students from Ullern Upper Secondary School spent two days in the beginning of March on a placement in the Department of Physics at the University of Oslo. Jakob, August, Jørgen and Magnus learned how to program the snake in the game Snake to survive. At the same time, they learned about artificial intelligence, neural networks and machine learning.

Every spring, Professors Anders Malthe-Sørenssen and Marianne Fyhn at the University of Oslo receive eight students from Ullern Upper Secondary School on a placement.

Marianne Fyhn’s research group consists of some of the leading neuroscientists in the world. The four biology students Chiara, Eline, Tora and Eilin from Ullern Upper Secondary School spent the placement training rats and learned how research on rats can provide valuable knowledge about the human brain.

Anders Malthe-Sørenssen is the Director of CCSE (the Center for Computing in Science Education), where the students Magnus Trandokken, August Natvik, Jørgen Hamsund and Jakob Weidel were on another placement.

“There are three PhD students here, who are teaching the Ullern students. At the end of the day, they will gain a better understanding of what artificial intelligence is. We wish to explain the concept to them and give them an insight into what machine learning, neural networks and programming are,” said Malthe-Sørenssen.

  • Scroll to the bottom of this page to read the definitions for machine learning, neural networks and artificial intelligence.

Malthe-Sørenssen and the PhD students tested a new teaching tool on the Ullern students. If it is successful, more students will be able to access it to learn about artificial intelligence. Malthe-Sørenssen and his research group also try to improve the teaching of advanced mathematics, physics and programming in upper secondary schools.

Students learning artificial intelligence, machine learning and neural networks

Øyvind Sigmundsson Skøyen (in the middle) was one of the PhD students that taught the students from Ullern Upper Secondary School. Here, he is helping Jakob Weidel, who is in his first year. To the right is August Natvik, who is graduating this year. Photo: Elisabeth Kirkeng Andersen

Making the snake immortal

Jakob, Magnus, August and Jørgen programmed the game Snake in the programming language Python. This is a programming language that is available for free, an “open source”. You can download it here.

The point of the game Snake is to keep a snake alive for as long as possible. It lives in a square, where it eats candy so that its tail grows. The purpose of the game is to make sure the snake doesn’t crash into itself while it is growing because if it crashes, the snake dies. But it is not that easy. Try it yourself here.

“The students will program the snake so that it can learn where it is smart to move to eat the candy, while at the same time avoiding to crash into its growing tail. It is a good way to understand a little artificial intelligence and machine learning,” said Malthe-Sørenssen.

The three PhD students Sebastian Winther-Larsen, Øyvind Sigmundsson Skøyen and Even Marius Nordhagen were there to teach the Ullern students.

Øyvind had just finished showing the students how to programme the snake when it was Even’s turn to teach.

“What du you already know about machine learning?” Even asked.

“I have seen a little bit on YouTube,” Jakob replied.

“I know the theory, but I haven’t tried it myself,” Magnus said.

Even explained that he would present the theories behind machine learning and neural networks first, and then let the students create a neural network for Snake.

“Linear regression – a theory we often use in mathematics – is a simple form of machine learning. It is about producing a function that gives us the best line between two points. We use something called the method of least squares,” Even said.

Ullern students learning artificial intelligence, machine learning and neural networks.

Espen Marius Nordhagen (to the right) explains to the students from Ullern that regression is a simple form of machine learning. August Natvik is following closely. Photo: Elisabeth Kirkeng Andersen

Even explained that machine learning is used in image analysis. A computer can be taught to recognise and see the difference between several objects in a picture. The objects can be cars, bikes, humans, or other things. The computer can then be taught to create the images, which are then called generative models. Voice recognition, such as the virtual assistant Siri for iPhone users, is also based on machine learning, just like self-driving cars and buses.

“In order to understand artificial intelligence, you have to know what a neural network is. The concept is inspired by biology, neuroscience, and how human beings learn and remember. A neural network is a simplification of the human brain. The brain is in reality much more complicated,” Even explained.

“What is actually the difference between machine learning and artificial intelligence?” Jørgen asked.

Even explained that regression is machine learning, but not artificial intelligence.

“If you have a neural network with several layers, a so-called ‘deep neural network’, it is artificial intelligence. Then you will observe that something is happening with the data you receive from the neural network, it will be something you do not understand and cannot model, but it is consistent with reality,” Even said.

Learned new subjects

Magnus, August and Jørgen are all in the third year and have specialised in the natural sciences, with different combinations of mathematics, physics, technology, research, programming and computer modelling.

After graduating, all three of them will go to military school. Afterwards, Jørgen and Magnus are tempted to study at NTNU.

“The Industrial Economics programme at NTNU seems really good. Maybe I will combine it with the Entrepreneurship Programme, which is also at NTNU. Then I can start my own company after I finished studying. I am also thinking about a career in the military,” said Magnus.

The Ullern students agreed that the placement at the Department of Physics had been difficult, but fun and educational too.

“They are really good at teaching here. It has been difficult, because we haven’t studied these subjects before and everything new is always difficult,” said Jørgen.

Jakob Weidel is still in his first year and is thinking about studying the same subjects as the other three Ullern students. He was asked to participate in the placement after he helped Tom Werner Halvårsrød, the IT administrator at Ullern Upper Secondary School, to programme Excel sheets, which are used in the school.

“I have made a few apps and developed a few websites and used different types of programming languages. I have never used Python before, so it has been fun to learn something new,” said Jakob.

(image caption) Anders Malthe-Sørenssen is a professor at CCSE (the Centre for Computing in Science Education) at the University of Oslo. He and his research group are active in many different areas of research, including improving how physics is taught and understanding how the brain works through advanced mathematical models. Photo: Elisabeth Kirkeng Andersen.

Anders Malthe-Sørenssen is a professor at CCSE (the Centre for Computing in Science Education) at the University of Oslo. He and his research group are active in many different areas of research, including improving how physics is taught and understanding how the brain works through advanced mathematical models. Photo: Elisabeth Kirkeng Andersen

Neural networks and neuroscience

Malthe-Sørenssen’s and Fyhn’s research groups collaborate in a field of biology and physics, which is about research into how the human brain works and neural networks, in the projects DigiBrain and CINPLA. CINPLA is an acronym for Centre for Integrative Neuroplasticity.

“Here at the Department of Physics, we create computer models of neural networks. Then, we compare our models with Marianne’s discoveries about how the brain works from her studies on rats and mice. So far, we have seen that our models give a good picture of what is actually happening in the brain, but we are far from finished,” says Malthe-Sørenssen.

His popular research group receives over 1 000 job applications every year, but they want to keep prioritising student placements.

“We are dedicated to contributing to improving the programming skills in schools. One of our employees has developed the new subject and the syllabus for programming and computer modelling, which will be implemented in upper secondary schools by autumn 2020. Programming will then be used to teach several subjects, including mathematics,” Malthe-Sørenssen says.

He thinks it is good to contribute to raising the level of skills in the local schools around the Department of Physics at the University of Oslo.

What is a placement?

Oslo Cancer Cluster and Ullern Upper Secondary School have an active school collaboration project. The collaboration gives students at the school the opportunity to take part in work placements at different companies and research groups at Oslo University Hospital, at the University of Oslo and with members of Oslo Cancer Cluster.

On the placements, the students get to learn about different subject areas directly from experts and they get the opportunity to do practical laboratory work. The purpose of the placements is to give the students an insight into the practical everyday life of different professions and what career opportunities that different academic degrees hold.

DEFINITIONS

Neural Networks: A neural network is a group term for data structures, and their algorithms, that has been inspired by the way nerve cells in the brain are organised. Neural networks are among the key concepts in machine learning and artificial intelligence.

Machine learning: Machine learning is a special area within artificial intelligence, where you use statistical models to help computers to find patterns in large data quantities. The machine “learns” instead of being programmed.

Artificial intelligence: Artificial intelligence is information technology that adapts its own activity and therefore seems intelligent. A computer that is able to solve assignments without instructions from a human on how to do it, has artificial intelligence.

Sign up to our monthly newsletter

 

Our funding support: up to €60 000 per SME

Our EU project DIGI-B-CUBE offers funding support of up to €60 000 per SME, for small to medium-sized enterprises that may be struggling during the corona crisis.

The COVID-19 pandemic represents an unprecedented challenge for healthcare systems and societies worldwide. There is an urgent need for novel diagnostics solutions, integrated detection systems and biosensing technologies that would, in a rapid, specific and efficient way, support the identification and tracking of infection chains and acquired immunity. Biological and biomedical imaging technologies are also essential for addressing many research questions, such as those related to SARS-CoV-2 infections, from basic research at the molecular and cellular level to medical applications and diagnostics. In addition, Biobanking processes are crucial in the race towards a COVID-19 vaccine and development of treatment options.

There is an urgent need to support Small and Medium-sized Enterprises (SMEs) capable of delivering innovation projects addressing the broad range of COVID-19 related challenges.

Through DIGI-B-CUBE project, we are announcing our funding support for SMEs to fight against COVID-19 through cross-sectoral collaborative projects. DIGI-B-CUBE offers direct financial support up to €60,000 per SME from relevant sectors including healthcare, medicine, biotech, biopharma, IT, robotics, automation, electronics, and nanotech. DIGI-B-CUBE supports digital innovations and solutions for the reconfiguration of the Medical Diagnostics and related value chains (depicted in the diagram below) towards a Health Economy 4.0 with a special focus on Biobanking, Bioimaging, Biosensing and related industries.

digibcube graphics

Given below are the details of the DIGI-B-CUBE open call: 

Project Name: Digital Enterprise Innovations for Bioimaging, Biosensing and Biobanking Industries (DIGI-B-CUBE)

Open Call Title DIGI-B-CUBE Open Call for Proposals for Innovation Projects (DIGI-B-CUBE-IA-2020-2021)

Open Call Publication Date: 22 April 2020

Deadlines:

Voucher Type 1st Deadline 2nd Deadline
Prototyping Voucher 29 July 2020 at 17:00 (CET) 03 February 2021 at 17:00 (CET)
Customised Solution Innovation Voucher 29 July 2020 at 17:00 (CET) 03 February 2021 at 17:00 (CET)
Continuous Open Call
Co-working Disruption Lab Voucher From 28 October 2020 to 27 October 2021, 17:00 (CET)

Expected Duration of Participation:

Voucher Type Project Runtime
Prototyping Voucher 1 to 3 months
Customised Solution Innovation Voucher 2 to 6 months
Co-working Disruption Lab Voucher 0.5 to 2 months

Maximum Funding Request per Proposal:

Voucher Type Max. funding per SME Max. funding per project
Prototyping Voucher €20 000 €60 000
Customised Solution Innovation Voucher €50 000 €150 000
Co-working Disruption Lab Voucher €10 000 €10 000

Purpose of the Vouchers and Respective Applicant Group:

Voucher Type Purpose Applicant Group
Prototyping Voucher Support to prototype or conceptualise a solution (proof of concept, feasibility study) for a digitalization challenge in the Medical Diagnostics and related value chains. Consortium consisting of minimum 2 SMEs and maximum 3 organizations;

From at least 2 different sectors (Example: An SME from healthcare/medicine/biotech/biopharma + An SME from IT and related sectors)

Customised Solution Innovation Voucher Support to jointly develop a novel product/service based on an existing proven concept that addresses a digitalization challenge in the Medical Diagnostics and related value chains. Consortium consisting of minimum 2 SMEs;

From at least 2 different sectors (Example: An SME from healthcare/medicine/biotech/biopharma + An SME from IT and related sectors)

Co-working Disruption Lab Voucher Support to further advance a successfully completed customised solution innovation voucher project in an incubator / accelerator / co-working space of the DIGI-B-CUBE clusters’ network (or) in labs, technical and innovation facilities of other relevant SMEs. One SME from a completed Customized Solution Innovation Voucher project consortium + a host organisation (host does not receive direct funding from this voucher)

Evaluation Process:

The evaluation process takes max. 4 weeks starting from the respective cut-off date/deadline. The applicant/s will receive an e-mail about the outcome of the assessment directly after the assessment is finalised.

Target Group:

SMEs from the following sectors are eligible to apply for DIGI-B-CUBE vouchers:

  • healthcare / medicine / biotech / biopharma
  • IT and related sectors (robotics, automation, electronics, nanotech etc)

Submission Language: English

Web address for full open call informationhttps://digibcube.eu/open-calls/

Web address for proposal submissionshttps://digibcube.eu/collaborative-platform/

E-mailinfo@digibcube.eu

Indicative budget for the call: Total budget €2 700 000. The following budget planned across the deadlines may change based on the number and quality of the applications received.

Voucher Type 1st Deadline 2nd Deadline
Prototyping Voucher approx. €360 000 approx. €240 000
Customised Solution Innovation Voucher approx. €1 050 000 approx. €700 000
Continuous Open Call
Co-working Disruption Lab Voucher approx. €150 000

Contact (Coordinator):

Dr. Gupta Udatha

Director (Digital & EU)

Oslo Cancer Cluster

Oslo, Norway

Email: gupta.udatha@oslocancercluster.no

Digi-b-cube logo

Funding opportunities for health and IT SMEs

DIGI-B-CUBE, funded under the European Union´s Horizon 2020 Programme, aims to unlock the cross-sectoral collaborative potential of SMEs by combining e.g. Artificial Intelligence (AI), Cognitive Computing Digital Technologies (CCDT) with the Bioimaging-Biosensing-Biobanking (B-CUBE) and related value chains to deliver market sensitive disruptive technologies and generating innovative solutions that enhance patient-centred diagnostic work-flows.

The project provides support to SMEs through matchmaking, coaching, digital transformation services and equity-free funds up to €60,000 per SME. The support helps SMEs design solutions and develop new products and services to accelerate innovations in personalised medicine. SMEs can access these services and apply for funding under the DIGI-B-CUBE Voucher Scheme by registering on the DIGI-B-CUBE Collaborative Platform at platform.digibcube.eu.

Use the DIGI-B-CUBE Collaborative Platform at platform.digibcube.eu to:

  • Get to know other organisations and identify collaboration partners online or during matchmaking events;
  • Register for DIGI-B-CUBE events;
  • Access services (digital maturity assessment tool, knowledge repository, training, competence network and board programme) to facilitate your digital transformation;
  • Apply for funding through the DIGI-B-CUBE Voucher Scheme;
  • Get follow-up coaching by the cluster organisations regarding further existing support measures and additional funding schemes.

Participate in the DIGI-B-CUBE Events to:

  • Identify value chains and associated challenges for SMEs for their digital innovation and collect data on existing processes and management systems;
  • Evaluate identified value chains and associated challenges for SMEs and develop customised solutions;
  • Take part in matchmaking events and face-to-face meetings to find collaboration partners from the IT and/or Health sector to apply for funding for joint digital innovation projects that address value chain issues;
  • Take part in digital transformation activities and follow-up coaching in order to successfully develop and scale-up digital innovation products and services.

Receive funding through the DIGI-B-CUBE Voucher Scheme

Benefit from four types of vouchers to tackle digitalisation challenges and:

  • Build cross-sectoral and cross-border partnerships composed of businesses that are challenge-owners and solution-providers;
  • Contribute to new Health industries, new digital Health services, effective Medical Diagnostics that will lead to Precision Medicine, Preventive Medicine and Healthcare Transformation.

Travel Voucher

Up to €2,000 per voucher
Up to €6,000 per SME

Get reimbursed for your travel costs (transportation, accommodation and event fees) incurred for attending DIGI-B-CUBE events. Applications must be submitted prior to the event.

Available from 20th September 2019 to 28th February 2022


Prototyping Voucher

Up to €20,000 per SME
Up to €60,000 per project

Receive funding to prototype or conceptualise a solution for a digitalisation challenge in the Medical Diagnostics and related value chains. Consortia consisting of minimum two SMEs and maximum three organisations from at least two different sectors will be funded.

1st Deadline: 29th July 2020
2nd Deadline: 3rd February 2021


Customised Solution Innovation Voucher

Up to €50,000 per SME
Up to €150,000 per project

Receive funding to jointly develop a novel product/service based on an existing proven concept that addresses a digitalisation challenge in the Medical Diagnostics and related value chains. Consortia consisting of minimum two SMEs from at least two different sectors will be funded.

1st Deadline: 29th July 2020
2nd Deadline: 3rd February 2021


Co-working Disruption Lab Voucher

Up to €10,000 per SME/project

Receive additional funding to further advance a successfully completed Customised Solution Innovation Voucher project in an incubator / accelerator / co-working space of the DIGI-B-CUBE clusters’ network (or) in labs, technical and innovation facilities of other relevant SMEs. Consortia can include one SME from a completed project consortium and a host organisation.

Available from 28th October 2020 to 27th October 2021

Note: An SME can apply for multiple vouchers but the overall maximum funding per SME is €60,000.


Who can apply?

SMEs that are interested in cross-sectoral collaborations, aiming to integrate innovations from IT into the B-CUBE industries and related value chains, to accelerate the goals of personalised medicine. SMEs should be established in one of the EU member states or H2020 associated countries.

Register on the DIGI-B-CUBE Collaborative Platform at: platform.digibcube.eu

 

 

EU disclaimer

Ketil Widerberg, general manager, Oslo Cancer Cluster

Health clusters to help against corona pandemic

Let the health industry contribute to the fight against COVID-19!

This week, Abelia wrote a letter to the Minister of Health and Care Services and the Minister of Trade, Industry and Fisheries, appealing that they use the Norwegian health industry against the corona pandemic.

The corona pandemic has put Norway and its health services in an extraordinary situation. The health industry will play a central role in how this pandemic is handled. There will be a need to think of new ways to deliver health services, in order to alleviate the health sector in the long and short term.

Health tech companies can meet this need by delivering innovative solutions, but we need to utilise this potential quickly and efficiently. A strategic collaboration between the public health services and the up-and-coming health tech companies can achieve this.

Abelia, Oslo Cancer Cluster and the other Norwegian health clusters are uniquely positioned to connect and mobilise members of the health industry. A fast-working advisory council could help to look at the needs the corona crisis creates, to discover innovative solutions, and to identify relevant market opportunities for Norway.

“The corona pandemic has shown the important role the health industry has. Now more than ever, it is crucial to use and understand health data, to implement novel digital solutions in our health services and to speed up drug development times,” said Ketil Widerberg, general manager, Oslo Cancer Cluster.

The proposal in the letter is to assemble an advisory council consisting of representatives from the Norwegian health clusters (Oslo Cancer Cluster, Norway Health Tech, The Life Science Cluster and Norwegian Smart Care Cluster) in close collaboration with the governmental funding bodies (Innovation Norway, the Research Council of Norway and SIVA).

Sign up to our monthly newsletter

NLSInvest & NLSDays: Investors’ Advice to Life Science Start-ups

Some of the leading Nordic investors offer their advice to life science start-ups regarding Nordic Life Science Days 2020 (NLSDays, 9-10 September).

NLSDays 2020 has many new things in store, including the launch of the first-ever Nordic Life Science Investment Day (NLSInvest).

NLSInvest is a new pre-event (8 September) to the annual NLSDays conference. This is an opportunity for start-up companies – ‘Rising Stars’ in our life science community – to pitch to a range of national and international investors, including pharmaceutical venture arms.

“I spent months gathering feedback from investors and companies across our ecosystem, and one thing has been consistently clear: investors want to meet start-ups at earlier stages, while these companies often struggle to afford large partnering meetings. NLSInvest was created to bridge that gap: to give investors and ‘Rising Stars’ an intimate pre-event, while offering small companies the opportunity to stay for the full NLSDays at no cost,” said Chelsea Ranger, NLSDays Program Director & NLSInvest Program Committee Chair.

We spoke with two investors from Industrifonden and Hadean Ventures to find out what start-ups should focus on when preparing to present their companies to investors:

What are you looking for when investing in life science ‘Rising Stars’?

“We invest broadly in the life science space and we have a particular focus on the Nordic region. We are looking for start-ups that develop products with high potential, both from a market and medical impact perspective. We also look for a strong team with high ambitions,” said Ingrid Teigland Akay, Managing Partner, Hadean Ventures.

“In general, I would say that there are three components: assets-plan, financing, and management. The company should have a protected asset with a plan that can provide sufficient return on investment, a trustworthy and reliable way to finance the plan, and a management team that can do it. Quality of data is of course also a key component. We need to believe that the data we invest in are true and that they belong to the company,” said Jonas Brambeck, Investment Director, Industrifonden.

What are some of the most exciting developments in Nordic life sciences?

“The life science ecosystem is maturing and, increasingly, we see start-ups with world-class science attracting both international capital and talent. We are on a very good path,” said Teigland Akay.

“When it comes to certain areas, we like therapeutics, oncology, rare diseases, and digital health, but we could also consider opportunistic cases. We also want to be actively involved with Board participation,” said Brambeck.

Why would you encourage Nordic life science companies to join NLSDays?

“NLSDays is the largest life science conference in the Nordics and a must-attend event for everyone who wants to understand the dynamics in the Nordics and meet high quality start-ups. I highly recommend it,” said Teigland Akay.

“NLSDays is the glue that binds our ecosystem. It bridges our countries, sectors, therapeutic and scientific areas, large and small companies into one place and frame-of-mind: learning, networking, and growing business ideas. It is a large industry event, yet an intimate and welcoming setting in which the Nordics collaborate to share our best,” said Ranger.

Do you believe you are a ‘Rising Star’ in the Nordic life science community – and are you looking to meet relevant investors?

Then apply now to be one of the 60+ selected companies to pitches investors during NLSInvest!

For more information, please contact Chelsea Ranger, NLSDays Program Director & NLSInvest Program Committee Chair.

FAQs

What is the different between NLSDays and NLSInvest?

NLSDays is the largest partnering and investor conference for the Nordic life science community. Last year, over 1 300 delegates attended NLSDays from over 40 countries and participated in over 3 000 partnering meetings.

Register now for NLSDays with Spring rates until 31 May 2020!

NLSInvest will launch on 8 September as a new pre-event to the annual NLSDays conference. Over 60 ‘Rising Stars’ within the Nordic life science community will be selected from a pool of applications and invited to pitch before a range of relevant, global investors.

NLSInvest is Open for Applications until 31 May 2020!

What are the selection criteria for companies wishing to apply to NLSInvest?

Please view this PDF with information about the selection criteria.

What happens if my NLSInvest application is selected?

You will receive a confirmation email from the selection committee and a complimentary registration code for NLSDays 2020. Practicalities related to your company presentation will be confirmed later by the organizers.

What if my application is not selected?

You’ll receive a notification email from the selection committee and a discount code for NLSDays 2020 registration.

How many / who attended NLSDays in 2019?

Over 1 300 delegates attended NLSDays 2019 from over 40 countries and participated in over 3 000 partnering meetings. Read more about who attended the conference.

Have any 2020 names been released for NLSInvest or NLSDays?

Read more in the NLSDays 2020 Program.

View the speakers at NLSDays 2020.

What happens if the conference has to be delayed due to COVID-19?

The same venue in Malmö is already booked for April 2021 so, in the event of delay, you will be able to choose between a full refund or 2021 participation.

NLS Invest

The Ullern students visited the Core Facility for Advanced Light Microscopy at Oslo University Hospital.

Advanced microscopy on the timetable

This article was first published in Norwegian on our School Collaboration website.

How can we learn more about cancer cells by using advanced microscopes?

A microscope is an important tool for scientists in many different branches of research. In February, four first-year students from the Researcher programme at Ullern Upper Secondary School got to test multiple different microscopes at the Core Facility for Advanced Light Microscopy, The Gaustad node, at Rikshospitalet (Oslo University Hospital).

Isha Mohal, Peder Nerland Hellesylt, Christofer Naranjo Woxholt and Henrik Eidsaae Corneliussen are sitting in a small, rectangular room, which belongs to the research group Experimental Cancer Therapy at Oslo University Hospital.

“If you sit next to me, you can see better what I am doing,” says Emma Lång to the students.

Emma Lång is a researcher at the research group Experimental Cancer Therapy. She explains to Henrik and Isha how the advanced microscope, connected to the computer behind her, can record videos of living cells. Photo: Elisabeth Kirkeng Andersen

Emma Lång is a researcher in the research group Experimental Cancer Therapy. She explains to Henrik and Isha how the advanced microscope, connected to the computer behind her, can record videos of living cells. Photo: Elisabeth Kirkeng Andersen

It is the second day of the work placement for the Ullern students. Lång will show them how she is setting up a very special microscope with the somewhat cryptical name “ImageXpress Micro”.

The microscope is so special that it is the only one in the entire Oslo region and Eastern Norway. The unique thing about the microscope is that it creates videos of thousands of living cells over a long time period. This enables the researchers to understand more about how the cells move.

This is important knowledge in the research on cancer and wound healing, which this research group is working on.

The students sit down beside Lång and follow what she is doing closely. The microscope is entirely automatic, so all the settings are done on a computer. Later the same day, the students will use the microscope themselves to record videos of cells that they have been working on from the day before.

Learning from practical work

This is the first work placement for the students from the Research programme – and they are really enjoying it.

“It is fun to see what the researchers are doing and to try it out ourselves in practice,” says Peder.

“We have done some work with pipettes and worked in the laboratory at school, so we are already familiar with some of the practical handiwork. It is fun to try it out in a real research setting,” says Isha.

She likes that the placement gives some insight into what a career in research and cellular biology can be like.

“I am more interested to work in cellular biology after this placement, but I haven’t decided anything yet. I think we are learning things in an exciting way. It is practical learning and not as theoretical as it is usually in school,” says Peder.

“I absolutely see this as an opportunity to become a researcher. It is great to have so much science subjects as we have on the Researcher programme,” says Henrik and Isha agrees.

“I am very interested in the natural sciences. We have a lot of theory in school and it is fun to come out into the hospital and into companies to see how researchers work – and to try it out ourselves,” says Isha.

Christofer also thinks it is interesting, but he is more interested in data and other general subjects.

“That’s great, Christofer,” Lång says. “Research needs more people with good data knowledge. Do you see the computer over there? It costs NOK 100 000 and it will be used to develop machine learning and a technique called ‘deep learning’ on the data produced from our microscopes. Maybe in a few years time, computers will be analysing the microscope images and videos that we are recording now.”

Images of cells

Yesterday, Isha, Peder, Christofer and Henrik worked on cells in the laboratory. They learned a technique to fixate cells. Then, they coloured the cells with antibodies that turn blue when they bind to the core of the cell and with a protein called actin that turns green. Actin performs several functions in the cell, it is both inside the cell structure and functions as threads of communication between the cells.

Stig Ove Bøe leads the research group was visited by the four students from the Research programme at Ullern Upper Secondary School for two days. Here, he is preparing the images of skin cells that the students worked on the day before. Photo: Elisabeth Kirkeng Andersen

Stig Ove Bøe leads the research group that was visited by the four students from the Research programme at Ullern Upper Secondary School for two days. Here, he is preparing the images of skin cells that the students worked on the day before. Photo: Elisabeth Kirkeng Andersen

Now, the students are looking at the results uploaded to a computer in an advanced image editing software program that can visualise the cells as two- or three-dimensional.

“These are the skin cells you coloured yesterday. Can you see that the cells make up one close network? The reason for this is that it is skin and it is supposed to be impenetrable. Can you also see that the single cells act differently at the edge than closer inside? It is our job to explain why and how,” Bøe explains to the students.

The students look and nod with interest.

After the placement, researchers at Rikshospitalet (Oslo University Hospital) have worked more on the images and videos that the students created.

These have been delivered to the students and will be used when they make a presentation of the placement and everything they learned to the rest of the students at the Research programme.

You can see the cell image below.

A three-dimensional image of the skin cells that the students have coloured. Photo: Emma Lång

A three-dimensional image of the skin cells that the students have coloured. Photo: Emma Lång

What is cell migration?

The research group “Experimental Cancer Therapy” led by Dr Stig Ove Bøe at Rikshospitalet are researching how cells move, which is called cell migration in scientific terms.

Cell migration plays a central role in many of the body’s physiological functions, such as the immune system and wound healing. Cell migration is also essential for cancer, since cancer cells can spread from the location of the tumour to other organs of the body.

Cells use different mechanisms to migrate. They can move as single cells or they can move collectively. Thousands of cells can, for example, cooperate so they can move in the same direction.

The research group uses many different microscopy-based methods to research cell migration. They are also developing new video methods to study living cells in microscopes.

The research group is also responsibly for the daily running of the Core Facility for Advanced Light Microscopy at Oslo University Hospital. The facility gives other research groups in the Oslo region access to and guidance of the use of advanced microscopy equipment.

Sign up to our monthly newsletter

COVID-19 virus affecting clinical trials in Norway

This press release was sent out on NTB on 13 March 2020 by LMI and Oslo Cancer Cluster.

As a precautionary measure, in the continuous efforts to limit the spreading of the COVID-19 virus, and to shelter patients as well as healthcare staff, external personnel are given restricted access to hospitals, which consequently affects monitoring, auditing and inspections of ongoing clinical trials.

The restrictions – which also include a temporary halt in patient recruitment for new clinical trials – are implemented at all large hospitals nation-wide and include a provisional standstill in monitoring of ongoing research, as well, consequently delaying its outcomes.

It is imperative to note, that the precautionary measures taken, are in no way related to which studies that are ongoing, which treatment that is researched, or which company that is responsible for conducting it.

Ongoing Dialogue

LMI have contacted the health authorities, requesting advice as to how their members should relate to health personnel and hospital contact, but are yet to receive any information.

LMI, Oslo Cancer Cluster and their members have introduced their own precautionary restrictions for their employees, aiming to limit the risk of spreading the virus and to allow health personnel to prioritise according to the current, extraordinary needs.

LMI and Oslo Cancer Cluster will continue to monitor the situation closely and encourage both members and non-members to report any restrictions they might receive.

About

Oslo Cancer Cluster is a non-profit membership organization dedicated to accelerating the development of cancer treatments.

LMI is the pharmaceutical industry association in Norway and consists of Norwegian and international companies that develop, produce, sell or market pharmaceuticals in Norway.

Contact persons

Ketil Widerberg, general manager, Oslo Cancer Cluster

kw@oslocancercluster.no

Hege Edvardsen, senior advisor, LMI

Hege.edvardsen@lmi.no

 

Sign up to our monthly newsletter

Corona virus

Corona outbreak in Norway

Due to the ongoing corona virus outbreak, we have unfortunately decided to postpone / cancel all our meetings and close our offices for the time being.

On Thursday 12 March 2020, the Norwegian Prime Minister Erna Solberg announced several nation-wide measures (information in Norwegian) in order to contain the coronavirus outbreak in Norway.

In adherence to these new recommendations, all our meetings will be cancelled or postponed until further notice. Please follow the event pages in our event calendar for further updates.

In addition, all Oslo Cancer Cluster employees will be working from home effective immediately and until further notice. If you need to schedule a meeting, all employees are available via telephone or e-mail. Please refer to our Team page for contact details.

Oslo Cancer Cluster Incubator will have staff on-site according to a duty roster. We ask all tenants of the Incubator to refrain from inviting any visitors to our facilities for the time being. Please contact the Incubator Team or consult this Interim Guidance if you have any questions or special requirements.

For updates and general guidelines about the corona virus outbreak, please consult Folkehelseinstituttet (for information in Norwegian) and the Norwegian Institute of Public Health (for information in English). These include washing your hands regularly, avoiding handshakes and not attending large gatherings.

Special advice for cancer patients. Cancer patients are among those at high risk of serious illness from infection. Cancer Research UK has more information (in English) for cancer patients and their caregivers. The Norwegian Cancer Society has written similar advice (in Norwegian).

Stay safe and take extra good care of each other. This is a Norwegian public health “dugnad” and we must all do what we can to contain the outbreak.

Sign up to our monthly newsletter

OCC, OUS, Jordan State Visit

State visit to Jordan

Oslo Cancer Cluster visited King Hussein Cancer Centre (KHCC) in Jordan this week to foster international collaboration on cancer.

Oslo Cancer Cluster, Oslo University Hospital and Ultimovacs took part in a state visit to Amman in Jordan this week. The reason behind our involvement was that we want to create more international collaboration on the development of better cancer medicines. We wished to introduce Oslo University Hospital and Ultimovacs to King Hussein Cancer Foundation (KHCF), with regards to a potential collaboration on for example cancer clinical studies and innovative cancer treatments.

Foto: Tom Hansen

Ketil Widerberg, General Manager of Oslo Cancer Cluster, spoke at the industry seminar to discover future partnerships between Norway and Jordan. Photo: Tom Hansen

Ketil Widerberg, General Manager of Oslo Cancer Cluster, spoke at the opening ceremony for the industry seminar, arranged by Innovation Norway. He emphasised that there is reason to hope in the face of cancer as a deadly disease. There are new innovative treatments, which use the immune system to treat cancer, and the use of new technology to analyze health data. If several countries cooperate with each other on data, we can discover new patterns and develop new therapies.

“We believe our countries together should bring the same urgency seen in infectious disease to cancer in the Middle East. Cancer is emerging as a major health issue in the region, and to both develop and give access to innovative treatments for cancer will be crucial in the coming years,” said Ketil Widerberg, General Manager of Oslo Cancer Cluster.

The Norwegian Minister of Trade and Industry Iselin Nybø (to the right) participated in the state visit to Jordan to explore opportunities for industry collaboration. Photo: Camilla Bredde Pettersen

The Norwegian Minister of Trade and Industry Iselin Nybø (to the right) participated in the state visit to Jordan to explore opportunities for industry collaboration. Photo: Camilla Bredde Pettersen

The audience included Harald V, King of Norway, Sonja, Queen of Norway, Abdullah II, King of Jordan, Rania, Queen of Jordan, Hussein, Crown Prince of Jordan, Ine Eriksen Søreide, Norwegian Foreign Minister, Iselin Nybø, Norwegian Minister of Trade, and industry representatives from the Norwegian and Jordanian delegations.

“We need global and internationally-oriented cooperation in cancer care in order to improve the lives of cancer patients. During this State Visit to Jordan, I am pleased to take part at the beginning of new and innovative partnerships between two highly innovative health and research institutions from Norway and Jordan. Jordan has the potential to serve as a hub for international partnerships in cancer care in the Middle East, and I look forward to the continuation of this partnership,” said Minister of Trade and Industry, Iselin Nybø.

During the visit, it was also discussed how Jordan can function as a power centre for better cancer treatments in the Middle East. It can potentially become a base for Norwegian relief to non-communicable diseases with an emphasis on cancer, which is an increasing cause of death in developing countries. Jordan is a relatively stable country with good infrastructure and could become a centre for a new type of Norwegian relief to the region.

A special thank you to Innovation Norway, The Norwegian Ministry of Foreign Affairs, The Norwegian Ministry of Trade and Industry, and all other organising partners involved, for making the visit a success.

Gustav Vik from Killevold school and Martin Dimov from Mailand school are enjoying the gatherings arranged by Talentsenteret for realfag: “This is very interesting because we are learning things that are not part of the curriculum and we like to learn about current topics.”

Research talents learned about immunotherapy

This article was first published in Norwegian on our School Collaboration website.

A group of talented science students from Oslo and Akershus spent two days learning about immunotherapy from former cancer researchers, who are now teachers at Ullern Upper Secondary School and researchers at Thermo Fisher Scientific.

Collaboration partners: Oslo Cancer Cluster, Thermo Fisher Scientific Norway, Ullern Upper Secondary School, Norsk teknisk museum (The Norwegian Museum of Science and Technology) and Oslo Vitensenters Talentsenter i realfag (Talent centre for the natural sciences)

In February, 25 students from 19 different schools in Oslo, which are a part of “Talentsenteret for realfag” (Talent Centre for the Natural Sciences), arrived together to Oslo Cancer Cluster Innovation Park and Ullern Upper Secondary School.

The students were there to participate in a specially tailored two-day programme about medical research and the use of immunotherapy to treat cancer.

The days were spent partly in a classroom to learn about the theory of the immune system and partly in a laboratory to learn how to isolate a type of cells in the immune system called T cells. The method the students learned about is used in modern cell therapies against cancer, which are called CAR T therapies.

Gustav Vik from Kjellervolla School and Martin Dimov from Mailand School are enjoying the gatherings arranged by Talentsenteret for realfag: “This is very interesting because we are learning things that are not part of the ordinary school syllabus and we like to learn about current topics.”

Kaja Flote from Hellerasten school is looking in the microscope to find T cells. She thinks it is exciting to learn more about the depth of the immune system and how it can be changed to fight cancer. Photo: Bente Prestegård.

Kaja Flote from Hellerasten School is looking in the microscope to find T cells. She thinks it is exciting to learn more about the complexity of the immune system and how it can be changed to combat cancer. Photo: Bente Prestegård.

The next day, the students visited the production facilities of Thermo Fisher Scientific Norway, located in Lillestrøm. This is where the company makes Dynabeads (also known as “Ugelstadkulene” in Norwegian) to be used in five billion diagnostic tests every year and in CAR T therapies against cancer.

The Norwegian TV channel TV2 has produced this news segment about Emily Whitehead (link in Norwegian), the first child in the world who received CAR T therapy to treat her cancer, which was deemed incurable. The segment was recorded in 2019, when Emily and her family visited the Norwegian employees at Thermo Fisher Scientific in Oslo. Emily is today 13 years old and has been cancer-free for over eight years.

You can read more about the students’ experience at Thermo Fisher Scientific in this article from 2017, when another group of students from Ullern Upper Secondary School visited the same production facilities.

The researcher Morten Fure from Thermo Fisher tells the students about Dynabeads, also known as “Ugelstadkulene”, CAR T therapy, immunotherapy, and cancer. He has prepared T cell solutions that the students will look at in the microscope. Photo: Bente Prestegård.

The researcher Morten Luhr from Thermo Fisher Scientific tells the students about Dynabeads (also known as “Ugelstadkulene”), CAR T therapy, immunotherapy, and cancer. He has prepared T cell solutions that the students will look at in the microscope. Photo: Bente Prestegård.

The background to the collaboration

“Talentsenteret i realfag” is a customised educational option for students who are especially strong academically. It is for those students who find that the standard school curriculum does not challenge them enough. Just like the school adapts the teaching for students who need extra help in subjects, they adapt the teaching for students who already know a lot and want to learn even more. This is a group of students with a high degree of motivation and a hunger for knowledge that is extraordinary.

The centre employs experts in different subjects to give the students the academic challenges they need. That is why this two-day programme in medicine and immunotherapy was held in February.

The programme was developed by employees from Thermo Fisher Scientific and two teachers from Ullern Upper Secondary School. Fet and Flydal Jenstad both have backgrounds as cancer researchers at the Institute for Cancer Research and the Institute of Cancer Genetics and Informatics respectively. Fet and Flydal Jenstad share the responsibility for the new researcher programme at Ullern Upper Secondary School. Read more about the researcher programme here (link in Norwegian).

Oslo Cancer Cluster and Ullern Upper Secondary School have a school collaboration project since 2009. The goal is to contribute to educating the researchers and entrepreneurs of the future.

Thermo Fisher Scientific is a global biotech company with strong Norwegian roots through the acquisition of the Norwegian biotech Dynal. Thermo Fisher Scientific is one of the members of Oslo Cancer Cluster and actively participates in the school collaboration between Oslo Cancer Cluster and Ullern Upper Secondary School.

Read articles about the other school collaborations Thermo Fisher Scientific have participated in:

 

Click here to sign up for Oslo Cancer Cluster Newsletter

Moina Medbøe Tamuly (to the left) and his colleage Sondre Tagestad from NTENTION test the drone glove on Devon Island.

From Ullern to Mars

Read this article in Norwegian on our School Collaboration website.

A former Ullern student with an unusual career came to inspire current students in December.

Moina Medbøe Tamuly was in his final year at Ullern Upper Secondary School in 2014. Before Christmas in 2019, he came back to Ullern to tell today’s students about his exciting life after graduation.

Since Moina Medbøe Tamuly exited the school gates of Ullern Upper Secondary School for the very last time in June 2014, he has managed to spend two years in military service, worked in Trondheim, Oslo, Beijing, Shanghai, Amsterdam, Las Vegas, Brazil and the Arctic.

Moreover, he has an adventurous personality, combined with a passion for technology, which made him start the company NTENTION with his friend Magnus Arveng.

Magnus had the idea of a glove that could control drones, which he and Moina, together with their skilled team, has brought to life. The ground-breaking gloves can simplify the steering of everything from drones to VR interaction, music and robot arms. Their vision has been to develop a technology that is a natural and seamless extension of the human, instead of being an external instrument.

This has aroused the interest of the founder of the Mars Institute, Dr. Pascal Lee, who is collaborating with NASA on missions to the Moon and the exploration of Mars. The adventurous journey brought Moina all the way to Devon Island, a Mars-like, uninhabited island in the Arctic, together with his colleague Sondre Tagestad in NTENTION. During their stay, they tested if the glove could be used as an interactive instrument in conceptual space suits.

NTENTION’s collaboration partners at the Mars Institute/SETI Institute say in the article above that the glove “is revolutionary for future human exploration of the moon and Mars – and potential other planets”.

Right before Christmas 2019, Moina went back to his old upper secondary school, Ullern, to tell the students there today what life after graduation can be like.

Not a straightforward task

Moina tells the students the journey to Devon Island and the collaboration with astronauts has not been simple and straightforward, but has included many ups, downs and detours.

The students have brought their lunches into Kaare Norum auditorium to hear what the former Ullern student has to say about life after graduation.

Moina Medbøe Tamuly is back on his old hunting grounds, telling Ullern students about life after graduation.

Moina Medbøe Tamuly is back on his old hunting grounds, telling Ullern students about life after graduation. Photo: Elisabeth Kirkeng Andersen

At Ullern, Moina studied physics, history, philosophy and chemistry.

“I wasn’t very good at physics. I thought it was a really demanding subject, but also very exciting,” Moina says.

“After I graduated, I was really sick and tired of school. Then I had to do military service, something I wasn’t exactly thrilled about in the beginning. I was immature and created some disorder, but eventually I started liking it so much that I stayed there for two years. I was even accepted to The Royal Norwegian Naval Academy, which would have been an adventurous opportunity that I still daydream about sometimes.”

After the military service, Moina studied Industrial Economy and Technology Leadership at NTNU. In the passionate and teeming student atmosphere at NTNU, Moina met his business partner and friend Magnus Arveng and their company NTENTION was born.

Moina says that when he was a student at Ullern, he liked the subjects, the other students, the teachers and working for the student council. The first period at NTNU was a shock after such an enjoyable period of upper secondary school and military service.

“When I moved to Trondheim to study at NTNU, everything became chaotic. I had a breakdown and became depressed. It was a big transition from the military service, where I had great co-workers and a lot of responsibility, to academic studies. Our company saved me. It was pure magic to come back to an environment where you cooperate closely with one another to reach results together – and to be able to see the results of what you do every day,” Moina says.

Moina believes this is a reality many students can recognise and that it is important to learn that things don’t always go the way you planned, no matter how hard you work.

The company the students started together now has 13 employees in different roles and functions.

Doctor Pascal Lee, Head of the Research Station on Devon Island and space researcher at the Mars Institute is trying out the glove from NTENTION. Photo: Haughton-Mars Project

Dr. Pascal Lee, Head of the Research Station on Devon Island and space researcher at the Mars Institute, is trying out the glove from NTENTION. Photo: Haughton-Mars Project

The journey is as important as the goal

“I am not here to talk about what I have achieved, but about my life and the journey to get here,” Moina says to the Ullern students.

After showing the drone glove to interested students by using presentation slides and a video, Moina asks if there are any questions from the audience. Many hands go up in the air and they wonder how on Earth NTENTION got in touch with researchers that collaborate with NASA.

“It was very random. We met Dr. Pascal Lee at a conference arranged by Energy Valley. We knew the organisers and they gave us a stand for free. The glove we had developed can be used for music and art too. DJs can use it to play their set and combine it with video. So, together with the artist duo Broslo, we had arranged a unique stand with exciting artwork and video clips. That is where we started talking with Lee.”

A friendship developed between Lee, Moina and the others in NTENTION. Moina wants to highlight that you often meet friendly professionals if you dare to get in touch with them, one of the most important lessons from his journey so far.

“Our solution was a good fit with his visions and the need to explore Mars, so we began to work together,” Moina says.

The Ullern students’ lunch break is almost over, so Moina begins to sum up.

Devon Island is where NTENTION and Moina have tested the drone glove for the Mars Institute. Photo: Moina Medbøe Tamuly.

Devon Island is where NTENTION and Moina have tested the drone glove for the Mars Institute. Photo: Moina Medbøe Tamuly.

Time will be the judge of whether the drone glove Moina has developed one day will be a part of the space suits and equipment astronauts will use when landing on the Moon and Mars.

“The world will be more complicated and difficult when you graduate from Ullern, but all the more exciting. The last years of my life have been a little chaotic. It has been about closing deals and travelling around the world to find opportunities without a regular schedule. I finally learned that all people need to have a little bit of structure and to be part of a whole to thrive. In the end, I have unique experiences. My intellect has been nourished, I feel truly inspired and I am humbled to be a part of the journey where we are working to spearhead technological developments,” says Moina.

Sign up to our monthly newsletter

Cancer Crosslinks 2020

Engaging presentations by leading international and Norwegian oncology experts at the 12th Cancer Crosslinks “Progress in Cancer Care – A tsunami of promises or Game Changing Strategies?”.

Oslo Cancer Cluster’s annual meeting gathered more than 350 delegates from all over Norway at the Oslo Cancer Cluster Innovation Park, and more than 50 participants followed the live stream. The record high participation shows the large interest in translational cancer research and the importance of the programme for the Norwegian oncology community.

Cancer Crosslinks has become one of the largest national meeting places for oncologists, haematologists, translational researchers, regulatory experts and industry representatives. The meeting offers a full day educational program.

The aim of the conference is to stimulate broader interactions between researchers and clinicians, to encourage translational and clinical research, and to inspire collaborations. Novel partnerships between industry, academia and authorities are essential to deliver new treatments and diagnostics to Norwegian cancer patients.

“At the start of 2020, cancer patients have more treatment options than ever before. Immuno-oncology is firmly established as the fourth pillar of cancer treatment and the tremendous progress in the field is reflected in increased survival rates,” said Jutta Heix, Head of International Affairs, Oslo Cancer Cluster. “However, many patients do not benefit from novel treatments and we still have significant gaps in our understanding of the complex biological mechanisms. Deciphering this complexity is a task for the decade to come. The Cancer Crosslinks 2020 speakers are shedding light on emerging concepts and key challenges and discuss how they are addressing them to advance cancer care.”

The audience at Cancer Crosslinks 2020.

The audience at Cancer Crosslinks 2020. Photo: Cameo Productions UB/Oslo Cancer Cluster

An inspiring programme

Referring to a record number of new oncology drug approvals in recent years and an enormous global pipeline of drugs in late-stage development, this year’s programme addressed the question “Progress in Cancer Care – A Tsunami of Promises or Game-Changing Strategies?”. Distinguished international experts from leading centres in the US and Europe presented emerging concepts, recent progress and key questions to be addressed for both solid and haematological cancers.

Cancer researchers and clinicians from all of Norway enjoyed excellent presentations and engaging discussions with speakers and colleagues.

“Cancer Crosslinks 2020 gave me an opportunity to listen to talks by international top scientists, and discuss some of the latest developments in translational cancer research with meeting participants from academia and industry in a relaxed and inspiring setting,” said Johanna Olweus, Head of Department of Cancer Immunology at the Institute for Cancer Research.

“Cancer Crosslinks is always a meeting that makes me proud of being part of Oslo Cancer Cluster. It is inspiring to see Norwegian and international participants come together to discuss recent progress in cancer research and how to develop cancer treatments for the patients,” said Øyvind Kongstun Arnesen, Chairman of the Board, Oslo Cancer Cluster.

The day programme was complemented with an evening reception in the city center where speakers and delegates continued their lively discussions and listened to an inspiring talk by Ole Petter Ottersen, President of Karolinska Institute, at Hotel Continental in Oslo.

Cancer Crosslinks was established by Oslo Cancer Cluster in 2009 in collaboration with the pharmaceutical company Bristol-Myers Squibb.

“Cancer Crosslinks 2020 has been a fantastic conference, where the presenters have given an excellent description of current and near future achievements within cancer research and the importance of understanding the underlying biology of cancer to rationally give patients the correct cancer therapy. In particular within immunotherapy, there is a need to understand the dynamic complexity of tumor immunology and how to apply the best and tailored immuno-oncology based treatment strategy for cancer patients,” said Ali Areffard, Disease Area Specialist Immuno-Oncology, Bristol-Myers Squibb.

This year, the pharmaceutical company Sanofi Genzyme Norway was a proud co-sponsor of the meeting.

“It was great to be able to provide a platform for interaction between the Norwegian scientific cancer environment and top international research capacities. Therefore, it was with huge enthusiasm Sanofi Genzyme co-sponsored this important conference. New treatment options in oncology are developing fast, where new treatment modalities provide clinicians with additional and superior options. New treatments specifically targeting the malignant cells, as well as activating the host immune response towards the cancer, provides tools to significantly improve current cancer treatments. This year’s Cancer Crosslinks conference gave an excellent insight into this,” said Knut Steffensen, Medical Advisor Hematology Nordic & Baltics, Sanofi Genzyme.

Interview with Prof. Jason Luke

View the interview with Prof. Jason Luke, by HealthTalk, in the video below:

Interview with Prof. Michel Sadelain

View the interview with Prof. Michel Sadelain, by HealthTalk, in the video below:

The speakers at Cancer Crosslinks 2020

Jason J. Luke, Director of the Cancer Immunotherapeutics Center, Associate Professor of Medicine, University of Pittsburgh Medical Center and Hillman Cancer Center

Jason J. Luke, MD, FACP, Director of the Cancer Immunotherapeutics Center, Associate Professor of Medicine, University of Pittsburgh Medical Center and Hillman Cancer Center, USA. Photo: Cameo UB Productions/Oslo Cancer Cluster

Stefani Spranger, Howard S. and Linda B. Stern Career Development Assistant Professor, Koch Institute for Integrative Cancer Research at MIT, Cambridge

Stefani Spranger, Howard S. and Linda B. Stern Career Development Assistant Professor, Koch Institute for Integrative Cancer Research at MIT, Cambridge, USA. Photo: Cameo UB Productions/Oslo Cancer Cluster

Harriet Wikman, Professor, Group Leader, Center for Experimental Medicine, Institute of Tumor Biology, University Medical Centre Hamburg-Eppendorf

Harriet Wikman, Professor, Group Leader, Center for Experimental Medicine, Institute of Tumor Biology, University Medical Centre Hamburg-Eppendorf, Germany. Photo: Cameo UB Productions/Oslo Cancer Cluster

Vessela Kristensen, Professor, Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital

Vessela Kristensen, Head of Research and Development and Director of Research at the Dept. of Medical Genetics, Oslo University Hospital, Norway. Photo: Cameo UB Productions/Oslo Cancer Cluster

Peter A. Fasching, Professor of Translational Gynecology and Obstetrics, University Hospital and Comprehensive Cancer Center Erlangen-EMN

Peter A. Fasching, Professor of Translational Gynecology and Obstetrics, University Hospital and Comprehensive Cancer Center Erlangen-EMN, Germany. Photo: Cameo UB Productions/Oslo Cancer Cluster

Karl Johan Malmberg, Professor, Group Leader Dept. of Cancer Immunology and Director STRAT-CELL, Oslo University Hospital, Norway.

Karl Johan Malmberg, Professor, Group Leader Dept. of Cancer Immunology and Director STRAT-CELL, Oslo University Hospital, Norway. Photo: Cameo UB Productions/Oslo Cancer Cluster

Michel Sadelain, Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center

Michel Sadelain, MD, PhD, Professor, Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, USA. Photo: Cameo UB Productions/Oslo Cancer Cluster

Bjørn Tore Gjertsen, Consultant Hematology, Haukeland University Hospital, Norway.

Bjørn Tore Gjertsen, Professor of Hematology, Centre for Cancer Biomarkers CCBIO, Dept. of Clinical Science, University of Bergen, Norway. Photo: Cameo UB Productions/Oslo Cancer Cluster

Hermann Einsele, Professor, Chair, Dept. of Internal Medicine II, Head of the Clinical and Translational Research Program on Multiple Myeloma, Wuerzburg University Hospital

Hermann Einsele, Professor, Chair, Dept. of Internal Medicine II, Head of the Clinical and Translational Research Program on Multiple Myeloma, University Hospital Wuerzburg, Germany. Photo: Cameo UB Productions/Oslo Cancer Cluster

 

Sign up to our monthly newsletter

Simone Mester mentoring students in the lab.

Mentor meeting with Mester

A few lucky Ullern students got to learn about cancer research from the PhD student Simone Mester at Oslo University Hospital.

The science and research programme at Ullern Upper Secondary School is completely new and the 32 students in the first class have received four mentors who will share their knowledge and experience with them. Early in December, the students were divided among the four mentors and got to visit them at their workplaces to hear more about what they do.

Simone Mester is a former student of Ullern Upper Secondary School and is today a cancer researcher at Rikshospitalet (Oslo University Hospital). Along with the three other mentors from the Oslo Cancer Cluster ecosystem, she has agreed to be a mentor for the students of the science and research programme at Ullern. Earlier in December, eight students visited her at her job.

“This is where I work,” Simone said as we arrived at the Institute for Immunology, which is located right next to Rikshospitalet.

Simone began the visit by telling the students about her background and the road that led her to where she is today.

Simone Mester tells Ullern students about how she started to do cancer research.

Simone Mester (above to the left) tell the Ullern students that she is part of the SPARK programme at the University of Oslo. Photo: Elisabeth Kirkeng Andersen

“I graduated from Ullern in 2012. That is when I got to do two work placements at the Radium Hospital – in Clinical Radiation Biology and Tumour Biology. That was the first time I got an impression of what everyday life for a researcher can be like and it was exciting!” said Simone.

She says that she combined the subjects mathematics, physics, chemistry and biology so that she would be able to study medicine. But as the application date drew closer, she became more and more unsure.

“I talked with Ragni, who is your teacher too, and she recommended that I study molecular biology at the University of Oslo. At the time, I didn’t fully understand what I was getting myself into and especially why I had to study all that physics,” said Simone.

During the course of her bachelor degree, Simone was still unsure and spent a lot of time with advisers at the Institute of Biology to get guidance on the best way forward. She decided to study a master degree and was included in a research group led by professors Inger Sandlie and Jan Terje Andersen, where she remains today as she is completing her PhD.

Researching new cancer medicine

“During my master degree, I wrote about how to tailor the duration of the effect of medicines and pharmaceuticals, and that is what I am still researching in my PhD. A lot of my time here is in the laboratory, where I am planning and conducting experiments on cells and mice, to see if I can achieve what I want,” Simone said.

“Now, I will show you what I spend most of my time on. It is about making proteins, so now I will show you the principal, and afterwards you can try to do the same in the lab. Moreover, you will meet a master student, Anette Kolderup, who will tell you about CRISPR,” said Simone.

CRISPR is short for “clustered regularly interspaced short palindromic repeats”. It is a family of DNA sequences found within the genomes of prokaryotic organisms, such as bacteria and archaea.

Quickly and pedagogical she shows the students the principals for modifying proteins through DNA modification, growing, amplifying and splitting cells.

“Now we will go to the lab, so you can try this yourselves,” said Simone.

We go one floor up, where there are offices and laboratories. The four girls go to Anette, who will show them what CRISPR is and how she uses the method in her master thesis, while the boys will start in the cell lab to make the same experiment that Simone just showed them.

Caption: Aleksander tries pipetting when he is working in the lab together with Simone. It is important to have a steady hand.

Aleksander tries to handle the pipette when he is working in the lab together with Simone. It is important to have a steady hand. Photo: Elisabeth Kirkeng Andersen

“Inside this hood, the work environment is completely sterile, so you need to wear lab coats and sanitize all the equipment and keep it inside the hood while we are working,” Simone explained.

Aleksander is the first to try and Simone shows him step by step how he can retrieve the proteins from a bottle she has prepared. Everyone soon understands that lab work is a craft that requires skillful hands. It is important to stay focused and remember which solutions that should be added and how, and when the pipettes should go on or off. Aleksander laughs when he has to change an unused pipette that he has touched, even with gloves on it is not allowed.

Then the students switch places and everyone gets to try their hands at everything. Two hours pass by quickly and a very happy group of students with their teacher Ragni leave to go home again.

Click here to sign up for Oslo Cancer Cluster Newsletter

2019 written in fireworks

Our highlights 2019

Are you wondering what we have been up to during the last year?

2019 has been an eventful year for our organisation and our members. We want to put a spotlight on some of the main developments, including successful events that were held, ongoing and new projects, our political initiatives and a section on biotech news from our members. Scroll down to learn more about what we have done. Click the images or titles to access full articles.

The year in pictures

Link to article on Cancer Crosslinks 2019

Cancer Crosslinks

17 January 2019

We kicked off the year with our annual conference for the Norwegian oncology community, namely Cancer Crosslinks. We offered a full-day educational programme featuring distinguished international and national experts. They presented recent advances in precision oncology and cancer immunotherapy. More than 300 participants joined Cancer Crosslinks on 17 January 2019 and enjoyed excellent talks and discussions presented by leading international oncologists and researchers and their Norwegian colleagues.


Link to article about Incubator Laboratory

Oslo Cancer Cluster Incubator expands the labs

1 March 2019

The year continued with more growth in the organisation. The Oslo Cancer Cluster Incubator expanded its laboratories to meet increasing demand from members. The startups have been successful and were in need of more space to perform their research. After moving around some office spaces, and a lot of groundwork to get the infrastructure in place, the two new labs were opened in March. Later in the year, our Incubator was also named one of the Top 20 Best Incubators in Europe, by Labiotech.eu.


The White Paper on the Health Industry and our input

5 april 2019

This year a white paper on the health industry in Norway came out for the first time ever. This was an important event because the document underlined some of our key issues, such as attracting more clinical trials to Norway, making better use of Norwegian health data and opening up for more public – privat collaboration. It was first released in April and a committee hearing was held in June, whereupon the document was approved by parliament in October.


Link to DIGI-B-CUBE project's website

Launch of EU Horizon 2020 project DIGI-B-CUBE

1 May 2019

In May, we launched a new Horizon 2020 project called DIGI-B-CUBE. DIGI-B-CUBE will foster the development of customized solutions and prototypes by providing innovative small and medium-sized enterprises (SMEs) in the EU and Associated Countries with access to vouchers of up to € 60,000. The voucher scheme will be launched in April 2020. Throughout the year, SMEs could engage in the project’s activities by participating in sectoral and cross-sectoral workshops as well as matchmaking sessions.


Link to article about Cambridge student's report and analysis

#InternationalClinicalTrialsDay

20 May 2019

This was also the first year that we celebrated International Clinical Trials Day on the 20 May 2019, because clinical trials are an important way for patients to gain access to new treatments. We wanted to put a spotlight on the lack of clinical trials in Norway and present some concrete suggestions on how this can be improved. So we asked for help from some of the brightest minds in the world! MBA students from Cambridge University agreed to write a report on patient recruitment to clinical trials in Norway, including incentives for how it can be improved.


Link to article on the event at Arendalsuka 2019.

Arendalsuka19 – Together for precision medicine

16 August 2019

During Arendalsuka 2019, we arranged a breakfast meeting on the development of cancer treatments of the future, together with LMI and Kreftforeningen. Arendalsuka has become an important arena for those who want to improve aspects of Norwegian society. We were there this year to meet key players to accelerate the development of cancer treatments. We wanted to highlight the cancer treatments of the future and whether Norway is equipped to keep up with the rapid developments in precision medicine.


Link to article about new researcher programme at Ullern.

New science and research programme at Ullern Upper Secondary School

17 August 2019

When the school year began, we were proud to announce the opening of a completely new science and research programme at Ullern Upper Secondary School. The programme is a collaboration between Oslo Cancer Cluster and Ullern Upper Secondary School. It is for students who wish to learn how researchers work. It will qualify students for university studies and specialise them in biomedical research, technology and innovation. Oslo Cancer Cluster will provide access to mentors, work placements and lectures.


Link to article on the Cancer Precision Medicine session at NLS days 2019.

NLS Days – Cancer Precision Medicine Session

12 September 2019

We were also present at the NLS Days in Malmö this year. We promoted the Norwegian life science industry and Nordic collaboration by standing together with other key players in one stand. This stand was visited by the Minister at the Norwegian Embassy in Stockholm. We also hosted the session on oncology titled “Cancer precision medicine: State-of-the-art and future directions”. The session covered recent advances in cancer immunotherapy and cell- and gene therapies.


 

TOP BIOTECH NEWS

The team of Vaccibody celebrating their recent successes. Click here to article about Vaccibody.

Vaccibody treats first patient with cervical cancer

23 February 2019

Our member Vaccibody has had an exciting year. From announcing that they have raised NOK 230 million in private placements, to showing proof-of-concept for their immunotherapy platform, called VB.10. Early in the year, they entered a clinical collaboration with pharma company Roche to test their treatment on patients with cervical cancer. During the summer, Vaccibody publicized that they had seen strong neo-antigen specific T cell responses in the patients of their clinical trials.


Woman in lab studying test tube samples. Click here to article about BerGenBio.

BerGenBio success with new treatment

3 April 2019

Our member BerGenBio has also had a successful year. Their immunotherapy drug bemcentinib has shown encouraging results in several clinical trials and they have received FDA Fast Track Approval. A Phase 2 combination trial for elderly patients with AML (acute myeloid leukemia) showed the treatment is well tolerated and has a promising efficacy. BerGenBio are also currently testing bemcentinib in combination with other immunotherapy drugs for patients with non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and melanoma (skin cancer).


Ultimovacs enter Oslo Stock Exchange. Click here for article about Ultimovacs.

Ultimovacs enters Oslo Stock Exchange

3 June 2019

Our member Ultimovacs, a Norwegian cancer vaccine company, raised NOK 370 million and entered the Oslo Stock Exchange. The funds will go to financing the development of their universal cancer vaccine, UV1. A large clinical study will document the effect of the vaccine. First for patients with malignant melanoma (a type of skin cancer) at around 30 hospitals in Norway, Europe, USA and Australia. Ultimovacs also announced a large randomised study for 118 patients with mesothelioma, which will be placed at six hospitals in the Nordics.


Image of Dr James Allison, Dr Padmanee Sharma. Click here for article about Lytix Biopharma.

Nobel laureate joins Lytix Biopharma board

14 June 2019

In June, our member Lytix Biopharma announced that the Nobel Laureate Dr James Allison and his wife oncologist Dr Padmanee Sharma will become strategic advisors for the company. Dr James Allison was, together with Dr Tasuku Honjo, awarded the 2018 Nobel Prize in Medicine last December. The renowned cancer researchers received the award for their ground-breaking work in immunology. It has become the basis for different immunotherapies, an area within cancer therapy that aims to activate the patient’s immune system to fight cancer.


Dr. Richard Stratford and Dr. Trevor Clancy, founders of OncoImmunity. Click here for article about OncoImmunity.

OncoImmunity joins NEC corporation

2 August 2019

In the end of summer, the Japanese tech giant NEC Corporation acquired our member OncoImmunity AS, a Norwegian bioinformatics company that develops machine learning software to fight cancer. NEC has recently launched an artificial intelligence driven drug discovery business and stated in a press release that NEC OncoImmunity AS will be integral in developing NEC’s immunotherapy pipeline.


From all of us, to all of you …

A Very Merry Christmas and a Happy New Year!

 

Students at the DNB Nordic Healthcare Conference.

Students helped create podcast

Our school collaboration project inspires science and health communication.

Ullern students were thrown head first into a live work environment this week. They gave technical assistance to the making of the podcasts Radium and Utbytte at the DNB Nordic Healthcare Conference 2019.

All the students are currently studying the media and communications program at Ullern Upper Secondary School, including a class on sound design. As an extra subject, they also started their own youth companies Marconi Media UB and Audio Mind UB.

Radium held a podcast marathon together with the DNB podcast Utbytte at this year’s conference, with six different sessions, interviewing CEOs and investors. Throughout the day, the Ullern students were expected to sound check, record, and edit the podcast – all on their own.

The students attended a planning meeting one week earlier. They also arrived the evening before to rig the set: a glass studio in the middle of the conference area.

The participants in the podcast Radium and Utbytte at DNB Nordic Healthcare Conference 2019 in the glass studio.

The Ullern students helped to rig the podcast studio the night before the conference.

“It is a really nice experience, because we are thrown into the real word and do things in practice,” Andrea Asbø Dietrichson from Marconi Media UB explained. “We have to do everything ourselves, even though we are beginners, but we are learning!”

“It has been interesting to hear what they are talking about (in the studio) and learn how it is to work during such a big event,” Theo Rellsve from Audio Mind UB added. “It is the largest event we have been to, with lots of people and things happening all the time. We are happy to take part!”

Ullern students recording the podcasts Radium and Utbytte at DNB Nordic Healthcare Conference

The Ullern students had to think on their feet to solve problems while recording the podcast.

 

The aim of the school collaboration project between Ullern Upper Secondary School and Oslo Cancer Cluster is to inspire students to develop their talents. One aspect of the project is to give students a taste of what real working life is like.

“Personally, I would like to work in media,” Andrea said. “It is really inspiring to be here. Media and communications is a broad subject, but sound design is something not a lot of people know.”

“Audiomind has a clear vision about our future as a company. We are happy that we can get this experience and use it towards developing the company further,” Theo said. “… And create the best podcast recording company in Norway.”

Elisabeth Kirkeng Andersen, Communications Specialist for Radforsk and one of the persons behind the podcast Radium, was very satisfied with the work the students had performed. She gave them a top score.

“They have everything under complete control,” she said. “It is really fun to see their learning curve. They only studied sound design for a few months, but they have already helped at two live shows and they are always calm and service-minded.”

Student helping in the glass studio.

Elisabeth Kirkeng Andersen was impressed by how helpful and service-minded the students from Ullern were.

Want to find out more?

 

Two of the speakers discussing with each other and laughing..

A café to advance T cell research

We want to accelerate cancer research in T cell immunotherapy!

In order to promote research collaboration, spread knowledge and exchange ideas, Oslo Cancer Cluster arranged a seminar together with Nature Research this week. The topic was T Cell Immunotherapy: Advances, Challenges and Future Directions.

What is T cell immunotherapy?

T cell immunotherapy is a rapidly growing area of research in cancer treatment. The research focuses on finding new ways to trigger the immune system to kill cancer cells.

The treatment method involves collecting T cells (a type of immune system cell) from a patient’s blood sample. The T cells are then modified in the laboratory so they will bind to cancer cells and destroy them.

One way to do this is called CAR T therapy. This involves adding a gene for a special receptor that binds to a specific protein (also called an antigen) on the patient’s cancer cells. The special receptor is called a chimeric antigen receptor (CAR). These cells are grown in large numbers in the laboratory and then infused in the patient to create an immune response.

Read more about CAR T cell therapies in this article from The National Cancer Institute

Image of researchers attending Nature Café on T cell immunotherapy in Oslo.

Many researchers attended the Nature Café for the opportunity to learn more about recent advances in T cell immunotherapy. Photo: Christian Tandberg

Why is cell therapy important?

Research into T cell immunotherapy is important, because it has the potential to treat and cure cancer. T cell immunotherapy can help cancer patients live longer and potentially has fewer side effects than traditional treatment methods, such as chemotherapy, radiation therapy and surgery.

However, more research is needed to make T cell immunotherapy work on all kinds of cancer. For example, some patients with haematologic cancer, cancers that develop in the blood-forming tissue, relapse into disease after treatment. Moreover, T cell immunotherapy does not work on all patients with solid cancer tumours yet.

Researchers wish to know why some cancers are resistant to T cell immunotherapy and why some patients acquire resistance to the treatment over time. Some patients also experience toxic side effects to T cell immunotherapy. Moreover, researchers are continually searching for possible new antigens (proteins) to target.

There are still many unanswered questions and that is why we need to accelerate the research.

Two researchers in the audience asking questions.

Members of the audience were eager to find out more about this rapidly growing area of research. Photo: Christian Tandberg

Why did we arrange this event?

The Norwegian research environment in cancer immunotherapy is world-class. But Norway is a small country and researchers need access to international partners and expertise to develop their findings.

The purpose of the event was to highlight recent findings in T cell immunotherapy. There was also the opportunity to discuss ongoing challenges and opportunities in the development of these types of treatments.

Among the guests were several prominent Norwegian cancer researchers, the pharma industry, hospital clinicians, biotech start-ups, and more. During the seminar, many of the participants in the audience asked follow-up questions and the café breaks were buzzing with conversations between researchers.

Three researchers in the audience discussing with each other.

The event was an opportunity to discuss with and learn from prominent researchers in the cell therapy field. Photo: Christian Tandberg

Watch the video below to see a few of the participants’ reactions:

Meet the speakers

The moderator for the event was Saheli Sadanand, Associate Editor, Research Manuscripts at Nature Medicine. Photo: Christian Tandberg

The moderator for the event was Saheli Sadanand, Associate Editor, Research Manuscripts at Nature Medicine. Photo: Christian Tandberg

 

The first speaker was Sara Ghorashian from the University College London

The first speaker was Sara Ghorashian from the University College London. Dr. Ghorashian is a consultant Paediatric Haematologist at Great Ormond Street Hospital for Children in London, and the co-investigator or lead UK investigator for six different CAR T cell clinical trials. She talked about her research to improve outcomes of CAR T cell therapy in patients with acute lymphoblastic leukemia. This is a type of cancer in the blood. Photo: Christian Tandberg

 

Attilio Bondanza, who is a physician-scientist and the CAR T cell program leader at Novartis Institutes of Biomedical Research in Basel, Switzerland.

The second speaker was Attilio Bondanza, who is a physician-scientist and the CAR T cell program leader at Novartis Institutes of Biomedical Research in Basel, Switzerland. Before joining Novartis, Dr. Bondanza was a professor at the San Raffeale University Hospital, where he led the Innovative Immunotherapies Unit. Dr. Bondanza talked about his work to model CAR T cell efficacy and CAR T cell-induced toxicities pre-clinically. Photo: Christian Tandberg

 

Sara Mastaglio, who is a physician scientist specialising in haematology at San Raffaele Scientific Institute, in Milan

The third speaker was Sara Mastaglio, who is a physician scientist specialising in haematology at San Raffaele Scientific Institute, in Milan. She has been actively involved in the development and clinical application of CAR T cell therapies. Dr. Mastaglio discussed her research on genome-edited T cells for the treatment of haematological malignancies. Photo: Christian Tandberg

 

Aude Chapuis, who is an assistant member of the Fred Hutchinson Cancer Research Center in Seattle

The last speaker was Aude Chapuis, who is an assistant member of the Fred Hutchinson Cancer Research Center in Seattle. In addition to running a lab, she sees patients as an attending physician at the Fred Hutch Bone Marrow Transplant Program at the Seattle Cancer Care Alliance. Dr. Chapuis discussed mechanisms of response and resistance to instruct next generations of T cell receptor gene therapy. Photo: Christian Tandberg

 

Want to find out more?

In February 2020, the journal Nature Research will publish an article with a more detailed overview of the speakers, their presentations and the research. We will provide a link here when it is available!

If you enjoyed this event, please subscribe to our newsletter to receive invitations to our upcoming events and a digest of our latest news.

 

We want to thank our sponsors for helping us make this event happen.

Sponsor logos: Novartis Oncology, ThermoFisher Scientific and Celgene

Image of Kaare Norum.

Kaare R. Norum has died

Kaare R. Norum died on Friday 22 November 2019, at an age of 86 years.

Kaare R. Norum was a professor of nutrition and interested in the connection between our diets and the risk of developing cancer. Norum was a driving force behind gathering the scattered cancer research environments in Oslo.

Norum initiated Oslo Cancer Cluster in 2006, together with Jónas Einarsson, CEO of RADFORSK. At the time, Norum and Einarsson realised that a natural cluster within oncology had developed around the Norwegian Radium Hospital.

The old Ullern Upper Secondary School was back then located on the premises next to the Norwegian Radium Hospital. When the old school was due to be refurbished, Norum and Einarsson had an idea. They wanted to build a new school instead, which would become more than just an ordinary school.

Norum signed the collaboration agreement with the school in 2008. During the following years, Norum, the cluster and the school worked so that the school could become part of a completely new innovation park. In this new building, cancer research would unite the school, the research environments and industry.

Making the dream a reality was at times arduous, but in the end, it was worth it. The old school was torn down in the spring of 2012 and Oslo Cancer Cluster Innovation Park was officially opened in August 2015.

The big auditorium in Ullern Upper Secondary School today is aptly named after Kaare Norum. He will always be the man that the students – the researchers of the future – will be inspired by.

 

Image of Jonas Einarsson and Kaare Norum.

Kaare Norum was active in the establishment of Oslo Cancer Cluster and Oslo Cancer Cluster Innovation Park. In this image, Jónas Einarsson and Kaare R. Norum participated in the opening of the Innovation Park on 24 August 2015. Photo: Gunnar Kopperud

 

Kaare Norum will be remembered as an ambitious man, who always wished to create new opportunities for science and development. He was generous and he promoted both people and projects.

He was a source of inspiration and support in the work with developing Oslo Cancer Cluster, and he meant a lot to us. He was a part of the board of Oslo Cancer Cluster as an honorary member since the establishment in 2006. He was also, during many years, an important mentor for Jónas Einarsson.

Kaare Norum was forthright and not afraid to challenge established truths or formalities when he looked for support in his most important issues. Lucky for us, in Oslo Cancer Cluster, we were one of his important issues.

Rest in peace, Kaare Norum.

 

Memorial message by,

Jónas Einarsson (CEO of RADFORSK)

Ketil Widerberg (General Manager of Oslo Cancer Cluster)

Øyvind Kongstun Arnesen (Chairman of the Board of Oslo Cancer Cluster)

 

 

Kaare R. Norum (24 December 1932 – 22 November 2019)

Norum was the principal of the University of Oslo from 1999 to 2001.

He wrote about 300 scientific articles and was known internationally for his research on nutrition. He also wrote several books in popular science and course books about health and nutrition.

Norum was Commander of the Royal Norwegian Order of Saint Olav and of the Swedish Royal Order of the Pole Star.

Read more on Kaare R. Norum’s Wikipedia page

A cancer doctor speaking to a room of students.

Who wants to be a doctor?

We join forces with Ullern Upper Secondary School and Oslo University Hospital every year to arrange theme days for students, so they can get a sense of what it is like to be a doctor.

On 18 November 2019, students from the health program with specialisation in biology and chemistry at Ullern Upper Secondary School, gathered in Kaare Norum Auditorium at Oslo Cancer Cluster Innovation Park to learn more about opportunities in medicine. The initiator is Truls Ryder, father of a former student at the school. Ryder is a surgeon at the Norwegian Radium Hospital and has this year once again planned theme days for the students together with his colleagues.

For almost five hours, the Ullern students listened to some of the best oncologists in Norway talk about how they treat cancer patients affected by different forms of cancer. The students are studying either science or health subjects in their third year.

The theme day is a part of the close collaboration between Ullern Upper Secondary School and the Norwegian Radium Hospital, Oslo University Hospital. For two days, 18 of the students who consider applying to medical or nursing school will follow the oncologists around the different departments of the Norwegian Radium Hospital.

“The students who have been chosen to job shadow are in their last year and will soon choose their next program of study,” Bente Prestegård said. She is the project manager for the school collaboration between Ullern Upper Secondary School and Oslo Cancer Cluster.

The purpose of the job shadowing is that students who participate will get an inside look into the opportunities that exist in medical subjects before choosing what to study next.

A fantastic initiative

Truls Ryder is the initiator behind the theme day and the following job shadowing, like he was last year. His children have gone to Ullern Upper Secondary School and he works as an attending physician at the Norwegian Radium Hospital.

“Thank you to the initiator Truls Ryder and his colleagues who have dedicated two days for this. It was really successful last year and we are incredibly happy to be able to offer the students this opportunity again,” Prestegård said.

Prestegård has contributed to the planning of the theme days with her long experience from other projects between members of Oslo Cancer Cluster and the school.

You can read about last year’s theme day and job shadowing here.

A varied program

The theme day today was spent in Kaare Norums Auditorium from 11:30 am to 4:00 pm. During these hours, the students have gained an in-depth introduction to modern cancer treatments, from radiology to plastic surgery, and what it is like to be a cancer patient and receive treatment.

“I look forward to the program myself, because there are many skilled experts, who will present what they do in cancer treatment and more. The goal with such a broad program is to give the students the greatest possible understanding of all the different directions and opportunities that medical study can offer,” said Ryder.

Program (Monday 18 November 2019):

11:30-11:55 Welcome, with Attending Physician Truls Ryder

11:55-12:20 Cancer treatment with focus on colon cancer, with Professor Kjersti Flatmark

Break

12:30-12:55 “Fight HPV” with Attending Physician Ameli Trope from Kreftregisteret

12:55-13:20 What is anesthesiology? with Professor Ulf Kongsgaard

Break

13:40-14:05 Melanoma, with Attending Physician Anna Winge-Main

14:05-14:30 Plastic surgery – more than just cosmetics! with Head of Clinic and Attending Physician Kim Tønseth

Break

14:40-15:05 Radiology – More than just x-rays! with Attending Physician Marianne Fretheim

15:05-15:30 What is it like to be a patient? with Jeanett Hoel, Chairman of the Norwegian Gynaecological Cancer Society and Attending Physician Kristina Lindemann

15:30-15:45 Summary and practical information concerning clinical rotation, with Attending Physician Truls Ryder

Sign up to OCC monthly newsletter!

Image of Ketil Widerberg, general manager of Oslo Cancer Cluster.

Tre viktige temaer i helsenæring

Næringskomiteens innstilling om helsenæringsmeldingen er klar. Dette mener Oslo Cancer Cluster om tre viktige temaer i innstillingen.

Næringskomiteens innstilling om helsenæringsmeldingen trekker frem mange viktige aspekter ved norsk helsenæring. Helse- og omsorgskomiteen kommenterer også meldingen i samme innstilling.

Oslo Cancer Cluster ønsker å kommentere spesielt tre temaer som disse to komiteene tar opp i innstillingen til Stortinget.

– Nå er det viktig at alle som ønsker en sterk norsk helsenæring følger opp hva meldingen betyr i praksis, sier Ketil Widerberg, daglig leder i Oslo Cancer Cluster.

Kliniske studier

Komiteen går inn for en bedre tilrettelegging for kliniske studier og bruk av helseregistre, slik Helsenæringsmeldingen foreslår. En samlet næringskomité mener videre at forventningene til innovasjon og samarbeid med forskning og næringsliv i oppdragsdokumenter til helseforetakene må følges opp med insentiver og finansieringssystemer.

– Vi applauderer at komiteen krever finansieringssystemer for dette. Vi ønsker å understreke hvor viktig det vil være å innføre en takst for kliniske studier som gjør at leger og andre helsearbeidere får tid og insentiver til å utvikle bedre behandling for pasienter – i samarbeid med industrien, sier Ketil Widerberg.

Oslo Cancer Cluster foreslo i sitt høringsinnspill til helsenæringsmeldingen å etablere et nasjonalt senter for kliniske studier, og at senteret knyttes til en felles database for helsedata hvor både myndigheter, forskning og industri kan få tilgang til løpende pasientdata fra behandling av den enkelte pasient.

Oslo Cancer Cluster foreslo også å etablere et nordisk senter for celleterapi. Det er vel innen rekkevidde, tatt i betraktning at Norge er ledende på immunterapi og spesielt celleterapi spesielt innen kreft – og at kreft er spydspissen i kliniske studier internasjonalt.

Begge disse forslagene fra Oslo Cancer Cluster har komiteen trukket frem i sin innstilling.

Norge har blitt det minst attraktive landet i Norden for kliniske studier. Oslo Cancer Cluster understreker at Norge må tørre å være først ute på to vesentlige områder for å snu denne utviklingen:

Norge må nå ta lederrollen i utviklingen av klinisk dokumentasjon og være et foregangsland i godkjenning av ny presisjonsmedisin.

Den muntlige høringen i Næringskomiteen kan sees i sin helhet på Stortingets nettsider.

Offentlig-privat samarbeid

– Oslo Cancer Cluster har alltid prioritert arbeidet for en sterkere kultur for samarbeid og dialog mellom helsetjenesten, akademia og næringsliv. Det er et kontinuerlig arbeid og vi ser med glede at komiteen stiller seg bak dette, sier Widerberg.

Komiteen peker på at Norge i løpet av de siste årene har bygd opp verdensledende helseklynger som nettopp Oslo Cancer Cluster og Norway Health Tech. Disse klyngene har utviklet økosystemer som bidrar til å etablere nye bedrifter og øke konkurransekraften.

Komiteen ber regjeringen “vurdere tiltak som kan sikre videreføring av klyngene som en møteplass mellom det offentlige og private og som bidragsytere til internasjonal vekst.”

For Oslo Cancer Cluster er det motiverende å se at dette blir poengtert.

Helsedata

– Helsedata er et tema som Oslo Cancer Cluster har engasjert seg i siden oppstarten for over ti år siden, men som vi ser nå blir stadig mer aktuelt grunnet sammensmeltingen av biologi og teknologi, sier Widerberg.

Komiteen peker på mange muligheter med helsedata, som er en viktig del av norsk helsenæring – ikke minst for å gi pasienter best behandling.

– Vi ser imidlertid behovet for en konkretisering av hvordan vi legger opp til bruk av helsedata i utvikling av legemidler. Vi trenger også en mer konkret plan for hvordan vi kan bruke helsedata for å forstå genetisk data for å bedre helsen vår, sier Widerberg.

Næringskomiteens innstilling om helsenæringsmeldingen ble behandlet i Stortinget 26. november 2019. Møtet ble filmet og ligger i Stortingets videoarkiv.

 

Les mer

 

Sign up to our monthly newsletter

Photo of the audience at the opening of EHiN 2019.

EHiN 2019 – highlights

Did you miss EHiN this year? Or simply want to catch up on the highlights relating to cancer research? Read our short summary below.

EHiN, short for e-health in Norway, is Norway’s national conference on e-health. It is a meeting place where decision-makers, the business community and the health sector gather to talk, share knowledge, learn from each other and collaborate.

This year, Oslo Cancer Cluster became a co-owner of EHiN (together with ICT Norway and Macsimum), because we believe new technologies and digital solutions are essential in the development of novel cancer treatments. This will only be possible if public and private organizations find new models of collaboration and EHiN is a great platform to create those future partnerships.

Read this interview to find out more about how new technologies can improve cancer research

 

Photo from the panel discussion on health data at EHiN 2019.

A conversation on health data during day 1 of EHiN 2019. Photo credit: Ard Jongsma / Still Water Photography

Capturing the value of health data

An engaging dialogue on the value of health data took place at the end of the first day.

Health data will revolutionize how we understand and how we treat diseases, such as cancer. Better diagnosis and monitoring will change how we design our healthcare systems. A central question is how we capture the value of this revolution. Some fear multinationals like Google and Facebook will exploit our unique health data for profit. Others fear that Norwegians will value and protect their health data too well, resulting in innovation happening elsewhere. Is there a golden mean between giving full access to health data and charging the highest price?

Ketil Widerberg, General Manager at Oslo Cancer Cluster, led the conversation with a panel of four. Joanne Hackett, Chief Commercial Officer at Genomics England, brought an international perspective and experiences of how they have collected 100 000 genomes from patients with rare diseases. Sigrid Bratlie, award-winning cancer researcher, shared her knowledge of new cancer treatments and the opportunities they present in conjunction with health data. Heidi Beate Bentzen, Doctoral Research Fellow at University of Oslo, represented some of the legal considerations when dealing with health data. Rajji Mehdwan, General Manager at Roche, contributed with the pharma industry perspective.

 

Photo of the expo area during EHiN 2019.

The crowded crowded expo area during EHiN 2019. Photo credit: Ard Jongsma / Still Water Photography

Networking in the expo area

The expo area is the heart and soul of EHiN. This is where public and private organizations can meet under informal circumstances and create new partnerships. These collaborations are what lead to knowledge sharing and that digital solutions can be implemented in the health sector.

This year, a pharma company was present in the expo area for the very first time, our member Roche. Roche are investing more in genetic testing and personalized medicines than ever before. But why are genetic tests important for cancer treatments? Cancer is more than a disease, it is about the composition of DNA, RNA and proteins – and how these relate to one another. Every cancer tumor is therefore unique, but by finding out more about the genetic sequence, one can develop personalized treatments that target the tumor effectively.

In the expo area, a variety of start-ups, IT companies, health clusters, public organisations and academic institutions were also present. For two days, the area was buzzing with interactions, meetings and talks.

We hope you carry on the conversations and that we see all of you again next year!

 

Ketil Widerberg, general manager, Oslo Cancer Cluster.

Machine learning improves cancer research

This interview was first published on EHiN’s official website. Scroll down to read it in Norwegian.

 

EHiN is important in order to realise the opportunities that digital technologies can give patients, society and industry.

Ketil Widerberg is the General Manager of Oslo Cancer Cluster, which is a co-owner of EHiN 2019. We asked Ketil Widerberg a few questions about why digitalization and EHiN are important for cancer research.

–Can you describe in short what Oslo Cancer Cluster is and what you do?

Oslo Cancer Cluster is a non-profit member organization that gathers public and private players. The goal is to transform cancer research into treatments that change patients’ lives. We are a National Centre of Expertise (NCE).

–You are now co-owners of EHiN. What do you wish to achieve with that?

Oslo Cancer Cluster has the last ten years developed and established well-known meeting places (such as Cancer Crosslinks) by combining different disciplines. In the future, digitalisation and precision medicine (e-health) will be a central area in cancer research.

EHiN is a perfect match in this area. EHiN will be an important platform in order to realise the opportunities that digital technologies can give patients, society and industry.

–What do you think AI will mean for cancer research?

Today’s breakthroughs in treatment will often only work on 3 out of 10 patients. Artificial intelligence will change medicine in two ways. First, how we understand cancer. In the same way as the microscope gave us the ability to see things on a cellular level, data will now help us to see patterns we never would have discovered.

Second, how we treat cancer will change. We have to be ready to give the right treatment to the right patient at the right time. One way of giving individualised treatments is to recognize patterns – patterns that show how a patient will react from a treatment.

After that, you can see in larger groups of people if this pattern is repeated. Then, you select the patients that have a positive response to the treatment. This will, to begin with, not be a perfect method, but if you repeat this process, the modern machine learning systems can make it better and better.

–We know that health research takes time. How can digital solutions improve this?

Digitalisation will accelerate the development of new treatments in several areas. One area is clinical studies. Digital technology can help to adjust studies according to patient responses and enable digital control arms that shorten years off the developmental period. Digital solutions can make clinical trials more flexible and efficient, by reducing the administrative burden on companies and at the same time make it simpler for patients to enroll.

Gradually, as the volume and speed of the data increases, we have the opportunity to use new machine learning algorithms – such as deep learning. The algorithms can identify digital biomarkers that will give faster and better development of new treatments.

–Why is EHiN an important meeting place for Norway?

EHiN is relevant for Oslo Cancer Cluster because the IT revolution is about to hit the oncology field. Personalized treatments, genomics and the use of health data will soon develop into one of the most important areas of “e-health”. This is also an area that is of great interest for the IT industry, for data storing, data analysis, machine learning, pattern recognition, connecting different data sources, and so on.

At the same time, the technology will also impact the academic world and the pharmaceutical part of the health sector, and contribute to set the rules for the whole value chain in health processes in decades to come. EHiN wishes, in collaboration with Oslo Cancer Cluster, to build Norway as an important international hub in the area of e-health – by gathering and showcasing the different activities at the conference and in other settings.

 

–Selvlærende datasystemer gjør kreftforskning stadig bedre

EHiN er ifølge Ketil Widerberg viktig for å få realisert gevinsten digital teknologi kan tilføre pasientene, samfunnet og næringslivet. Widerberg er daglig leder for Oslo Cancer Cluster, som i høst 2018 gikk inn som medeier av EHiN.

Vi stilte Ketil Widerberg noen spørsmål om hvorfor digitalisering og EHiN er viktig for kreftforskning.

–Kan du beskrive kort hva OCC er og hva dere gjør?

OCC er en non-profit medlemsorganisasjon som samler offentlige og private aktører. Målet er å gjøre kreftforskning til produkter som endrer pasienters liv. Vi er et NCE (National Centre of Expertise).

Dere har blitt med på EHiN. Hva ønsker OCC å oppnå med det?

Oslo Cancer Cluster har de siste 10 årene utviklet og etablert anerkjente møteplasser (som Cancer Crosslinks) ved å kombinere forskjellige fag-grener. Fremover vil digitalisering sammen med presisjonsmedisin (e-Helse) være et sentralt område innenfor kreft.

EHiN er en perfekt match for dette området. I tråd med OCC sin strategi vil EHiN være viktig for å få realisert gevinsten digital teknologi kan tilføre pasientene, samfunnet og næringslivet.

–Hva tror du AI kan bety for forskning rundt kreft?

Dagens behandlingsgjennombrudd vil ofte bare virke på 3 av 10 pasienter. Kunstig intelligens vil endre medisin på to måter. Hvordan vi forstår kreft. På samme måte som mikroskopet ga oss evnen til å se helt ned på cellenivå, vil data nå hjelpe oss til å se mønster vi aldri ellers ville oppdaget.

Hvordan vi behandler kreft vil forandre seg. Vi må derfor klare å gi den rette behandlingen til den rette pasienten til rett tid. En måte å kunne gi individbasert behandling er å gjenkjenne mønster. Mønster som viser hvordan en pasient vil reagere på en behandling.

Deretter se i større grupper mennesker om dette mønsteret gjentar seg. Da kan man plukke ut de pasientene med positivt utbytte av behandlingen. Dette vil i begynnelsen ikke være en perfekt metode, men hvis man gjentar denne prosessen, kan moderne selvlærende datasystemer gjøre den stadig bedre.

–Vi vet at helseforskning tar lang tid. Hvordan kan digitale løsninger bidra på dette?

Digitalisering vil akselerere utviklingen av ny behandling på flere områder. Ett område er kliniske studier. Digital teknologi kan gjøre at studier justeres etter respons og muliggjøre digitale kontrollarmer som korter år av utviklingstiden. Kliniske forsøk kan bli fleksible og effektive ved å redusere administrative byrder på firmaer, og samtidig gjøre det enklere for pasientene.

Etter hvert som volumet og hastigheten på data øker, har vi mulighet til å bruke nye maskinlæringsalgoritmer – som dyplæring. Det kan identifisere digitale biomarkører som vil kunne gi raskere og bedre utvikling av ny pasientbehandling.

–Hvorfor er EHiN en viktig møteplass for Norge?

EHiN er faglig relevant for OCC fordi IT-revolusjonen er i ferd med å slå inn på onkologi feltet. Persontilpasset medisin/behandling, genetikk og bruk av helsedata vil snart utvikle seg til et av de viktigste områdene innen “e-helse”. Dette er også et område som er av stor interesse for IT-bransjen (datalagring, analyse, machine learning, mønstergjenkjenning, kobling av ulike datakilder osv.).

Samtidig vil teknologien også få konsekvenser for den akademiske verden, samt den farmasøytiske delen av helsesektoren, og bidra med å legge rammene for hele verdikjeden i helseprosessene i tiårene fremover. EHiN ønsker, i samarbeid med OCC, å bygge Norge som en viktig internasjonal hub på området e-Helse ved å samle og vise frem ulike aktiviteter på konferansen og også i andre sammenhenger.

 

Sign up to OCC monthly newsletter

The mentors of the student research program at Ullern Upper Secondary School meet the students for the first time.

Meet the mentors

Read the questions and answers from when the students at Ullern Upper Secondary School met their mentors for the very first time.

In the middle of October, 32 students at the researcher program at Ullern Upper Secondary School got to meet their four mentors for the next year. After a short introduction, there were many questions from the students to the mentors. It took an hour and a half before their curiosity settled down and it was time for pizza.

Simone Mester: “I am a former student of Ullern Upper Secondary School and now I am doing a PhD in molecular biology. In the long term, I could imagine working in the private sector developing pharmaceuticals.”

Øyvind Kongstun Arnesen: “I am a doctor and worked many years in Lofoten. After that, I worked some years as a surgeon in an emergency room, before I began working for a large German pharmaceutical company called Boehringer Ingelheim. Eight years ago, I became CEO for Ultimovacs. Ultimovacs are trying to develop the worlds first cancer vaccine.”

Jónas Einarsson: “I am a doctor, and did the first part of my medical degree on Iceland, because my grades weren’t the best. Then, I worked many years as a general practitioner in Lardal, before moving to Oslo and becoming the manager of the first private hospital in Norway. In parallel with this, I did a degree in economy and management at BI. Finally, I became the CEO of Radforsk, who among other things, initiated the Oslo Cancer Cluster Innovation Park and this school collaboration.”

Bjørn Klem: Bjørn is the fourth mentor, but he was unfortunately ill during the first meeting. Janne Nestvold, Laboratory Manager at Oslo Cancer Cluster Incubator, came in his place. Nestvold has a PhD and has worked as a researcher for many years.

 

After the introductions, the teachers at the researcher program, Ragni Fet and Monica Flydal Jenstad held a short presentation of the upcoming work with the mentors.

Then, there were several questions from the audience.  We were really impressed by the amount and quality of the questions, that concerned both education, job opportunities and, research and development, which both Kongstun and Mester are a part of. The questions rained down and the answers came in a session that continued for over an hour and a half. You can read some of them below. Then it was time for some pizza and mingle.

The next time the students and the mentors will meet will be in the beginning of December. The students will meet in the mentors’ workplaces and see with their own eyes what they do on an everyday basis.

 

Questions and answers:

What kind of medical specialisation does Jónas and Øyvind have?

“We are both general practitioners and have not specialised. You do not have to.”

 

What kinds of jobs can you do after you are finished, Simone?

Simone: “I can do a postdoc to become a researcher in academia. I am still a student while I am doing my PhD, but I receive a salary. It is normal to do two postdocs, then you can become group leader or professor. I don’t think I will follow that route, I would much rather work in a private company or start something myself. I think that seems more exciting.”

Jónas: “Simone will get a job immediately in one of our companies if she wants it.”

 

Are there many developments every day to find a cancer vaccine?

Jónas: “It takes time, so the short answer is no.”

 

What is the greatest challenge with the cancer vaccine that Ultimovacs are developing?

Øyvind: “To make it work? A good and difficult question.”

Øyvind explained further about the development and testing of the vaccine at Ultimovacs.

 

What is your PhD about, Simone?

Simone: “I develop technology that prolongs the half-life of medicines. It is a patient-focused PhD, since it is a big inconvenience for the patient to take medicines often, but I hope we can succeed in prolonging the half-life so that patients can take the medicine once a week or once a month.”

 

What should one study if one wants to work with medical development or pharmaceutical development?

Jónas: “Molecular biology, physiology, IT, physics, chemistry, biology, statistics  – there are many opportunities.”

Øyvind: “In our company, we have physiologists, doctors, protein chemists, dentists and pharmacists working right now.”

 

When you went to upper secondary school, did you know that you would be doing what you do today?

Jónas: “I chose the natural science, but did not know anything else.”

Øyvind: “I only knew I wanted to study natural science.”

Simone: “I was thinking about studying a medical degree, but I am happy that I chose molecular biology.”

Janne: “I thought about becoming a researcher and thought it seemed exciting. You should absolutely think widely and not just the easiest solution when you are still in upper secondary school. You will benefit from that when you begin to study at university.”

 

Have you always been interested in biology, or was there something special you saw that made you excited about it? 

Jónas: “Yes, always.”

Øyvind: “Biology in itself is very fascinating. There is so much we do not know, like where memories are stored in the brain, for example. We know very little about how the body works, so that is very fascinating.”

 

The cancer vaccine you are developing, will it work against all cancers or only specific types of cancer?

Øyvind: “It will work to treat and protect against most cancer types.”

 

What did Bjørn do in PhotoCure, the company he worked for before becoming manager for Oslo Cancer Cluster Incubator?

Jónas: “He was Head of Research. He is a very smart guy, and he has also worked a lot with the regulatory side.”

 

Sign up to OCC monthly newsletter

ThermoFisher Scientific Norway lectures students at Ullern

A peak into the cancer research world

Ullern Upper Secondary School is unique, because it shares its building with world-class cancer researchers. Last month, all new Ullern students got to experience this first-hand.

This year’s School Collaboration Days in Oslo Cancer Cluster Innovation Park were held right before the autumn holiday. All the first-year classes at Ullern Upper Secondary School were given a guided tour around the Innovation Park to get to know the companies that they share their everyday lives with.

The purpose of the School Collaboration Days is to give the first-year students at Ullern Upper Secondary School an understanding of what the different companies in the Innovation Park and departments of Oslo University Hospital do.

The common denominator for all of them is cancer and many are developing new cancer treatments. While the Cancer Registry of Norway are collecting statistics and doing cancer research, Sykehusapotekene (Southern and Eastern Norway Pharmaceutical Trust) produce chemotherapy and antibodies for patients that are admitted to The Norwegian Radium Hospital and the Department of Pathology (Oslo University Hospital) gives the cancer patients their diagnoses.

 

IN PICTURES

The student guided tours of Oslo Cancer Cluster Innovation Park

Jonas Einarsson lecturing to students at Ullern

True to tradition, Jónas Einarsson, CEO of the evergreen fund Radforsk, opened the School Collaboration Days in Kaare Norum auditorium with a common lecture. In this image, Einarsson is talking about the development of the Montebello area, which Oslo Cancer Cluster Innovation Park is a part of. The first Radium Hospital was opened in 1932 and the following year Ullern School was moved from Bestum to the same place that houses Oslo Cancer Cluster Innovation Park today.

 

Kreftregisteret lecturing to students at Ullern.

Elisabeth Jakobsen, Head of Communications of the Cancer Registry of Norway, tells the first year students about what they do and the risk factors for developing cancer. Also, she asked the students several questions about how to regulate the sales of tobacco, e-cigarettes and many other things.

 

Thor Audun Saga, CEO of Syklotronsenteret ("the Norwegian medical cyclotron centre"), talks to Ullern students.

Thor Audun Saga is the CEO of Syklotronsenteret (“the Norwegian medical cyclotron centre”). He told the students about what they do, what a cyclotron is and how they use cyclotrons to develop cancer diagnostics.

 

ThermoFisher Scientific Norway lectures students at Ullern

The management of Thermo Fisher Scientific Norway are also housed in the Oslo Cancer Cluster Innovation Park. They told the students about the Norwegian invention called “Ugelstadkulene”. This is both the starting point for million of diagnostic tests across the world and revolutionary (CAR T) cancer treatments, 45 years after they were invented.

 

Students guided through the Oslo Cancer Cluster Incubator Laboratory

The tour was ended with a walk through the laboratory of the Oslo Cancer Cluster Incubator. The students were given an inside look at the work done and instruments used by the cancer researchers in the lab. This area is only one or two floors above their regular class rooms. The student could see first-hand the opportunities there are in pursuing a career in research, entrepreneurship and innovation.

Mandag 7. oktober la finansminister Siv Jensen (til venstre) fram nasjonalbudsjettet og et forslag til Stortinget om statsbudsjett for 2020. Foto: Stortinget

Mer til e-helse og sykehus

I Statsbudsjettet 2020 foreslår regjeringen flere temaer som er relevante for Oslo Cancer Cluster, blant annet å øke investeringer i e-helseløsninger, satse mer på sykehusene og utvide opsjonsskatteordningen for små oppstartsselskap. Men det står lite konkret om kreft.

– Helse og omsorg har stor plass i budsjettet også til neste år, sa finansminister Siv Jensen i finanstalen hun leverte fra Stortingets talerstol 7. oktober 2019.

Jensen ramset deretter opp satsingsområdene som regjeringen har på helse i Statsbudsjettet 2020:

  • mer moderne sykehus med ny teknologi og nye behandlingsformer, flere fastleger og legespesialister
  • oppfylle opptrappingsplanen for rusfeltet 
  • kortere ventetid for pasienter ved sykehusene
  • bedre omsorgstjenester

Du kan lese hele finanstalen på regjeringens nettside.

Lite konkret om kreft

Statsbudsjettet 2020 nevner lite konkret om kreft, faktisk bare to punkter.

  1. Regjeringen foreslår å øke bevilgningene til nasjonalt screeningprogram for tarmkreft med 24,7 millioner kroner i 2020. Det blir en samlet bevilgning på om lag 97 millioner kroner.
  2. Radiumhospitalet skal videreutvikles som et spesialisert kreftsykehus. Dette nevnes i omtalen av den planlagte sykehusomleggingen i Oslo.

Kliniske studier nevnes ikke spesifikt i Statsbudsjettet 2020.

100 millioner til Gaustad og Aker

Regjeringen foreslår at 100 millioner kroner går til nye sykehus på Aker og Gaustad i Oslo. Samtidig foreslås en låneramme på 29,1 milliarder kroner til prosjektet. Det skal legge til rette for at Helse Sør-Øst og Oslo universitetssykehus kan gå i gang med prosjektering og bygging av et nytt, stort akuttsykehus på Aker og et samlet og komplett regionsykehus inkludert lokalsykehusfunksjoner på Gaustad.

I tillegg foreslås en lånebevilgning til universitetsarealer ved det nye sykehuset i Stavanger.

Satsing på e-helse

Regjeringen foreslår et løft for den nasjonale e-helseutviklingen, med 373 millioner kroner. Dette skal få opp tempoet på digitaliseringen i helsetjenesten og legge til rette for å utnytte norske helsedata bedre.

– Norge har omfattende og verdifulle helsedata som er bygget opp over lang tid. Regjeringen ønsker å gjøre disse lettere tilgjengelig for forskere og andre som har behov for å analysere helsedata. Helseanalyseplattformen vil kutte ned på unødvendig byråkrati og tidstyver. Regjeringen foreslår å øke bevilgningen med 131 millioner kroner, sier helseminister Bent Høie i en pressemelding om temaet.

Regjeringen vil også etablere et «standardisert språk», et kodeverk og terminologi i helse- og omsorgssektoren, for å bedre pasientsikkerhet og skape mer samhandling.

Til sist vil regjeringen øke bevilgningene til modernisering av Folkeregisteret i helse- og omsorgssektoren og til forvaltning og drift av de nasjonale e-helseløsningene kjernejournal, e-resept, helsenorge.no, grunndata og helseID.

Pressemeldingen om satsingen på e-helse kan du lese på regjeringens nettside.

Les mer om prioriteringer i budsjettforslaget for Helse og omsorgsdepartemente på side 25 i Statsbudsjettet 2020. 

Dobbelt opsjonsfordel for start-ups

Regjeringen vil utvide ordningen for gunstig skattemessig behandling av opsjoner i små oppstartsselskaper. Maksimal opsjonsfordel per ansatt dobles fra 500 000 kroner til en million kroner. Regjeringen foreslår også å utvide ordningen til å omfatte flere selskap.

I tillegg til at opsjonsfordelen dobles, økes maksimalt antall ansatte i selskap som kan være i ordningen fra 10 til 12. Det gjør at flere små selskap kan benytte ordningen.

Opsjonsskatteordningen for små oppstartsselskap ble innført fra 2018. Under denne ordningen kan ansatte få opsjoner som gir rett til å kjøpe aksjer i selskapet til en fastsatt pris. Ordningen innebærer blant annet at skatteplikten på opsjonene utsettes salg av aksjene kjøpt ved hjelp av opsjonene. Denne skatteutsettelsen er begrenset til en maksimal opsjonsfordel, som nå foreslås doblet.

Utvidelsene må godkjennes av ESA før de kan tre i kraft. Regjeringen opplyser at den jobber for at endringene vil bli godkjent før nyttår, slik at de kan gjelde fra 1. januar 2020.

Flere relevante temaer i Statsbudsjettet

  • Skattefunn: Regjeringen foreslår endringer i Skattefunn-ordningen som skal stimulere næringslivet til å investere enda mer i forskning og utvikling (FoU). Forslagene øker den årlige Skattefunn-støtten med 150 millioner kroner fra 2020. Samtidig foreslår regjeringen flere tiltak som gir bedre kontroll med ordningen. Les mer om skattefunnforslaget på regjeringens nettside.  
  • Protonsenter: 26 millioner foreslås til protonsenter i 2020.
  • Fastlegene: Regjeringen foreslår å bruke om lag 350 millioner kroner til å styrke og videreutvikle fastlegeordningen. De varsler flere tiltak for å styrke ordningen i en handlingsplan som skal komme våren 2020.
  • Legespesialisering: Regjeringen foreslår 10 millioner kroner til allmennleger i spesialisering (ALIS)-kontor i Bodø, Trondheim, Bergen, Kristiansand og Hamar. Tilskuddet gis for å bistå kommuner i regionen til å planlegge, etablere, inngå og følge opp ALIS-avtaler.
  • Statsbudsjettet 2020 er på 1 414,6 milliarder kroner. Staten forventer å tjene 245 milliarder kroner på olje– og gassvirksomheten til neste år.
  • Du kan fordype deg i Statsbudsjettet 2020 på regjeringens temaside.

Sign up to OCC monthly newsletter

Bente Prestegård from Oslo Cancer Cluster and Ragni Fet from Ullern Upper Secondary School with two of the students in the research program.

Educating the cancer researchers of tomorrow

Ullern Upper Secondary School and Oslo Cancer Cluster are paving the way for students to become the researchers of the future.

A new program has been launched this autumn for Ullern students who wish to learn how researchers work. It will qualify students for university studies and specialise them in biomedical research, technology and innovation. It is the only researcher program for upper secondary school in Norway.

“The researcher program at Ullern will be a place where students are encouraged and guided to become independent students, with a need to explore, an understanding of methods and a desire to learn,” said Ragni Fet, teacher at Ullern Upper Secondary School. “They will learn to gather good and reliable information, they will do research in practice through varied experiments, and they will gain real insight into job opportunities in the research industry.”

The program is a joint initiative between Oslo Cancer Cluster and Ullern Upper Secondary School, who have been collaborating since 2009. This has offered students in the natural sciences, health, media and electricity special opportunities to learn science subjects outside a traditional classroom setting.

“The purpose of launching a researcher program at Ullern Upper Secondary School is to recruit the researchers, scientists and entrepreneurs of the future,” said Bente Prestegård, Project Manager at Oslo Cancer Cluster. “We know that these jobs are needed, and we want to teach students about what it means to be a researcher or entrepreneur. With better insight into the professions, the students will be able to make a safe career choice.”

 

With a passion for science

About 30 students have already begun this unique program at Ullern Upper Secondary School. One of them is Henrikke Thrane-Steen Røkke.

“I chose the researcher program because I personally enjoy studying the natural sciences and innovation, and I wanted more of those subjects. I had entrepreneurship as an elective at secondary school and thought it was a lot of fun. I think it seemed very exciting and wanted to learn more,” Henrikke explained. “I hope I can gain insight into what it is like to work as a researcher. I hope we can see and experience a lot of it in practice and to work in depth with some subjects in certain areas.”

The program is especially well suited for students with an interest in the natural sciences, such as Peder Nerland Hellesylt, who also recently begun the program.

“I applied to this program because I have always had an interest for the natural sciences and mathematics,” Peder said. ”I think this program is very interesting because we aren’t just sitting and writing, but get practical tasks too, for example experiments.”

 

Mixing theory with practice

Ullern Upper Secondary School is located right next to The Norwegian Radium Hospital, The Institute for Cancer Research, The Norwegian Cancer Registry and the Oslo Cancer Cluster Incubator, with its over 30 big and small companies. The students are therefore never far from world class researchers. This offers the unique opportunity to take advantage of the co-localisation and use mentors from the research milieu in the teaching.

“Through the collaboration with Oslo Cancer Cluster, we will obtain external lecturers to the class rooms; bring the students to multiple, exciting innovation companies and laboratories; and the students will attempt real research experiments themselves. We are raising the level and are ambitious for the sake of the students,” Ragni Fet said.

 

Sign up to OCC newsletter

The panel discussion at the Precision Medicine session at NLS Days 2019.

Forward-looking session on cancer precision medicine

Emerging therapies, digital solutions and AI were central topics when international experts met during the oncology session at the Nordic Life Science Days 2019.

Oslo Cancer Cluster hosted the session on oncology titled “Cancer precision medicine: State-of-the-art and future directions” at the Nordic Life Science Days this year. The session covered recent advances in cancer immunotherapy and cell- and gene therapies. International experts met to discuss how big data, artificial intelligence and digital solutions are changing drug development, diagnostics and patient care.

 

AI revolutionizing cancer research

Dr. Mark Swindells on artificial intelligence and drug discovery.

Mark Swindells on artificial intelligence and drug discovery.

Mark Swindells, PhD, COO Exscientia, presented how artificial intelligence is changing and driving drug discovery now.

“On average 2 500 compounds need to be synthesized and tested to develop a candidate molecule for clinical trials. We want to apply AI to this artisan area of drug discovery. By reducing the amount of compounds synthesized and tested, we will reduce the overall cost and time to get drugs to market,” Swindells said.

This is a fast moving area and one of the examples of technical innovation Swindells gave was Exscientia’s Active Learning algorithms, which have been benchmarked to work as well as – and in some cases better than – the most successful humans.

In the area of precision oncology, Swindells said: “We are particularly interested in the acquisition of resistance in oncology as an area where our technology could be applied.”

 

Kaisa Helminen, CEO Aiforia, focussed on how the use of artificial intelligence can make image analysis more accurate and efficient.

Dr. Kaisa Helminen on artificial intelligence and image analysis.

Kaisa Helminen on artificial intelligence and image analysis.

“Due to the ageing population, more samples need to be analysed and many countries suffer from serious shortage of pathologists. Many patients are left waiting for their diagnosis and treatment. Manual, visual image analysis is slow and highly subjective. There is a risk for misdiagnosis, which can be dramatic for the patient and costly for the healthcare system.”

Aiforia has built an AI platform that supports medical experts in diagnostics.

“For the first time we are bringing AI tools for doctors’ use, so they can easily create their own AI algorithms,” Helminen explained. “Instead of visually estimating something from samples, we bring accurate, numerical information. AI algorithms are consistent from day to day, week to week, removing the human error component,”

We are bringing AI tools for doctors’ use.

 

Marko Kuisma, Chief Commercial Officer at Kaiku Health, then presented a new digital platform for better patient monitoring, using machine learning tools.

Marko Kuisma on digital tools for better patient monitoring.

Marko Kuisma on digital tools for better patient monitoring.

Scientific evidence demonstrates that patients who use a digital symptom monitoring solution have an overall survival benefit, experience improved quality of life and go through less visits to the emergency room and hospitalisations.

“The traditional interventions that clinicians make are reactive and come with a delay,” Kuisma explained. “With digital symptom monitoring, interventions are still reactive, but more timely, because you can detect the symptoms early on. When applying machine learning, we make that monitoring proactive and predictive, taking action before symptoms and adverse effects develop.”

“… taking action before symptoms and adverse effects develop.”

 

Identifying gene mutations

Jørn Skibsted Jakobsen Md. Ph.D.,Vice president Science and Medicine TA Urology/Uro-Oncology, Global Clinical Research and Development, Ferring Pharmaceuticals, introduced emerging gene therapies to treat non muscle invasive bladder cancer (NMIBC) bladder cancer.

Jørn Skibsted Jakobsen on a radical new gene therapy.

Jørn Skibsted Jakobsen on a radical new gene therapy.

If a NMIBIC patient doesn’t respond to BCG (a type of immunotherapy drug), a cystectomy is still considered the gold standard treatment. This involves surgically removing all or parts of the urinary bladder, creation of a urinary diversion using a piece of the small intestine and leads to a significantly decreased quality of life for the patient.

Jakobsen introduced a new gene therapy to treat NMIBC patients that are unresponsive to BCG treatment.

“Early research suggests mutations in the surrounding tissue of the tumour potentially predict the subsequent recurrence of the disease,” Jakobsen said. “What if we were able to identify those mutations? And then create a personalised gene-based antibody directed at identified mutations. You could potentially treat patients before the recurring disease.”

“You could potentially treat patients before the recurring disease …”

 

Novel targets and pathways

Carl Borrebaeck, Professor, Lund University, and Kristian Pietras, Professor of Molecular Medicine, Lund University presented L2CancerBridge, a collaboration between the Swiss Centre of Lausanne and Lund University. They are exploring a new model for translational research in breast cancer and tumour immunology.

Carl Borrebaeck introduced L2CancerBridge.

Carl Borrebaeck introduced L2CancerBridge.

The tumor immunology team in Lausanne is focused on identifying novel targets on immunoregulatory cells as T cells and dendritic cells, with the goal of identifying new targets for CAR-T cells. The breast cancer team is focused on studies of tumour cells and their microenvironment with the goal to identify signalling pathways.

“We have been able to find signalling pathways between malignant cells and connective tissue,” Pietras said.

These pathways are crucial for basal-like breast cancer, the most aggressive breast cancer subtype, and block the development of resistance to endocrine therapy. Blocking them allows the use of effective endocrine therapies in cancers that previously did not have any targeted treatment options.

 

Gaspar Taroncher-Oldenburg, PhD; Editor-at-Large, Nature Publishing Group, moderated the session for the second year in a row.

“I have been impressed by how much thought both co-hosts of the event—Jutta Heix from the Oslo Cancer Cluster and Carl Borrebaeck from Lund University—put into weaving together a compelling story that is timely and relevant, both locally and globally.” Taroncher-Oldenburg said.

“Of course, much of the credit for the session being successful goes to the panelists, who again this year captured the audience’s attention through a combination of intriguing presentations and a dynamic roundtable discussion that broadly illustrated different aspects–present and future—of precision medicine in oncology.”

“A compelling story that is timely and relevant, both locally and globally.”

The Norway for life science stand at NLS days 2019.

Norway for life science

The biggest key players from the life science industry in Norway came together in Malmö with a common goal: to promote Norwegian life science and build Nordic collaboration.

The life science industry in Norway is booming and collaboration across Nordic borders is of increasing importance. That is why Oslo Cancer Cluster arranged the stand “Norway for Life Science” this year at the Nordic Life Science Days in Malmö.

Among the participants of the stand were governmental institutions, cluster organisations, private companies and academic institutions.

 

Promoting collaboration

On Wednesday, a delegation from the Norwegian Embassy in Sweden attended for an informal meet and greet with the Norwegian life science milieu. This was an excellent opportunity to share knowledge about Nordic cooperation and to strengthen joint activities within the life sciences.

See the video with Kirsten Hammelbo, Minister / Deputy Head of Mission, Norwegian Embassy below.

 

Standing together

The participants of the stand were altogether positive about the initiative and agreed it was a constructive platform to build new relationships. We asked some of the participants the same question: Why is it important for you to be here at NLS days?

“Our main focus here at NLS Days is Nordic collaboration, both public and private, to promote the life science industry.”
Catherine Capdeville, Senior Adviser, Innovation Norway

“It is important to follow what is happening in the industry and in other innovation environments. We are here to nurture our existing contacts and find new partners.”
Morten Egeberg, Administrative leader, UiO Life Science

“Firstly, it is important to show that Norway stands together. This is a significant meeting place. We consider the Nordic countries to be our home market, so we try to present what we do here. It is important for one actor to take responsibility, like Oslo Cancer Cluster does, so that we can collectively gather here.”
Anita Moe Larsen, Head of Communication, Norway Health Tech

“In the long term, we have research projects where we are looking for contacts in the life science industry – both partners of collaboration and potential clients. We are here to promote the centre and let everyone know that we exist.”
Alexandra Patriksson, Senior Adviser, Centre for Digital Life

“We are here to strengthen our collaboration with the best research environments in neuroscience. We want to show that the health industry in Norway is growing and what we can do when we stand together.”
Bjarte Reve, CEO, Nansen Neuroscience Network

“We are happy to contribute to make Norwegian life sciences visible and to show what Norway can offer as a host country, and attract potential investors and collaborating partners in research and innovation. And especially to make visible and be a part of the Norwegian community in this field. It is unusual in Norway that so many different players, both public and private, stand together in one stand – with one common goal.”
Espen Snipstad, Communications Manager, LMI

 

Full list of partners:

 

Sign up to OCC monthly newsletter